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Abstract 
With over 90 different serotypes of Streptococcus pneumoniae unevenly 
distributed around the world, current vaccine formulations vary significantly in 
their ability to protect against invasive pneumococcal disease (IPD). The adult 
pneumococcal vaccine is composed of capsular polysaccharide from 23 of the 
most prevalent disease causing serotypes. Purely polysaccharide vaccines are 
unable to protect those most at risk; infants under the age of two. This has led 
to the development of a paediatric conjugate vaccine, composed of capsular 
polysaccharide from seven of the most common disease causing serotypes, each 
chemically conjugated to a carrier protein. Although efficacious at protecting 
the target age group from disease caused by homologous serotypes, it fails to 
protect against the non-vaccine serotypes. Serotype specific vaccination is a 
short-term solution to pneumococcal disease. As the most common serotypes are 
eradicated by vaccination, previously less common serotypes fill the vacant 
niche and cause serotype replacement disease. A solution to this problem would 
be the development of pneumococcal vaccines containing antigens that elicit 
non-serotype specific protection. 
Pneumolysin, the pore-forming toxin produced by S. pneumoniae, may play a 
role in future pneumococcal vaccine. It is a major virulence factor produced by 
all invasive isolates and has previously been demonstrated to confer non-
serotype specific protection. In this thesis, pneumolysin retained the ability to 
bind to cell membranes and form pores even when other antigens were fused 
genetically to the N terminus. Pneumolysin performed as a highly immunogenic 
mucosal adjuvant, with substantial mucosal and systemic immune responses to 
the fused antigen, when nanograms quantities when applied to the mucosal 
surface of the nasopharynx. A fusion between pneumococcal surface adhesin A 
(PsaA) and pneumolysin (PLY) was created to investigate potential protection 
conferred by the antigen specific response. Vaccination of Balb/c and MF1 mice 
with PsaAPLY conferred no protection against challenge with virulent S. 
pneumoniae TIGR4. 
The toxicity of pneumolysin is problematic and existing pneumolysin mutants 
possess residual cytotoxicity. By ablating the toxicity of pneumolysin with 
formalin it permits its use in parental vaccines. The pneumococcal histidine 
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triad proteins (Pht) are a recently identified family of surface exposed proteins 
that have homologues in other Streptococcus species and are therefore novel 
potential vaccine candidates. Intramuscular vaccination with both of these 
antigens in the presence of adjuvant resulted in protection in both young and 
aged mouse models of pneumococcal pneumonia. Intranasal vaccination with 
PhtD and detoxified PLY, singly and in combination, in the presence of Labile 
Toxin (LT) from Escherichia coli was protective in a young mouse model of 
colonisation. 
In vivo models of disease require the sacrifice of a large number of animals at 
time points to investigate the impact of vaccine or pharmaceuticals on disease 
progression. Real-time photonic imaging of bioluminescent bacteria offers 
significant advantages over conventional methods for monitoring and combating 
bacterial disease in animals. Not only does this approach reduce the time and 
costs associated with such experiments, but also it considerably reduces the 
number of animals used. Furthermore, because bioluminescent imaging allows 
the same group of animals to be monitored over time, animal-to-animal 
variations are overcome by including the zero time point as an internal control. 
Models of pneumococcal pneumonia were established in MF1 mice. 
Newly established bioluminescent models were then used to investigate the 
impact of vaccination with the paediatric pneumococcal conjugate vaccine as 
proof of principle. Mice vaccinated with Prevnar® (or the equivalent quantity of 
alum alone as a negative control) were challenged with a bioluminescent 
serotype 4 S. pneumoniae strain, TIGR4 Xen 35. Only mice that received Prevnar 
were completely protected against IPD. There was no impact of vaccination on 
persistence of pneumococci in the nasopharynx. The impact of experimental 
prophylaxis with oseltamivir phosphate (OP) on invasive pneumococcal disease 
was also investigated. OP is an inhibitor of neuraminidase and is used to treat 
influenza infections. Pneumococcal NanA has been crystallised with oseltamivir 
carboxylate in the active site of the enzyme. It was hypothesised that inhibition 
of pneumococcal Nan might reduce severity of disease and enhance survival. 
Mice were challenged with bioluminescent serotype S. pneumoniae strain A66.1 
Xen 10. Mice treated with OP experienced fewer symptoms and a moderate 
increase in survival. In addition, pre-treatment of murine mucosa with 
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recombinant pneumococcal NanA greatly increased the severity of the 
subsequent pneumococcal infection.  
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His-Tag Histidine Affinity tag 
HRP  Horseradish peroxidase 
HU  Haemolytic Units 
HIV  Human immunodeficiency virus 
Hyl  Hyaluronidase 
IFN-  Interferon gamma 
Ig  Immunoglobulin 
IL  Interleukin 
ILY  Intermedilysin 
i.n.  Intranasal 
i.p.  Intraperitoneal 
i.v.  Intravenous 
IPTG  Isopropyl--D-Thiogalactopyranoside 
Kb  Kilobase 
kDa  Kilodalton 
L  Litre 
LAL  Limulus Amebocyte Lysate 
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LB  Luria Broth 
LPS  Lipopolysaccharide 
LytA  Autolysin A 
M  Molar 
mAb  Monoclonal Antibody 
mg  Milligram(s) 
min  Minute(s) 
ml  Millilitre 
MLST  Multi-Locus Sequence Typing 
mM  Millimolar 
MW  Molecular weight 
n  Group size 
Nan  Neuraminidase 
NK  Natural Killer 
nm  Nanometre 
NO  Nitric Oxide 
OC  Oseltamivir carboxylate 
OD  Optical Density 
OP  Oseltamivir phosphate (Tamiflu®) 
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PBS  Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
PCV  Pneumococcal Conjugate Vaccine 
PdB  Pneumolysin carrying W433F substitution 
PdT  Pneumolysin carrying triple mutations: D385N, C428G, W433F 
PFO  Perfringolysin O 
Pht  Pneumococcal histidine triad protein 
Pia  Pneumococcal iron acquisition protein 
Piu  Pneumococcal iron uptake protein 
PLY  Pneumolysin 
PPV  Pneumococcal Polysaccharide Vaccine 
PS  Polysaccharide 
Psa  Pneumococcal surface adhesion protein 
psi  Pounds per square inch 
Psp  Pneumococcal surface protein 
rpm  Revolutions per minute 
RT  Room Temperature (~20C) 
S. pneumoniae Streptococcus pneumoniae 
SDM  Site-directed mutagenesis 
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SDS-PAGE Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
SEM  Standard Error of the Mean 
sec  Second(s) 
SLO  Streptolysin O 
SMPRL  Scottish Meningococcal and Pneumococcal Reference Laboratory 
Spp.  Species 
ST  Sequence Type 
TEM  Transmission Electron Microscopy 
TIGR  The Institute for Genomic Research 
TIGR4  Serotype 4 S. pneumoniae genome sequenced by TIGR  
(ATCC number: BAA-334) 
TLR  Toll-like Receptor 
TNF  Tumour Necrosis Factor 
U  Units 
V  Volts 
v/v  Volume/volume 
WT  Wild type 
Xen 7  Bioluminescent S. pneumoniae strain serotype 2 D39 
Xen 10 Bioluminescent S. pneumoniae strain serotype 3 A66.1 
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Xen 35 Bioluminescent S. pneumoniae strain serotype 4 TIGR4 
  
Chapter 1 Introduction 
1.1 Streptococcus pneumoniae 
Streptococcus pneumoniae, also known as the pneumococcus, is a Gram-positive 
facultative anaerobe. It is capable of colonising the nasopharynx of mammals, 
including humans, and was discovered simultaneously by Pasteur in France and 
Steinberg in America in 1881 (Baltimore, 1998). Until 1995, pneumococci were 
divided into 90 serotypes based on the immunogenicity of their capsular 
polysaccharide (Lund, 1970; Henrichsen, 1995), increasing to 91 in 2007 with the 
description of serotype 6C (Park et al., 2007a; Park et al., 2007b). Initial 
classification of serotypes was on the chronological order of discovery (Dochez, 
1913; Lister, 1913), however cross-reactivity between serotypes led to 
reclassification using the Danish nomenclature. Some serotypes remained the 
same, such as 1 and 2. Others, such as serotypes 6 and 26 by American 
nomenclature, had such similar capsules that they were reclassified as serotype 
6A and 6B (Lund, 1957). The immune reaction involved in serotyping is known as 
the Quellung reaction and was developed by Neufeld (Neufeld, 1902). Quellung 
(or swelling) reactions are performed with anti-sera raised against the 
homologous capsular polysaccharide and it is the reaction between the two that 
gives rise to the name. The technique is still used today. The Quellung reaction 
has its limitations, as it is unable to identify serotypes for which no anti-sera is 
available, and it cannot type strains that are unencapsulated or have reduced 
expression of capsular genes. In addition, many of these serotypes are rarely 
recovered from serious disease, and only about 15 serotypes cause the majority 
of disease worldwide (Hausdorff et al., 2000; Robinson et al., 2001; Hausdorff, 
2002). Although this increases the probability of developing vaccines that target 
the most frequent types, the distribution of serotypes can vary with age, 
geography and time, posing greater challenges for vaccine development. 
The advent of molecular biology has increased the specificity of typing. New 
techniques such as Multi Locus Sequence Typing (MLST) have been developed as 
a typing scheme that is accurate and simpler to perform (Enright & Spratt, 
1998). Seven house-keeping genes are sequenced (aroE, gdh, gki, recP, spi, xpt 
and ddl) and each allele is assigned a number depending on its sequence in the 
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MLST website (http://spneumoniae.mlst.net/). This „digital barcode‟ is known 
as the sequence type (ST). MLST is a powerful technique that enables 
standardisation across different laboratories. Different STs can exist within the 
same serotype and it has also revealed capsule switching (Jefferies et al., 2004; 
Beall et al., 2006; Jacobs et al., 2009) which make it a powerful tool for 
monitoring genetic variation in pneumococcal disease on a global scale. 
However, MLST also has its limitations. Thorough analysis of entire genomes 
using microarrays has revealed that isolates that identical in serotype and ST 
exhibit variation in gene content, indicating that variation exists with groups 
that are considered identical by serotyping and MLST (Silva et al., 2006; Obert 
et al., 2007). Microarrays remain too expensive and labour intensive to become 
a routine method of identification. Supplementing the MLST sequencing with 
essential virulence genes may increase the power of the technique until 
microarray technology becomes more affordable or next generation genome 
sequencing becomes more routine (Hanage et al., 2005; Dagerhamn et al., 
2008). 
1.2 Host susceptibility 
There are a number of factors that are associated with increased host 
susceptibility to pneumococcal carriage and subsequent disease. These include 
overcrowding (as found in day care centres, large families in cramped housing, 
homeless shelters and prisons), smoking, antibiotic use, ethnicity and extremes 
of age from the very young to the very old (1989; Glaser et al., 1990; Hoge et 
al., 1994; Nuorti et al., 2000; Sheffield & Root, 2000; Coles et al., 2001; 
Crossley, 2001; Iles et al., 2001; Dunais et al., 2003; Neto et al., 2003; Regev-
Yochay et al., 2003). The most common serotypes isolated from European 
children prior to the introduction of the pneumococcal conjugate vaccine were 
6A, 6B, 9V, 14, 18C, 19F and 23F; and the range of carried serotypes decreases 
with age (Bogaert et al., 2004a). An important point is that carriage must 
prelude disease, therefore minimising carriage would reduce incidence of 
invasive disease. 
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1.3 Carriage of S. pneumoniae 
S. pneumoniae occupies the crowded niche of the upper respiratory tract in 
humans at least once in their lifetime. Nasopharyngeal colonisation is a highly 
dynamic, rapidly evolving, transient environment with intense intra- and 
interspecies competition. Other bacterial species jockeying for position in this 
highly competitive niche include Haemophilus influenzae, Moraxella 
cattarrhalis, Neisseria meningitidis, Staphylococcus aureus and other 
Streptococcal spp (Leiberman et al., 1999; Masuda et al., 2002; Bogaert et al., 
2004b). Colonisation of the nasopharynx is essential for transmission from host to 
host. S. pneumoniae has been shown to produce H2O2 and lysogenic 
bacteriophages which inhibit or kill other microflora in the nasopharynx giving 
the pneumococcus a competitive advantage for colonising this environment 
(Selva et al., 2009). The pneumococcus also produces bactericins, to which it is 
resistant, to kill competing organisms (Dawid et al., 2009). S. pneumoniae is 
highly transformable and lysis of neighbouring bacterial cells would enable the 
acquisition of genetic material from other species. An example of this is the 
acquisition of genes that encode low affinity penicillin binding proteins from 
other species such as Streptococcus mitis (Dowson et al., 1994) to confer 
penicillin resistance. S. pneumoniae have also been shown to become competent 
in the presence of antibiotic stress (Iles et al., 2001; Prudhomme et al., 2006). 
1.4 Diseases caused by S. pneumoniae 
S. pneumoniae is ordinarily asymptomatically carried. As an opportunistic 
pathogen it can cause non-invasive diseases such as otitis media (AOM), sinusitis 
and bronchitis, as well as the more severe invasive diseases; pneumonia, 
meningitis and bacteræmia. It is notoriously difficult to calculate disease 
burden, particularly in developing countries with poor healthcare infrastructure 
and disease surveillance. However, in 2005 the World Health Organisation 
estimated that 1.6 million people die of pneumococcal disease every year; this 
estimate includes the deaths of between 700,000 and 1 million children under 5 
years, principally from developing countries (2007). Mortality due to 
pneumococcal disease is also higher in developing countries due to poor access 
to medical assistance and financial constraints. The magnitude of the burden of 
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pneumococcal disease in the elderly in developing countries is ill defined. 
Human immunodeficiency virus (HIV) infected individuals and others that are 
severely immunocompromised are at greater risk of pneumococcal disease.  
1.4.1 Pneumococcal pneumonia 
In developing countries, where patients are often treated without seeing a 
doctor, the WHO defines clinical pneumonia simply as an acute episode of cough 
or difficulty breathing associated with an increased respiratory rate 
(Organisation, 1990; WHO, 1990). The WHO definition of radiologically confirmed 
pneumonia (Cherian et al., 2005) attempts to elucidate both syndrome and 
etiology, and was designed as an epidemiologically specific endpoint to evaluate 
the efficacy of vaccines against pneumococcal pneumonia (Cutts et al., 2005). 
However, many children do not satisfy the specific criteria and so research to 
refine pneumonia classification is a necessary prelude to future research on the 
etiology of the disease. In industrialised countries, S. pneumoniae is also one of 
the most common causes of community-acquired pneumonia (CAP) accounting 
for at least 30% of all CAP cases hospitalised, with a case fatality rate of 11 to 
44%. Annual incidence of CAP in the USA in 2002 was 18.3 cases/100,000 elderly 
persons, and pneumococcal pneumonia accounted for at least 5.5 cases/100,000 
population (Kaplan et al., 2002). Invasive pneumococcal disease carries a high 
mortality, even with advanced supportive care and antibiotics; for adults the 
mortality rate averages 10-20%, whilst it may exceed 50% in the high-risk groups 
(Johnston, 1991b; Amdahl et al., 1995; Rello, 2008; Rodriguez et al., 2009). 
Underlying conditions such as cancer and infection with the human 
immunodeficiency virus (HIV) can predispose individuals to IPD from serotype 
11A, whereas other serotypes appear to cause invasive disease immediately after 
colonisation in healthy adults (Sjostrom et al., 2006). 
1.4.2 Pneumococcal bacteræmia 
Bacteræmia is a bloodstream infection or sepsis caused by the presence of 
bacteria in the blood. Bacteræmia frequently follows pneumonia and progression 
of disease in this normally sterile site is usually rapid and is associated with a 
high mortality. A recent study in Kenya reported an annual incidence of 
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presentation to the hospital with pneumococcal bacteræmia of 597 cases/100,00 
in children less than 5 years and that one in six of these cases was fatal (Brent et 
al., 2006). Antibiotics (in particular the -lactams and clarithromycin) are 
usually efficacious in the treatment of pneumonia and bacteræmia. This may not 
be the case much longer as antibiotic resistant strains are increasing in number. 
Evolution of bacteria to subvert antibiotics is swift and so attention has primarily 
focused on the development of preventative treatments such as vaccines. 
1.4.3 Pneumococcal meningitis 
Meningitis is characterised by inflammation of the meninges (fluid filled 
membranes that surround the brain and spinal cord) and can be caused by viral 
or bacterial pathogens. S. pneumoniae is responsible for severe meningitis with 
40-75% of cases in the developing world resulting in death or serious disabilities 
(Goetghebuer et al., 2000). There are often devastating sequelae associated 
with recovery from pneumococcal meningitis, with a high possibility of learning 
difficulties, focal neurological difficulties, mental retardation and hearing loss in 
survivors (Bohr et al., 1984; Bohr et al., 1985; Rasmussen et al., 1991). 
Treatment with antibiotics is efficacious, but the use of non-lytic antibiotics 
such as daptomycin would reduce inflammation caused by the release of 
pneumolysin and other products into the CSF (Mook-Kanamori et al., 2009). 
The mechanism by which colonising pneumococci proceed to cause meningitis 
remains unclear. Initially it was thought that pathogens must enter the blood 
prior to invasion of the central nervous system (CNS). However, there have been 
reports that demonstrated that S. pneumoniae can enter the CNS directly via the 
olfactory neurons (van Ginkel et al., 2003) and in an animal model it is possible 
to have high bacterial loads in the brain without concomitant bacteræmia (Marra 
& Brigham, 2001). Following the onset of bacteræmia, circulating pneumococci 
can breach the blood brain barrier (BBB) and colonise the CSF. Once in the CSF 
there is a massive inflammatory response by the host that results in acute brain 
injury (Hirst et al., 2004). This attachment to the proximal endothelial barrier 
was recently shown to be mediated by neuraminidase A (NanA) and the lectin-
like domain was shown to be critical to this adhesion, both in an in vitro human 
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brain microvascular endothelial cell (hBMEC) culture as well as in an in vivo 
infection model (Uchiyama et al., 2009). 
1.4.4 Pneumococcal otitis media and sinusitis 
Otitis media is an infection of the middle ear, which situated behind the 
tympanic membrane, and connected to the nasopharynx via the Eustachian tube. 
It is particularly common in children, 79% of which will experience at least one 
AOM episode before their first birthday and 91% before their second birthday 
(Paradise et al., 1997). Almost half of these children with have three or more 
during their first three years of life. Children are particularly prone to AOM as 
their narrow Eustachian tubes are more easily blocked due to inflammation 
caused by other infections. The Eustachian tubes are also more horizontal in 
position and drain poorly in comparison to adults (Corbeel, 2007). Bacteria can 
infiltrate the Eustachian tube and begin to replicate. This leads to inflammation 
caused by bacterial products as well as the influx of inflammatory immune cells. 
Fluid build up in the middle ear can lead to deafness that may become 
permanent and can cause severe pain due to pressure exerted on the tympanic 
membrane.  
Treatment usually involved antibiotics, although repeated prescriptions can 
increase the number of AOM episodes a child experiences. Although otitis media 
and sinusitis are rarely fatal, they are responsible for an enormous burden of 
morbidity. Prior to the introduction of the pneumococcal conjugate vaccine into 
the United States childhood immunisation programme, it is estimated that 
medical costs and lost wages due to AOM amounted to $2 to $5.3 billion a year in 
the United States (Bluestone et al., 1992; Schappert, 1992; Klein, 2000; 2004a). 
In addition, over 15 million antibiotic prescriptions a year were issued for 
treatment of AOM in the United States alone (Auinger et al., 2003). In 
decreasing order of importance the major serotypes responsible for AOM 
worldwide are: 19F, 23F, 14, 6B, 6A, 19A and 9V. Serotypes 3, 1 and 5 were 
shown to be more important in children older than 60 months and younger than 
6. Four serotypes (23F, 19F, 14 and 6B) accounted for 83% of all penicillin-
resistant observations (Hausdorff et al., 2002). However, other studies failed to 
identify AOM associated serotypes or clonal groups (Hanage et al., 2004). 
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1.5 Known virulence determinants 
S. pneumoniae produces an array of virulence factors involved in pathogenesis 
including capsular polysaccharide, cell surface-associated proteins and toxins. 
Full genomic sequencing studies and signature-tagged mutagenesis have resulted 
in the identification of many putative virulence factors (Polissi et al., 1998; Lau 
et al., 2001; Hava & Camilli, 2002). Many of these have yet to be ascribed 
function and many bear no resemblance at the DNA level to existing protein 
products within the databases. The more characterised virulence factors and 
their roles in pathogenesis are summarised in Table 1-1 below. 
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Table 1-1 Pneumococcal virulence factors and their roles in pathogenesis of pneumococcal disease. 
Virulence factor Abbreviation Location Function(s) 
Capsular 
polysaccharide 
CPS Outer 
surface 
Lack of activation of alternative complement pathway (Fine, 1975; Giebink, 1977; 
Silvenoinen-Kassinen, 1986) 
Resistance to phagocytosis (Matthay, 1981; Silvenoinen-Kassinen, 1986; Neeleman, 
1999) 
Deposition of opsonically inactive complement components (Angel, 1994; Neeleman, 
1999) 
No or low immunogenicity of some serotypes (Van Dam, 1990) 
Masking cell surface antigens from host immune system and altering expression 
during disease (Hammerschmidt et al., 2005) 
Cell wall (inc. 
teichoic acids, 
phophorylcholine, 
peptidoglycan and 
lipoteichoic acids) 
CW Beneath 
capsule 
Activation of the alternative complement pathway, resulting in anaphylatoxin 
production (Winkelstein, 1977; Ren et al., 2004; Yuste et al., 2005) 
Provides a surface for anchoring surface-exposed proteins via choline binding 
domains. 
Enhancement of vascular permeability, mast cell degranulation and 
polymorphonuclear neutrophil (PMN) activation (Johnston, 1991a) 
Interleukin-1 produced which cytopathic for endothelium (Riesenfeld-Orn, 1989; 
Geelen, 1993) 
Mediator of attachment to endothelial cells (Geelen, 1993) 
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Autolysin A 
 
 
 
Autolysin B 
Autolysin C 
LytA 
 
 
 
LytB 
LytC 
Cell wall Breaks down cell wall to release cytosolic proteins such as PLY (Lock et al., 1992) 
Upregulated in epithelial-bound bacteria in a stimulated middle ear pressure in vitro 
model (Li-Korotky et al., 2009) 
Penicillin treatment releases LytA which stimulates TLR2 and induces IL-8 promoter 
activity (Moore et al., 2003) 
LytA-/- strain attenuated in intraocular model of endophthalmitis (Ng et al., 2002) 
Non-autolytic murein hydrolase responsible for separating daughter cells at polar 
region of cells (De Las Rivas et al., 2002) 
Murein hydrolase capable of autolysis following incubation at 30C (Lopez et al., 
2000) 
Immunogenic in adults and children after 4-5 months of age (Holmlund et al., 2009) 
Pneumococcal 
surface protein C 
 
 
 
 
Cbp D 
PspC/SspA/C
bpA 
 
 
 
 
Cbp D 
Attached 
to cell 
wall 
 
 
 
 
 
Strain specific contribution to virulence in murine pneumonia & bacteræmia model. 
Mediates complement evasion which contributes to virulence (Kerr et al., 2006) 
Different PspC alleles bind the complement inhibitor C4b and down-regulate the 
classical pathway (Dieudonne-Vatran et al., 2009) 
PspC expression on surface of bacteria is significantly higher in blood than in 
peritoneum (Quin et al., 2008) 
PspC & PspA act synergistically to reduce C1q-independent C3 deposition and immune 
adherence to erythrocytes (Li et al., 2007) 
Binds Factor H, increases adherence to human cells in vitro and enhances invasion in 
vivo (Quin et al., 2007) 
Produced exclusively by competent cells and induces autolysis in a LtyA/C mutant in 
presence of divalent cations (Eldholm et al., 2009) 
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Cbp F 
Cbp E 
Cbp G 
Cbp F 
Cbp E 
Cbp G 
 Inhibits LytC and regulates pneumococcal autolysis (Molina et al., 2009) 
CbpE mutants show a decreased adherence to the nasopharynx  
CbpG, a putative serine protease is involved in sepsis and mutants show a decreased 
adherence to the nasopharynx (Gosink et al., 2000)  
Hyaluronidase Hyl Surface 
(secreted) 
Hydrolyses hyaluronic acid into monosaccharides (Rapport et al., 1951) 
Increases rate of meningitis when co-administered in a murine intranasal infection 
(Zwijnenburg et al., 2001) 
Augments PLY-mediated damage of human ciliated epithelium (Feldman et al., 2007) 
Acetylated vitamin C derivatives selectively inhibit Hyl (Spickenreither et al., 2006)  
Competitively inhibited by human hyaluronan-binding protein 1 (HABP1) (Yadav et 
al., 2009) 
Neuraminidase A 
 
 
 
 
 
 
NanB 
NanC 
Nan 
 
 
 
 
 
 
NanB 
NanC 
Surface 
exposed 
Increased clearance of NanA mutant from middle ear of chinchilla model (Tong et al., 
2000) 
Forms biofilm in an in vitro model with human epithelial cells and in vivo in a 
chinchilla AOM model (Parker et al., 2009; Reid et al., 2009) 
Exogenous administration of NanA in a colonisation model increase counts in 
nasopharynx and favoured translocation to the lungs (Trappetti et al., 2009) 
Promotes adherence of the pneumococcus to the BBB and in an in vitro model 
(Uchiyama et al., 2009) 
Desialylates host proteins to evade clearance mechanisms and contributes a 
protease-independent mechanism to enhance survival (King et al., 2004) 
Present in 96% of isolates (Pettigrew et al., 2006) and a NanB mutant persists in the 
nasopharynx but does not increase in number (Manco et al., 2006)  
Present in 51% of isolates (Pettigrew et al., 2006) 
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Hydrogen peroxide H2O2 Produced 
during 
aerobic 
growth 
Slows ciliary beat and causes epithelial damage (Feldman et al., 2002) 
Inhibits/kills other bacterial species competing to colonise the nasopharynx (Pericone 
et al., 2000) 
Pili RrgA, RrgB, 
RrgC 
Attached 
to cell 
wall via 
sortases 
and 
extends 
beyond 
CPS 
Initial adhesion to host cells and important for ability to invade host (Barocchi et al., 
2006) 
Backbone of pilus provided by RrgB and assembled by sortase 1, with RrgA and C 
acting as accessory proteins (Manzano et al., 2008) 
Pneumococcal 
surface adhesin A 
PsaA Surface Transport of Mn2+ and Zn2+ ions into the bacterial cytoplasm (Jedrzejas, 2001; 
Johnston, 2004) 
Up-regulated in transparent phenotype cells attached to epithelia and down-
regulated in opaque phenotype cells in supernatent of a pressurised middle ear 
model (Li-Korotky et al., 2009) 
Pneumococcal 
surface protein A 
PspA Surface Inhibition of C3 complement activation and deposition (Miyaji, 2002; Ren et al., 2004; 
Yuste et al., 2005) 
Decreases immune adherence to erythrocytes by inhibition of C1q binding and 
deactivation of the classical-pathway-mediated C3 deposition (Li et al., 2007) 
Pneumolysin 
 
PLY 
 
Cytoplasm 
 
Cytolytic at high concentrations (Boulnois, 1992) 
Cytotoxic at lower concentrations (Boulnois, 1992) 
Inhibition of ciliary movement and disruption of epithelium (Feldman, 1990; Rubins 
JB, 1993) 
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Pneumolysin cont. PLY Cytoplasm Inhibition of bactericidal activity of PMN (Paton, 1983a) 
Inhibition of lymphocyte proliferation (Ferrante, 1984) 
Inhibition of antibody synthesis (Ferrante, 1984) 
 
Interleukin-1 and tumour necrosis factor- production by monocytes 
increased(Houldsworth et al., 1994) 
Activates classical complement cascade by binding of Fc fragment of antibody 
resulting in inflammation of host tissues (Paton et al., 1984; Mitchell et al., 1991).  
Depletion of serum opsonic activity by activation of complement (Mitchell & Andrew, 
1997), 
PLY-/- strain attenuated in intraocular model of endophthalmitis (Ng et al., 2002) 
Pyruvate oxidase SpxB Cytoplasm Up-regulated in transparent phenotype and down-regulated in opaque phenotype 
cells in supernatent of a pressurised middle ear model (Li-Korotky et al., 2009) 
Extremely high mRNA transcript expression in nose compared with the lungs and 
blood of infected mice (Mahdi et al., 2008) 
Caseinolytic 
protease C 
 
Clp P 
ClpC 
 
ClpP 
Cytoplasm Required for release of LytA and PLY in vitro. 
Required for growth of pneumococcus in lungs and blood of murine model. Does not 
affect overall outcome of disease (Ibrahim et al., 2005) 
Required for maintenance of virulence in response to elevated temperatures and 
oxidative stress (Ibrahim et al., 2005) 
Streptococcal 
lipoprotein 
rotamase A 
SlrA Surface Functional, cyclophilin type peptidyl-prolyl isomerase that contributes to colonisation 
by reducing uptake by professional phagocytes (Hermans et al., 2006) 
Pneumococci lacking SlrA were severely impaired in a novel AOM model (Stol et al., 
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2009) 
Pneumococcal 
adhesion and 
virulence protein A 
PavA Surface Binds to immobilised human fibronectin and is attenuated in a sepsis model (Holmes 
et al., 2001) 
Zinc 
metalloprotease B 
ZmpB Surface Induces tumour necrosis factor  and lung inflammation in murine pneumonia model 
(Blue et al., 2003) 
Pneumococcal 
histidine triad 
protein D 
PhtA 
PhtB 
PhtE 
PhtD 
 
PhtA 
PhtB 
PhtE 
Surface Deletion of all Pht proteins is required to abolish virulence, relative to wild type, due 
to functional redundancy and it is required for inhibition of complement through 
binding of Factor H (Ogunniyi et al., 2009) 
 
Pht proteins contain histidine triad motifs capable of binding zinc, which is scarce in 
the nasopharynx and it is binding of zinc, rather than other divalent cations, causes a 
change in conformation that changes the pattern generated through trypsin digestion 
(Horsham, 2009) 
Pht proteins provide protection against sepsis (Adamou et al., 2001) 
Pneumococcal iron 
acquistion protein 
A 
PiaA Surface Lipoprotein component of pneumococcal iron ABC transporter and is required for full 
virulence in mouse model. 
100% conserved and absent from oral streptocci (Whalan et al., 2006) 
Pneumococcal iron 
uptake protein A 
PiuA Surface Lipoprotein component of pneumococcal iron ABC transporter and is required for full 
virulence in mouse model. 
Highly conserved (0.3% variation) conserved but also present in other oral streptocci 
(Whalan et al., 2006) 
Highly protective but via opsonophagocytosis, rather than inhibition of iron transport 
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(Brown et al., 2001; Jomaa et al., 2005; Whalan et al., 2005; Jomaa et al., 2006) 
Putative proteinase 
maturation protein 
A 
PpmA Surface PpmA deficient cells are phagocytosed in a strain dependent manner and are less 
capable of persisting in the nasopharynx of mice (Cron et al., 2009) 
Pneumococcal 
collagen-like 
protein A 
PclA Surface? Found by analysis of sequenced genomes in selected strains as part of two open 
reading frames. The other coded for a transcriptional regulator. Analysis of clinical 
isolates found in 39% of the strains examined. Deletion mutants were unattenuated in 
a pneumonia model but were defective in adherence in vitro (Paterson et al., 2008) 
Plasmin- and 
fibronectin-binding 
protein 
PfbA Surface Identified due to LPXTG. Mutants attenuated in adhesion. Caused morphological 
changes in epithelial cell lines that did not occur with wild type cells. Anti-PfbA 
antibodies inhibited growth in whole blood culture (Yamaguchi et al., 2008) 
Protein required for 
cell wall separation 
of group B 
streptococcus 
PcsB Surface Underexpression of PcsB created a cell separation defect, causing the cells to form 
chains with excess but ordered cell wall synthesis at every cell equator and septum 
(Barendt et al., 2009) 
Severe depletion led to rapid cessation of growth accompanied by the appearance of 
aberrantly shaped cells with unusual regions of cell wall synthesis (Ng et al., 2004) 
High temperature and osmolarity leads to an increase in expression (Mills et al., 
2007) 
Serine/threonine 
protein kinase 
StkP Cell 
membrane 
associated 
Highly conserve protein that contributes to penicillin sensitivity independently from 
genes encoding penicillin-binding proteins (Dias et al., 2009; Osaki et al., 2009) 
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1.5.1 Capsule 
The capsular polysaccharide of S. pneumoniae is a major virulence factor that 
enables the bacteria to evade and resist phagocytosis (Wood & Smith, 1949; 
Macleod & Krauss, 1953; Jonsson et al., 1985; Gordon et al., 2000). 
Unencapsulated strains have are greatly reduced in virulence and are rarely 
recovered from invasive disease. Immunocompromised hosts are prone to 
infections with unusual opportunistic pathogens that would not affect an 
immunocompetent host. Unencapsulated pneumococci are capable of infecting 
these compromised hosts. Pneumococci recovered from eye infections are 
frequently unencapsulated (Martin et al., 2003; Crum et al., 2004). 
Changes in colony morphology from transparent to opaque are due to thickening 
of the capsule. Opaque colonies are usually recovered from the blood while 
transparent colonies are associated with colonisation. Recently it has been 
shown that colony morphology in the nasopharynx depends on the intimacy of 
the association with host tissues. Nasal colonisation involves two populations of 
pneumococci, a transparent-phase population loosely associated with the nasal 
surface and an opaque population more intimately associated with or within the 
nasal mucosa and submucosa. Transparent colonies are readily removed by nasal 
washing, whereas opaque colonies are isolated from homogenised nasal tissues 
(Briles et al., 2005; Dawid et al., 2009). These morphologies are thought to be 
reversible and aid in transition from carriage to invasive disease 
(Hammerschmidt et al., 2005). 
1.5.2 Pili 
Capsule has long been thought of as the initial point of contact of the 
pneumococcus with host cells. However, pneumococci were shown to possess pili 
that protrude beyond the capsule polysaccharide and are responsible for initial 
adhesion to host cells Barocchi et al following genomic comparisons with other 
Streptococcal spp. (Barocchi et al., 2006). Introduction of the pilus islet rlaA 
into encapsulated rlaA-negative pneumococcal strains permitted pilus 
expression, enhanced adhesion to lung epithelial cells in vitro and gave a 
competitive advantage upon mixed intranasal challenge in mice. The pilus islet 
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is carried in a minority of pneumococcal isolates from IPD in humans 
(approximately 27%) and carriage of the islet is a clonal property of pneumococci 
(Aguiar et al., 2008). A second pilus islet was identified from the genome of 
INV104, a publicly available sequenced serotype 1 strain, by virtue of its 
organisation in comparison with the pilus-encoding island of Streptococcus 
pyogenes. It was shown to be present in 16.4% of their S. pneumoniae collection, 
and interestingly both islets were present in the ST271 clonal complex (Bagnoli 
et al., 2008). More recently, the odds of co-colonisation with S. aureus was 
shown to be lower for individuals carrying a piliated S. pneumoniae strain 
(Regev-Yochay et al., 2009). 
1.5.3 Cell wall and surface exposed proteins 
The pneumococcal cell wall (CW) is crucial to the display of an array of surface-
associated virulence factors and is intimately involved in the attachment of the 
bacterium to host epithelial cells. The cell wall is a potent inducer of 
inflammation and challenge with cell wall components can reproduce many of 
the symptoms of pneumonia (Tuomanen et al., 1987), otitis media (Ripley-
Petzoldt et al., 1988; Carlsen et al., 1992; Tuomanen, 2000; Hoffmann et al., 
2007) and meningitis (Riesenfeld-Orn et al., 1989; Tuomanen, 1996; Hoffmann et 
al., 2007) in experimental models. It is composed of peptidoglycan with teichoic 
acid attached to acetylmuramic acid residues. Lipoteichoic acid is attached the 
cell membrane by a lipid moiety. Both forms of teichoic acid contain 
phophorylcholine that has been shown to be responsible for binding the choline 
binding domains of many pneumococcal proteins.  
There are three main groups of surface-exposed proteins within the 
pneumococcus: LPXTG-anchored proteins, lipoproteins and choline-binding 
proteins. Strains vary in the proportion of these surface proteins at the genomic 
level as determined by sequencing and signature tagged mutagenesis screens 
(Polissi et al., 1998; Lau et al., 2001; Hava & Camilli, 2002). Some of these are 
illustrated in below: 
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Figure 1-1 Summary of the main virulence factors of S. pneumoniae.  
From (Mitchell, 2003). ABC, ATP-binding cassette; PavA, pneumococcal adhesion and 
virulence A; PsaA, pneumococcal surface antigen A; Psp, pneumococcal surface protein. 
1.5.3.1 LPXTG proteins 
LPXTG proteins are attached to peptidoglycan in the cell wall via sortases. 
Different sortases are involved in processing and attaching the different surface-
exposed proteins (Paterson & Mitchell, 2006). Neuraminidase A (NanA) and 
hyaluronidase (Hyl) are two well-characterised examples of LPXTG-anchored 
proteins. Neuramindases cleave the terminal sialic acid from polysaccharides, 
such as glycolipids, glycoproteins and oligosaccharides, on the cells of the host. 
Desialylation of host airway components including human lactoferrin, secretory 
component and IgA2 deposited on the surface of the pneumococcus inhibits 
clearance and promotes survival and adhesion (Tong et al., 2002; King et al., 
2004; King et al., 2006; Uchiyama et al., 2009). Hyl degrades hyaluronic acid, a 
key component in mammalian connective tissue and extracellular matrix thereby 
promoting invasion of epithelial layers (Paton et al., 1993; Feldman et al., 
2007).  
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1.5.3.2 Lipoproteins 
Surface exposed lipoproteins are involved in transport of metal ions, sugars and 
other small molecules. These include pneumococcal surface adhesin A (PsaA), 
substrate binder for the manganese transport system (Dintilhac et al., 1997; 
Rajam et al., 2008), pneumococcal iron uptake protein A (PiuA) and 
pneumococcal iron acquisition protein A (PiaA) (Jomaa et al., 2005; Whalan et 
al., 2005; LeMessurier et al., 2006; Whalan et al., 2006), streptococcal 
lipoprotein rotamase A (SlrA) involved in colonisation of the host and AOM 
(Hermans et al., 2006; Stol et al., 2009) and putative proteinase maturation 
protein A (PpmA) involved in pneumococcal pneumonia (Cron et al., 2009). 
1.5.3.3 Choline-binding proteins 
Choline-binding proteins (CBP) possess carboxy terminal repeat regions that non-
covalently anchor the protein to the phosphorylcholine of the cell wall. Four to 
five repeats are usually sufficient to mediate binding to choline. Pneumococci 
possess 13 to 16 different choline-binding proteins including choline binding 
protein A (CbpA, also known as pneumococcal surface protein C), pneumococcal 
surface protein A (PspA), and the autolysins (LytA, N-acetyl-muramoyl-L-alanine 
amidase; LytB, -N-acetylglucosaminidase and LytC, -N-acetylmuramidase) 
(Bergmann & Hammerschmidt, 2006). The non-CBP domain located at the N 
terminus in most cases is responsible for the functional activity of each CBP.  
1.6 Pneumolysin as a novel mucosal adjuvant 
Libman first described pneumolysin (PLY) in 1905. It was known as one of the 
thiol-activated toxins produced by bacteria, as it was toxic and susceptible to 
oxidation, and irreversibly inactivated by cholesterol. However, this description 
is now considered inappropriate and the group is now known as the cholesterol-
dependent cytolysins (CDCs). The CDCs are produced by a large number of 
bacterial species and, with the exception of PLY, are secreted toxins (Johnson, 
1977). However, it has been shown that secretion of the toxin may occur in the 
absence of autolysin and during the exponential growth phase (Balachandran, 
2001). Use of pneumolysin in vaccination studies date back to 1983 when PLY 
was first utilised in protection studies (Paton, 1983b). Expression of PLY in either 
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Escherichia coli or S. pneumoniae resulted in toxins with identical haemolytic 
activity. Growing large volumes of pathogenic bacteria poses health and safety 
risks and so the gene was sequenced and cloned preferentially into E. coli strains 
for expression (Paton, 1986; Walker, 1987; Mitchell et al., 1989). However, 
expression of proteins in pneumococcal strains has experienced a resurgence in 
recent years as it avoids the Gram negative problem of contaminating LPS in 
purified protein preparations.  
1.6.1 Structure of pneumolysin 
Pneumolysin is a single 53-kDa protein that is expressed by virtually all serotypes 
of S. pneumoniae (Paton, 1983b; Kanclerski, 1987). Some serotypes express a 
mutant forms that are non-haemolytic but antibodies to wild type PLY can cross-
react with them (Kirkham, 2006). A crystal structure for PLY has not been 
elucidated and much information about its structure and activity has been 
extrapolated from the X-ray structure of perfringolysin O (PLO), a CDC from 
Clostridium perfringens (Rossjohn et al., 1997). PLY shares 42% amino acid 
sequence homology and 48% nucleotide sequence homology with PLO (Tweten, 
1988). PLO has been shown to consist of four domains, rich in -sheets, and to 
form dimers in solution. It is suggested that this prevents untimely pore 
formation before membrane binding (Gilbert, 2005). In contrast, PLY does not 
form dimers in solution (Solovyova et al., 2004), but it is capable of 
oligomerisation in solution over time (Gilbert et al., 1998; Gilbert, 1999; 
Solovyova et al., 2004). A schematic model for the layout of the domains of the 
CDCs can be seen in Figure 1-2 below. 
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Figure 1-2 Crystal structures of ILY (Polekhina et al., 2005) (left) and PFO (Rossjohn et al., 
1997) (centre).  
A schematic diagram (right) indicates the layout of the four domains of the CDCs 
(reproduced with kind permission of Dr. Graeme Cowan). 
The mechanism of pore formation by the CDCs remains largely controversial 
despite years of study. There are several models of pore formation that range 
from assembly of the high molecular weight pore by addition of monomers 
inserted into the membrane to assembly of the complete ring as a pre-pore 
followed by insertion into the membrane. 
A number of the finer points remain uncertain and are discussed here. 
1.6.2 Binding 
The initial event in the mode of action is binding to the cell membrane. 
Cholesterol inhibition of haemolysis has been known for some time now 
(Johnson, 1972) and it has also been shown that CDCs are capable of binding to 
artificial membranes containing cholesterol (Ohno-Iwashita, 1991). ILO is also 
capable of binding to CD59, and it is possible that other CDCs also have this 
property (Giddings et al., 2004). Giddings et al, 2003 demonstrated that 
cholesterol depletion of erythrocyte membranes did not prevent binding and 
oligomerisation of PLY, PFO or ILY but prevented insertion of the toxins into the 
membrane (Giddings et al., 2003). This suggests that the role of cholesterol is 
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not in the initial binding step but it is involved in insertion of the pore into the 
membrane, required for a second binding step, to enable conformational change 
or to maintain membrane fluidity. It therefore seems plausible that although in 
artificial systems cholesterol is sufficient for pore formation, this may not be the 
case in whole cell systems. 
1.6.3 Oligomerisation and pore formation 
The current model involves a process that is outlined over the page. Briefly, 
monomers move transiently through the membrane and join up with other 
monomers to form pre-pores with a varied number of subunits. Then, an 
unknown force induces the conformational change in domain 3 causing the two 
helices to form a -hairpin and insert into the membrane. This causes the entire 
pore to collapse vertically into the membrane with a loss of ~30Å in height due 
to the conformational change of domain 2. 
 
Figure 1-3 Prevailing prepore model for formation of functional pores (Tilley et al., 2005). 
(A) View of six fitted subunits showing the pore lining. (B) Overlay of prepore and pore 
structures, with the domains colored (D1, blue; D2, green; D3 red; D4 yellow). The cross-
section of one side of the pore structure was rotated by 13° in order to bring the membrane 
bilayers into register and allow comparison of the protein subunit conformational changes 
relative to the membrane surface. Green arrow indicates direction of movement from the 
extended to the bent conformation. 
The described process above is the current prevailing model. However, it fails to 
explain a number of discrepancies in the data. In electron micrographs of toxin-
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treated erythrocyte membranes, arcs of toxin are clearly visible, in addition to 
the normal ring-shaped structures. A study on PLY-induced channels revealed a 
difference in functionality of wild-type toxin versus the mutant (Korchev, 1992). 
The wild type toxin created small and medium sized channels that displayed 
cation selectivity and the mutant only created large channels. In addition to 
large, circular pores, the „gated‟ personality of the small and medium channels 
might be explained if the arcs had inserted into the membrane and created a 
pore that had a lipid boundary.  
In the study by Czajkowsky et al, 2004, atomic force microscopy was used to 
visualise the collapse of the pores into the membrane and the change in height 
that accompanied this collapse. Arcs are clearly visible in the images and the 
difference in height from the membrane is approximately 73Å and not the 113Å 
of the pre-pore height. The arcs are only mentioned in the figure legend and 
their relevance is not discussed (Czajkowsky et al., 2004). Palmer et al, 1998, 
proposed another model where oligomerisation and pore formation happens 
simultaneously, and monomers joined oligomers sequentially until a full pore is 
formed. This does not account for the un-inserted arcs and pre-pores seen and is 
in direct conflict with the pre-pore model (Palmer, 1998). 
A hybrid model like that proposed by Gilbert et al accounts for many of the 
discrepancies seen in the pre-pore model and is outlined in Figure 1-4 below 
(Gilbert, 2002). Briefly, monomers bind to the membrane and begin 
oligomerisation. However, insertion and pore formation does not rely on the 
pore being complete and arcs can also insert. This model also allows for the 
double arc features seen in electron micrographs. 
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Figure 1-4 Hybrid model for functional pore formation that explains the presence of arcs.  
Adapted from (Gilbert, 2002). (A) is currently the prevailing model, where only full pores 
insert after formation of a pre-pore. (B) is that proposed by Palmer et al, and in this case, the 
nascent CDC oligomer forms a pore when still an arc and, in that state, increases in size. 
The result is a mixture of protein-only and protein-lipid pores. (C) is the Gilbert et al hybrid 
and there are two oligomeric states, pre-pore and pore; however, the moment of transition 
depends on factors other than the completeness of the oligomeric ring. This model allows 
for double-arc pores, as shown, but it is consistent with prepore formation. 
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1.7 Pneumococcal surface adhesin A as a sample fusion 
A region of PsaA was chosen that lacked the signal peptide to ensure that it 
would be possible to purify. PsaA had previously been shown to protect against 
colonisation (Briles et al., 2000a; Briles et al., 2000b; Palaniappan et al., 2005). 
PsaA, along with PLY, appear to have the most potential as vaccine candidates 
as they are highly immunogenic in animal models and are conserved across the 
serotypes (Paton et al., 1983; Talkington et al., 1996; Briles et al., 2000a; 
Ogunniyi et al., 2001). As previously mentioned, combinations of pneumococcal 
proteins would be desirable in a vaccine to protect the host against different 
stages of infection and to ensure complete coverage of the serotypes. Delivery 
as a fusion to the mucosal surface would induce antibodies in the location where 
they would be most relevant. Fusion proteins could then be simply combined 
into a single vaccine.  
1.8 Current vaccination strategies 
Current S. pneumoniae vaccines are based on the use of the bacterial capsular 
polysaccharide (CPS), which induce serotype-specific antibodies that activate 
and fix complement and promote bacterial opsonisation and phagocytosis by 
immune cells (Plotkin, 2008). The two types of currently licensed vaccine are 
the pneumococcal capsular polysaccharide (PPV), based on purified CPS, and 
pneumococcal conjugate vaccines (PCV), obtained by chemical conjugation of 
CPS to a carrier protein (Chu et al., 1983). 
1.8.1 23-valent polysaccharide vaccine (PPV23) 
The PPV23 vaccine was licensed in 1983 and contains 25 g of serotypes 1, 2, 3, 
4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F 
and 33F. These serotypes account for 90% of IPD in industrialised countries. Two 
are currently available on the market. Pneumovax 23™ is marketed by Merck and 
Pneumo 23™ is marketed by Sanofipasteur. Following a single intramuscular 
injection good seroconversion is seen in 60-80% of adults and children over the 
age of 2. Vaccination of children between 2 and 5 years of age saw protection 
against IPD caused by vaccine serotypes of 62% (Fiore et al., 1999). It is 
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recommended for solid organ transplant recipients and elderly people over 65 
years old. Vaccination of the latter group in Scotland during winter 2003/2004 
resulted in a decrease in IPD of one third, consistent with results from other 
developed countries (Mooney et al., 2008). Despite this, a recent meta-analysis 
has shown little or no evidence that the PPV23 vaccine protects against 
pneumonia in adults (Huss et al., 2009). There is also evidence that vaccination 
with PPV23 results in protective immunity of shorter duration than in younger 
adults (Simell et al., 2008) and that boosting with PPV23 depletes sensitised B-
cells and may induce long-lived T regulator suppressor cells (Musher et al., 
2008). 
However, PPV23 is only efficacious in adults and children over two years of age. 
Children under two are unable to mount an appropriate immune response to a 
purely polysaccharide vaccine.  
1.8.2 7-valent pneumococcal conjugate vaccine (PCV7) 
In the UK vaccination schedule the PCV7 vaccine, also known as Prevnar, is used 
in the prevention of IPD in children under two. In the USA it is known as 
Prevenar™ and is marketed by Wyeth. PCV7 consists of capsular polysaccharide 
from serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, individually chemically 
conjugated to CRM147, a detoxified diptheria toxin. The conjugation of protein 
to polysaccharide results in a T-cell dependent response. Rather than entering 
the polysaccharide pathway, it is instead processed like a protein antigen.  
Introduction of the PCV7 vaccination to the childhood schedule in the USA in 
2000 resulted in a decrease in IPD from 97 cases/100,000 to 24 cases/100,000 in 
2005; disease caused by vaccine serotypes fell from 80 cases/100,000 to 4.6 
(Mahon et al., 2006). A significant decrease in AOM and bacterial rhinosinusitis 
was also noted (Fletcher & Fritzell, 2007; Benninger, 2008). Protection from IPD 
and clinical pneumonia in HIV-infected infants was also observed (Bliss et al., 
2008). Individuals over 65 also benefited from the welcome side effect of herd 
immunity. Interruption of transmission of vaccine serotypes in children by 
vaccination resulted in fewer IPD episodes in their grandparents, a decrease of a 
third (McBean et al., 2005).  
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In the USA, Prevnar costs $71.04/dose in state funded programmes and 
$83.88/dose in the private sector. For a four dose regime in the state and 
private sectors this is equal to $284.16 and $335.52 respectively (CDC, 2009). In 
2006 the GAVI Alliance (formerly the Global Alliance for Vaccines and 
Immunisations), an organisation that coordinates private and public spending to 
create global access to vaccines, made funding available through to 2015 for 
PCV7 introduction into 72 countries with the lowest gross per capita income 
(<$1000 per year). The prices paid in the USA are unaffordable to these 
countries. To complement the financial support of the GAVI Alliance, a new 
mechanism called the Advance Market Commitment (AMC) has been established. 
This is a binding contract from developed nations that guarantees vaccine 
makers a viable market for next-generation PCV and ensures a stable and cost 
effective supply for low-income countries (2008). As shown by Sinha et al., 2007, 
at a vaccine cost between $1 and $5, purchase and accelerated uptake of 
pneumococcal vaccine in GAVI-eligible countries is projected to be cost 
effective, substantially reduce childhood mortality and make a substantial 
contribution towards achieving the United Nations Millennium Development Goal 
4, which seeks to reduce mortality in children under 5 by 66% by 2015. 
However, replacement disease or serotype replacement has already been 
observed. From 2004, a 96% decrease in vaccine serotypes was matched by a 
141% increase in non-vaccine serotypes in Alaska Native children in the presence 
of high levels of PCV7 coverage. 28.3% of the increase in non-vaccine related 
serotypes was due to 19A (Singleton et al., 2007). This was a predictable 
outcome, as the clearance of the most prevalent serotypes from their 
commensal niche would leave space for other serotypes to increase in 
importance. 40% of AOM isolates in a study in Rochester, New York, during 2004-
2006 expressed the 19A capsule. Eight different molecular STs expressed the 19A 
capsule; most of the strains were multi-drug resistant. In the case of ST-2722, it 
was resistant to all Food and Drug Administration (FDA)-approved AOM anti-
microbials (Pichichero & Casey, 2007; Xu et al., 2009). Phase three clinical trials 
are currently underway to assess the efficacy of a 9 and 11-valent vaccine 
respectively to increase coverage of the vaccine in countries such as the USA and 
the UK. Increasing the valency of the parental vaccines is unlikely to be a 
strategy that can be pursued long term, as an increase in valency will lead to a 
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increase in cost, and it does not solve the issue of serotype replacement. A more 
promising strategy would be to investigate the application of serotype 
independent protein based vaccines, using immunogenic antigens capable of 
conferring protection from IPD and non-invasive disease.  
1.9 Potential candidates for the next generation of 
pneumococcal vaccines 
The use of conserved protein antigens for the next generation of pneumococcal 
vaccine should confer broad serotype-independent protection against 
pneumococcal disease in all age groups. Recombinant protein vaccines are 
cheaper than the PPV23 and PCV7 vaccines, making protein-based vaccines 
globally accessible. Table 1-1 lists many of the known surface-exposed 
pneumococcal virulence factors that are candidates for inclusion in the protein-
based vaccine. Opsonophagocytosis of the pneumococcus is the principal 
mechanism of clearance from host tissues. Antibodies raised against surface-
exposed proteins are likely to be protective if they promote opsonophagocytosis. 
However, surface-exposed proteins are subject to selective pressure from the 
host immune system and tend to be variable between serotypes. Cytoplasmic 
proteins are more conserved as they are protected from such environmental 
bombardment. Combinations of protein antigens have been shown to provide a 
synergistic effect that was more than the sum of its parts (Brown et al., 2001; 
Jomaa et al., 2006; Ogunniyi et al., 2007). Other considerations in rational 
vaccine design are the expression of pneumococcal virulence factors during the 
process of disease. Although a virulence factor may not be involved in 
colonisation and adherence, it may still be a valid vaccine candidate if it 
mitigates IPD. For example, in Table 1-2 below, PspC has the dual property of 
promoting colonisation and invasion of the CSF. Vaccination would therefore 
neutralise both of these properties. 
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Table 1-2 Relative contributions of pneumococcal virulence determinants to the 
establishment of an infection and its spread from one anatomical compartment to another.  
Summarised from Oriheula and colleagues (Oriheula, 2004).
 
 Virulence determinantsb 
Contribution to: PspC NanA SpxB LytA PLY 
Prolonged nasopharyngeal colonisation Y     
Transition to lower respiratory tract Y Y    
Bacterial replication in lung   Y Y Y 
Translocation to lung   Y Y Y 
High-titre replication in the blood    Y Y 
Invasion of the cerebrospinal fluid Y Y    
b PspC, pneumococcal surface protein C; NanA, neuraminidase A; SpxB, pyruvate 
oxidase B; LytA, autolysin A; PLY, pneumolysin. 
As can be seen from Table -2, transitions between body sites require distinct 
virulence determinants from those involved in organ-specific replication. 
Depending on the requirements of vaccination, further studies like this would 
elucidate the most appropriate points at which to induce either humoral or cell-
mediated immunity. 
1.10 Novel adjuvant strategies 
The induction of protective immunity at the mucosa surface is difficult. The 
route is a relatively simple one to administer, but few protein antigens are 
immunogenic when administered without adjuvants. To date, most mucosal 
adjuvants have been based on bacterial toxins such as Tetanus Toxin from 
Clostridium tetani, Cholera Toxin (CT) from Vibrio cholerae or Labile Toxin (LT) 
from Escherichia coli. These toxins and their toxoids are tolerated in parental 
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vaccines such as Prevnar. Vaccine manufacturers have reason to be cautious at 
the prospect of using toxins in an intranasal vaccine. In Switzerland in 2000-2001 
an intranasal vaccine against influenza was introduced that utilised LT as an 
adjuvant. Shortly afterwards physicians began to notice an increase in Bell‟s 
palsy, a paralysis of the facial nerves. The LT was found to bind to the olfactory 
bulb in the nasopharynx and travel in a retrograde action to the facial nerves. 
The relative risk of Bell‟s palsy in vaccines was estimated to be 19 times that of 
control patients. (2004b; Couch, 2004; Mutsch et al., 2004; Zhou et al., 2004; 
Stowe et al., 2006; Chou et al., 2007; Lewis et al., 2009) This vaccine was 
swiftly withdrawn and all toxin-based vaccines were treated with greater 
caution.  
Despite these difficulties, toxins and their detoxified versions (whether 
chemically or genetically) are fantastic at stimulating an immune response. They 
are attractive as small quantities are required to behave as an adjuvant. PLY has 
a number of advantages over other protein antigens. It can bind to cell 
membranes and potentiate an immune response. Antibodies to PLY are produced 
during carriage and acute otitis media infection (Rapola et al., 2000; Rapola et 
al., 2001; Simell et al., 2001; Baril, 2004; Garcia-Suarez Mdel et al., 2004; Huo 
et al., 2004; Laine et al., 2004; Holmlund et al., 2005),  and human anti-PLY 
antibodies passively protect mice from challenge. Although there are alleles of 
the pneumolysin gene, these do not preclude serotype independent protection. 
Anti-carrier protein antibodies have been shown to suppress subsequent 
responses to conjugates in mice (Peeters, 1991) as well in humans (Barington, 
1993), and the effect has been attributed to FcRII-mediated inhibition of 
antibody production. PLY has not yet been applied as a carrier protein and so 
would not encounter this inhibition. Use of PLY at the same concentration as 
other toxoids previously used (such as cholera and tetanus toxoids) resulted in 
hypothermia, clinical symptoms and morbidity of mice within half an hour 
(Douce, 2005). Clearly for human vaccines such toxicity is desirable. Unlike CT, 
each toxin unit can act independently or in concert to form pores in mammalian 
membranes. PLY is easy to manipulate genetically to ablate both pore-forming 
ability (introduction of a double amino acid deletion, known as ∆6 from Kirkham 
et al., 2005) and complement activation (a single amino acid substitution D385N 
abrogates complement activation as shown in Mitchell et al., 1991). Even with 
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the loss of these activities, recombinant PLY is still capable of activating TLR4, 
suggesting that another region of the molecule is involved (Malley et al., 2003). 
It should be possible to elucidate what regions of PLY are responsible for each of 
the activities documented in Table 1-1, and therefore reconstruct a form of PLY 
that is capable of only generating a response that is immunogenic, rather than 
damaging to the host.  
A serendipitous discovery was made in our laboratory when it was discovered 
that PLY could act as a mucosal adjuvant, but only when it was genetically fused 
to its partner protein. Unlike other bacterial toxins, a bystander effect was not 
observed. There was considerable interest in using an immunologically relevant 
antigen as a fusion to PLY as a means of generating antibodies that could provide 
protection from IPD.  
1.11 In vivo models of S. pneumoniae pathogenesis 
1.11.1 Acute otitis media 
Animal models are considered essential for studying the common pathogens of 
AOM, the role of pathogen-specific immune responses and testing strategies for 
vaccination against this disease in humans. Doyle (1989) established the criteria 
for an organism to be considered pathogenic in a particular model: (1) the 
organism induces similar pathologies to those in patients with the disease; (2) 
the pathologies can be objectively documented; and (3) the organism is shown 
to reproduce in the same anatomical location. Current models of S. pneumoniae 
are summarised in Table 1-4 below. 
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Table 1-3 Summary of animal models of AOM.  
Adapted from (Sabirov & Metzger, 2008) 
Animal species Chinchilla Gerbil Guinea pig Rat Mouse 
Pathogen recovery frequency (%) >90 >90 100% >90 100% 
Pathogen frequency (%) >90 >90 70 >90 100 
Inbred strains - + + ++ +++ 
Genetic mutant models - - - + +++ 
Experimental reagents - + ++ +++ +++ 
Naturally occurring AOM - + +++ ++ + 
Cost +++ + ++ + + 
Key - absent; + to +++, minimal to highly significant. 
Various rodent models have been used in the study of AOM. The large bulla 
present in chinchillas (Giebink et al., 1980; Fulghum & Marrow, 1996; Ehrlich et 
al., 2002) and gerbils (Fulghum & Marrow, 1996; Parra et al., 2004) is easily 
accessible for inoculation through the overlying skin and for repeated sampling 
of middle ear fluid. Chinchillas are susceptible to many human pathogens and it 
is possible to induce AOM following colonisation of the nasopharynx. However, 
the unique S shape of the auditory canal makes it difficult to examine and 
challenge via the tympanic membrane route. In rats (van der Ven et al., 1999; 
Fogle-Ansson et al., 2006), mice (Krekorian et al., 1990; Melhus & Ryan, 2003; 
Ryan et al., 2006; Sabirov & Metzger, 2008) and guinea pigs (Ryan & Bennett, 
2001) the structural features are very similar but they have much smaller bulla 
than chinchillas and gerbils. Induction of AOM in these species requires 
inoculation via the tympanic membrane or through surgical exposure of the 
inferior bulla. All of these routes of infection require the injection of inoculum 
into the site of interest. This does not mimic the natural route of infection and 
the process of injecting inoculum causes physical disruption to the middle ear 
that may interfere with the course of infection.  
One animal that is being increasingly used is the mouse, due to the ease of 
manipulation, availability of genetic mutants and experimental reagents for 
advanced protocols and lower cost. More recent mouse models of AOM have 
attempted to infect the middle ear in a more natural manner. (McCullers et al., 
2007) intranasally infected mice with a piliated 19F S. pneumoniae strain that 
Chapter 1  58 
 
 
caused AOM in approximately 70% of naïve mice before stably colonising the 
nasopharynx. Subsequent infection of colonised mice with influenza virus led to 
recurrent AOM in 63% of mice. Both de novo and recurrent AOM episodes were 
seen in the virus infected mice. An ideal AOM model would involve intranasal 
colonisation with any strain of pneumococcus and then establish AOM in 100% of 
mice infected. A model capable of achieving this was discussed by Dr. Kim Stol 
at the 6th International Symposium on Pneumococci and Pneumococcal Diseases 
in Iceland in June 2008 and was recently published (Stol et al., 2009). Mice are 
intranasally inoculated with pneumococci while under anaesthesia and then 
allowed to recover in a cabinet where air pressure is increased stepwise to 40 
kPa. This translocates the bacteria from the nasopharynx to both middle ears 
when the mouse swallows to equalise pressure. This model has the advantage of 
being non-invasive, mimics the natural route of infection, is relatively simple to 
use and does not require pre- or post-infection with other organisms to establish 
disease. It also allows for quantification and histology to be performed on 
matched samples. 
1.11.2 Invasive pneumococcal disease 
Models of pneumococcal disease can be used for assessing the host response, 
identifying virulence genes, or determining the efficacy of vaccines and 
pharmaceuticals. Table 1-6 below illustrates the wide range of animals used in 
the investigation of IPD. However, due to ease of genetic manipulation, low cost 
and availability of ex vivo reagents, the mouse has become the model of choice 
for IPD. It is notoriously difficult to directly compare experiments as outcome is 
reflected by the choice of animal strain, bacterial strain and route of challenge 
used, even using the same protocol.  
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Table 1-4 Summary list of animal models used to model IPD.  
Adapted from (Orihuela, 2006) 
Species Purpose Reference 
Mouse Pharmokinetics using bioluminescent 
bacteria 
(Francis et al., 2001; 
Kadurugamuwa et al., 
2005b) 
 Pathogenesis of mutants deficient in 
key virulence determinants 
(Orihuela et al., 2004a) 
 Identification of novel virulence 
determinants 
(Hava & Camilli, 2002) 
 Vaccine efficacy (Briles et al., 2003) 
 Therapy/assessment of neuronal 
damage 
(Zweigner et al., 2004) 
Rat Pharmokinetics/antimicrobial efficacy (Bermpohl et al., 2005; 
Gracia et al., 2005) 
 Neuronal damage (Bermpohl et al., 2005) 
 Cirrhosis (Alcantara et al., 2001) 
Chinchilla Nasopharyngeal colonisation/vaccine 
assessment 
(Tong et al., 2005) 
 Viral/S. pneumoniae synergism (Tong et al., 2001) 
Ferret Influenza & S. pneumoniae synergism (Peltola et al., 2006) 
Rabbits Antimicrobial efficacy/meningitis (Ribes et al., 2005) 
 Endocarditis (Pichardo et al., 2005) 
 Pneumonia (Yershov et al., 2005) 
Monkeys Antimicrobial efficacy (Cook et al., 2004) 
 
IPD can be induced by a variety of routes including intranasal (i.n.), 
intratracheal (i.t.), intraperitoneal (i.p.) and intravenous (i.n.). Each model has 
advantages and disadvantages. I.p. is technically the easiest route and, although 
it is not a natural route of infection, it reproducible results in bacteræmia and is 
a test of efficacy of vaccines and antimicrobials. Rodents are especially sensitive 
to i.p. challenge with bacteria. 101 to 103 cfu usually result in morbidity within 
2-3 days. I.v. challenge results in a sepsis model with „seeding‟ to other organs 
within the body. Both i.p. and i.v. routes of infection bypass existing normal 
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barriers to infection, such as the epithelia, and so infective doses are 
correspondingly lower. Challenge via i.n. or i.t. routes result in a broader 
spectrum of disease. I.t. inoculation results in a lobar pneumonia that more 
accurately replicates that seen in human disease (Mitchell, 2009). However, it is 
technically challenging to perform, slow and bypasses any mucosal immunity 
that may exist, unlike i.n. challenge. I.n. challenge can be applied to both 
invasive and colonisation models, depending on the size of the inoculum volume. 
Inoculation of 10 l/dose into a single nare under general anaesthesia will 
remain confined to the nasopharynx and establish colonisation. In 1997, Wu et al 
established with several serotypes that 100% colonisation in adult mice required 
a dose of 107 cfu/10 l volume. 106 cfu/10 l or less resulted in less than 100% 
colonisation (Wu et al., 1997). Inoculation of 50 l will result in inhalation into 
the lungs and the establishment of bronchoalveolar pneumonia (Douce, 2007). 
Some inoculum may be swallowed unintentionally but if anaesthesia is adjusted 
so the reflex response is lost, then this is kept to a minimum. 
1.11.3 Meningitis 
Meningitis is the result of bacterial penetration of the cerebrospinal fluid (CSF), 
either through the cerebral vascular endothelium (Uchiyama et al., 2009) or 
through axonal transport through the nerves in the olfactory bulbs into the brain 
(van Ginkel et al., 2003). It is an occasional complication in experimental i.n. 
models of IPD. However, accompanying bacteræmia complicates analysis.  
Reproducible models of pneumococcal meningitis without concomitant sepsis 
and pneumonia require the instillation of inoculum directly into the cisterna 
magna. This model was established in rabbits by Dacey and Sande in 1974 and 
permitted repeated withdrawals of infected CSF throughout the course of 
infection (Dacey & Sande, 1974). As a model bacterial entry mechanisms are 
ignored but it has proven to be exceptionally valuable in the study of infection in 
the subarachnoid space without the complications of sepsis. The accumulation of 
large numbers of bacteria and leucocytes in the CSF with accompanying 
increases in intracranial pressure and cerebral edema causes neuronal damage 
primarily in the dentate gyrus of the hippocampus. The close parallels of these 
pathological events to those that occur in humans have led to extensive use of 
the model in the study of meningitis. Most antibiotics are very poor at crossing 
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the blood brain barrier (BBB) and so it is a model that permits testing of novel 
pharmaceutical agents against meningitis (Orihuela, 2006).   
1.11.4 Bioluminescent imaging 
Most pneumococcal models currently in use are based on those in sections 
1.11.1-1.11.3 above. However, large numbers of animals must be sacrificed at 
different time points post infection to examine the impact of vaccination or 
pharmaceuticals on pneumococcal disease. Each time point is a separate group 
of animals, therefore there is an increase in group-to-group variation that makes 
data statistically harder to analyse. This then necessitates the use of even larger 
group sizes to compensate. With large group sizes come associated purchasing 
and housing costs, especially in vaccination protocols when animals may be on 
procedure for 10 weeks or more. It also increases the number of animals that 
experience suffering whilst on procedure. Home Office Inspectors in the UK 
encourage the application of the three Rs: Reduce, Refine, Replace. 
To that end, new models have been developed in recent years that exploit 
bioluminescence and fluorescence. Pneumococci can be genetically engineered 
to express fluorescent proteins such as enhanced green fluorescent protein 
(eGFP) or luciferase (Francis et al., 2001). Xenogen Inc., now part of Caliper Life 
Sciences, has produced a number of light emitting organisms that can be used in 
various in vivo models. The organisms express both luciferase and the enzymes 
that produce its substrate, unlike eukaryotic cell lines that are optically silent 
and require the injection of the substrate luciferin for bioluminescence to be 
emitted. However, Caliper have recently launched cell lines known as 
BiowareUltra® Red, where eukaryotic cells are dually labelled with luciferase 
and Red Fluorescent Protein tdTomato 
(http://www.caliperls.com/assets/021/8059.pdf). This allows the total number 
of cells to be measured with fluorescence and the number of actively 
metabolising cells to be measured with bioluminescence.  
Unlike fluorescent molecules such as eGFP, or luciferase in eukaryotic cells like 
those detailed above, luciferase expressing pneumococci do not require 
excitation or exogenously supplied substrate and produce light throughout 
exponential growth in the presence of sufficient oxygen and aldehyde substrate. 
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The development of bioluminescent pneumococci permits investigators to 
examine bacterial distribution within living mice using a highly sensitive CCD 
camera and the corresponding software (Francis et al., 2001; Orihuela et al., 
2003). Imaging is non-invasive and thus allows repeated visualisation of disease 
progression within the same animal. A distinct advantage of this is that the 
numbers of animals required to complete a study dramatically decreases. 
Bioluminescence is also semi-quantitative as, above a threshold between 105 and 
106 cfu/g tissue, the amount of emitted photons corresponds to the number of 
bacteria. All published work to data that utilises bioluminescent pneumococci 
has been summarised in Table 1-8. In most cases A66.1 Xen 10 was employed to 
monitor disease, as it performs well in a pneumonia model. None of these 
bioluminescent models had been established in our laboratory. Notable 
exceptions to the application of A66.1 Xen 10 and TIGR4 Xen 35 include: 
protection from disease mediated by vaccines, applications of novel 
pharmaceuticals in the mitigation of disease, establishment in a colonisation 
model and establishment of a peritoneal model that could be compared to 
previous protection studies. 
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Table 1-5 Summary of published work performed to date with bioluminescent pneumococci. 
Bacterial 
strain 
Animal Route of 
infection 
Purpose Reference 
D39 Xen 7, 
HUSTMBIG  
Xen 9, A66.1 
Xen 10, 
EF3030 Xen 11 
& 140301 Xen 
12 
Female 
BALB/c 
Intranasal & 
intratracheal 
Establishment of 
pneumonia & 
colonisation models, 
with amoxicillin 
treatment of 
pneumonia 
(Francis et al., 
2001) 
A66.1 Xen 10 Female 
Balb/c 
Intracisternal or 
lumbar  
Monitor meningitis and 
ceftriaxone treatment 
efficacy 
(Kadurugamuwa 
et al., 2005b) 
D39 Xen 7 Female 
BALB/cJ 
Intranasal, 
intratracheal & 
intravenous 
Evaluate contribution 
of virulence factors to 
IPD 
(Orihuela et al., 
2004a) 
D39 Xen 7 or 
TIGR4 Xen 35 
Female 
BALB/cJ; 
male New 
Zealand 
white 
rabbits 
Intratracheal & 
intracisternal 
respectively 
Expression of 
pneumococcal genes 
in body specific sites 
(Orihuela et al., 
2004b) 
A66.1 Xen 10 C57BL/6 & 
C57BL/6 
TLR2-/- 
Intracerebral Examine susceptibility 
of TLR2-/- knockout to 
meningitis 
(Echchannaoui et 
al., 2002) 
A66.1 Xen 10 Female 
FVB/N-Tg 
(GFAP-luc) 
Intracisternal Monitor meningitis and 
ceftriaxone treatment 
efficacy and 
accompanying 
neuronal injury  
(Kadurugamuwa 
et al., 2005a) 
A66.1 Xen 10, 
D39 Xen 7 & 
TIGR4 Xen 35 
BALB/c Intranasal Evaluate the strain-
specific invasiveness 
of different bacteria 
(Orihuela et al., 
2003) 
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Aims of this project 
The aim of this project was to construct a genetic fusion of PLY to a 
pneumococcal protein that was immunologically relevant (PsaA) for the purpose 
of stimulating an immune response against the carried antigen. Protection 
against challenge would then be determined. A more traditional vaccination and 
protection protocol with PhtD and dPLY would also conducted in both young and 
old models of IPD and in a young model of colonisation. 
As the project progressed, an in vivo imaging system was acquired. In vivo 
pneumococcal disease models encompassing pneumonia would be developed 
with two bioluminescent pneumococcal strains. This would be done with a view 
to assessing novel vaccinations and pharmaceutical interventions in 
bioluminescent models of pneumococcal disease. Prevnar vaccination would be 
used as the paradigm for vaccination success and Tamiflu® would be 
investigated as a novel pharmaceutical intervention in an IPD model.  
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Chapter 2 Materials and Methods 
  
2.1 Bacterial strains 
S. pneumoniae strains were grown from a single colony in BHI (Brain Heart 
Infusion broth: Oxoid) at 37C without shaking to mid log phase (OD600nm 0.6) and 
stored in 1ml aliquots at -80C with Microbank beads (Pro-Lab Diagnostics, 
Cheshire, UK) or in 10% glycerol (Sigma-Aldrich, Dorset, UK). Prior to freezing, 
strain purity was verified by streaking the culture on BAB (Blood Agar Base: 
Oxoid) supplemented with 5% horse blood (E&O Laboratories, Bonnybridge, UK) 
and optichin sensitivity checked with an optichin disc. E. coli strains were grown 
overnight from a single colony with the appropriate antibiotic in LB (Luria Broth: 
Sigma-Aldrich) at 37C with shaking at 180rpm. 1ml aliquots were then stored at 
-80C in 10% glycerol. 
Table 2-1 List of bacterial species and strains used in this project. 
Species Strain name Plasmid/ 
property 
Source Antibiotic 
sensitivity 
E. coli DH5 pET33bPLY G. Cowan Kanamycin 
E. coli DB3.1 pET33bGtwyPLY This work Zeocin 
E. coli DH5 pET33bPsaAPLY This work Kanamycin 
E. coli BL21 (DE3)  pET33bPsaAPLY This work Kanamycin 
E. coli DH5 pQE31PsaA C. Rush Ampicillin 
S. pneumoniae TIGR4 (ATCC BAA-334) Sequenced strain T. Mitchell Gentamycin 
S. pneumoniae GSK strain 60 60-00-4795 (16F) C. Blue Gentamycin 
S. pneumoniae GSK strain 98 98-00-2011 (33F) C. Blue Gentamycin 
S. pneumoniae A66.1 Xen 10 Bioluminescent (Francis et 
al., 2001) 
Kanamycin 
S. pneumoniae TIGR4 Xen 35 Bioluminescent (Francis et 
al., 2001) 
Kanamycin 
 
2.2 Preparation of E. coli plasmid DNA 
10ml of overnight E. coli were centrifuged at 4000g for 15 min at 4C to pellet 
cells. The culture media was discarded and plasmids carrying fusions generated 
through Gateway cloning were purified using a plasmid miniprep kit (Qiagen) and 
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following the manufacturers instructions. DNA quantity and quality was 
monitored by agarose gel electrophoresis. 
2.3 Construction of eGFP tagged proteins 
Dr. Graeme Cowan constructed, expressed and purified eGFP tagged versions of 
WT PLY in the following manner: the coding sequence of PLY was amplified by 
PCR using primers 9Y and 9Z (Table 2-2). The PCR product was ligated into 
BamHI/SacI (Promega) digested pET33b (Merck Biosciences, Nottingham, UK) to 
produced pET33bPLY and transformed into TOP10 E. coli (Invitrogen). The 
pET33b expression vector was selected (Novagen, , UK) to allow high-level 
inducible protein expression with the addition of a poly-histidine tag to facilitate 
protein purification. The GFP coding sequence was amplified from pNF320 
(Freitag et al. 1999) by PCR using primers 20G and 20H (Table 2-1). The PRC 
product was cut with NheI and BglII (Promega), ligated into NheI/BamHI digested 
pET33bPLY and transformed into TOP10 E. coli. Mutations F64L and S65T 
(Cormack et al. 1996) were introduced into GFP by site directed mutagenesis as 
described in section 2.3.1 using primers 24W and 24X (Table 2-2) to give 
enhanced (e)GFP. Sequences were confirmed by sequencing at the Molecular 
Biology Sequencing Unit (MBSU) at the University of Glasgow. Plasmids 
transformed into BL21 (DE3) E. coli cells (Stratagene) for protein expression.
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Table 2-2 Primers for PCR and DNA sequencing. 
Primer Primer sequence 5‟  3‟ 
7F TAA TAC GAC TCA CTA TAG GG 
7G GCT AGT TAT TGC TCA GC GTG 
9Y CGG GAT CCG GCA AAT AAA GCA GTA AAT GAC TTT 
9Z GAC GGA GCT CGA CTA GTC ATT TTC TAC CTT ATC 
20G GTC AGG CTA GCA TGA GTA AAG GAG AAG AAC 
20H CCA CGC AGA TCT TTG TAT AGT TCA TCC 
20J CAA TAC TTT CTC CCT GAT GG 
28S ATA GGA TCC AGC TAG CGG AAA AAA AGA T 
28T TAT AAG CTT GGC TTA TTT TGC CAA TCC 
48E GGG GAC AAG TTT GTA CAA AAA AGC AGG CTT CGC TAG CGG 
AAA AAA AGA T 
48F GGG GAC CAC TTT GTA CCC GAA AGC TGG GTC TTT TGC CAA 
TCC TTC AGC 
49Q CAC ATT ATA CGA GCC GGA AGC AT 
49R CAG TGT GCC GGT CTC CGT TAT CG  
 
2.3.1 Site directed mutagenesis 
Complementary forward and reverse primers (25-40 bases) were designed 
against the region of the protein to be mutated with the desired mutation made 
in the centre of each primer (Table 2-3). PCR conditions were set up in 50µl 
dH2O with 5µl 10x reaction buffer, 125ng of each primer, 1-3µl purified plasmid 
DNA, 2mM dNTPs and 1µl PfuTurbo® polymerase (2.5U). The polymerase is a 
high fidelity enzyme that reads the entire plasmid on each cycle, resulting in the 
creation of plasmids carrying the desired mutation. PCR conditions depend on 
the desired mutation (12 cycles for point mutations and 18 cycles for deletions 
or insertions) and the size of the template plasmid. 
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PCR conditions: 95C for 30 sec 
12 or 18 cycles of   95C for 30 sec 
  55C for 1 min 
  68C for 2 min/kb of plasmid 
Final extension of 68C for 10 min 
Figure 2-1 PCR conditions for site directed mutagenesis. 
 
Following PCR, the parental DNA was digested with 10U of DpnI/50µl. The DNA 
from a dam+ E. coli strain is methylated. According to the manufacturers 
instructions, DNA from almost all strains of E. coli is methylated with the 
exception of the JM110 and SCS110 series. The unmethylated PCR product is not 
digested and can then be transformed into E. coli cells such as XL-1 blue super 
competent cells for protein expression and purification. 
Table 2-3 Primers used for site directed mutagenesis 
Primer Primer sequence 5‟  3‟ 
24W CAC TTG TCA CTA CTC GAC TTA TGG TGT TCA ATG C 
24X GCA TTG AAC ACC ATA AGT CAG AGT AGT GAC AAG TG 
 
2.4 Construction of PsaA tagged proteins 
The plasmid pQE31PsaA was generously supplied by Dr. Cathy Rush and consisted 
of full length PsaA cloned from S. pneumoniae D39 using primers 28S and 28T in 
Table 2-2. PsaA tagged versions of WT PLY were created using Gateway cloning 
in the following manner: a restriction digest containing BamHI/NheI digested 
pET33bPLY was heat inactivated at 70C and was blunt ended using 0.1 l mung 
bean nuclease (New England Biolabs) was added per g DNA. The reaction was 
incubated at 30C for 30 min and then column purified. 5‟ phosphates were 
removed from the blunt ends by addition of 1 l calf intestinal alkaline 
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phosphatase (CIAP) in 11 l CIAP buffer to 100 l mung bean digested 
pET33bPLY. The reaction was incubated at 37C for 30 min, followed by 56C for 
15 min. Finally the plasmid was column purified.  
2.4.1 Gateway® fusion technology 
The principles of Gateway cloning are shown in Figure 2-2. 
 
Figure 2-2 Principles of Gateway® fusion technology.  
Entry vectors containing the gene of interest with adjacent attL sites are combined with the 
destination vector pET33bGatewayPLY that contains the ccdB death cassette flanked by 
attR sites at the C terminus of PLY. LR clonase enzymes switch the cassettes to generate a 
by product containing the ccdB death cassette in the zeo
R
 backbone and, in this example, 
the expression vector pET33bPsaAPLY, with the PsaA fragment flanked by attB sites and in 
frame with PLY. The expression vector was then transformed into BL21 (DE3) cells for 
inducible protein expression. 
Ligation of 2 l Gateway® reading frame cassette C.1 (10 ng) into 1 l blunt-
ended, CIAP treated pET33bPLY was carried out using 1 l T4 DNA ligase 
(Invitrogen) in an equal volume of T4 DNA ligase buffer. A final volume of 10 l 
was reached using dH2O and the reaction incubated overnight at 15C. The 
ligation reaction was diluted 5 fold and used to transform Library Efficiency™ 
DB3.1 competent E. coli cells. Transformation reactions were plated on selective 
LB agar overnight at 37C. Successful transformants were screened for correct 
orientation of the insert by PCR with primer pairs 7F & 49Q and 7G & 49R and 
restriction digest with PstI. This plasmid is known as the destination vector. 
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2.4.2 BP-LR cloning reaction 
The coding sequence for the PsaA fragment was amplified by PCR from S. 
pneumoniae D39 using primers 48E and 48F (Table 2-2A). A BP reaction was set 
up as in Table 2-4A and incubated overnight at 25C. 5 l from each reaction 
mixture was removed and the LR reagents were added to the remaining 20 l 
and incubated for 2 h at 25C (Table 2-4B). Following this, enzymes were 
inactivated with 3 l proteinase K and incubated for 10 min at 37C. DH5 cells 
were heat shocked and transformed with 1 l LR reaction before plating onto 
kanamycin LB agar plates. Plates were incubated overnight 37C and selected 
transformants checked with primer pair 7F & 20J before being used to prepare 
glycerol stocks. Plasmids were sent for sequencing at MBSU as before. These 
studies were done in collaboration with Ms. Ruth Wale and Dr Graeme Cowan. 
Table 2-4 Gateway cloning reactions. 
(A) BP Reaction   (B) LR reaction  
Reaction reagent Volume 
(l) 
 Reaction reagent Volume 
(l) 
attB DNA (PCR antigen 
fragment) 100-200 ng 
5    
attP DNA (pDONR/Zeo 
vector) 150 ng/ml 
2.5  BP reaction mixture 20 
5 x BP reaction buffer 5  0.75M NaCl 1 
BP Clonase™ enzyme mix 5  Destination vector 
(pET33bGtwyPLY) 150 
ng/ml 
3 
TE buffer 7.5  LR Clonase™ enzyme mix 6 
Final volume 25  Final volume 30 
 
2.5 Protein expression 
All proteins were expressed in E. coli BL21 (DE3) (Stratagene). A single colony of 
was inoculated aseptically into 5 ml Luria broth (LB) with appropriate antibiotic 
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selection and incubated overnight at 37C with shaking at 180 rpm. The 
overnight culture was then diluted 1:400 in 2 litres of Terrific Broth (TB, see 
Appendix for recipe) in a dimpled flask and incubated in a shaking incubator set 
to 37C and 180 rpm until OD600nm 1.0 was reached. Sterile isopropyl β-D-1-
thiogalactopyranoside (IPTG) was then added to a final concentration of 1 g/ml 
and the flask was incubated for a further 3-6 hours. Cells were harvested by 
centrifugation at 4000g for 30 min at 4ºC using a 4K15 centrifuge. Pelleted cells 
were frozen overnight at -20ºC then resuspended in 20ml PBS containing DNAse I 
and benzamidine (Sigma-Aldrich) per litre of harvested culture. To disrupt cells 
and release the expressed protein, cells were passed through the One-Shot Cell 
Disruptor (Constant Systems Ltd, Warwick, UK) at pressure of 15000 psi. Cell 
lysate were centrifuged at 20000g for 30 min at 4ºC to remove cell debris. 
2.6 Purification of PLY and fusion constructs 
2.6.1 Immobilised metal affinity chromatography 
Cell lysate containing His-tagged proteins were filtered using 0.22µM syringe 
filters (Sartorius, Hannover, Germany). The histidine tag allows purification of 
proteins using immobilised metal affinity chromatography (IMAC). The principle 
of IMAC is based on the interaction between histidine and metal cations. Cell 
extract is passed through a Ni-NTA (Nickel-Nitrilotriacetic acid resin) column 
(charged with immobilised nickel cations) and the histidine tagged protein is 
retained on the column and non-specific proteins are eluted. An imidazole 
gradient, from 0-300mM (Search, 2002), is then introduced to compete with 
histidine in binding to the nickel charged column resulting in the elution of the 
histidine-tagged protein. This technique was used for all proteins. The histidine-
tagged proteins were purified from crude lysate using Fast Performance Liquid 
Chromatography (FPLC) on a Nickel-charged NTA column (Qiagen Superflow) 
with elution on a 0-300mM continuous imidazole gradient in PBS. Samples of 
eluted fractions were run on 10% SDS-PAGE and stained with Coomassie Blue 
using standard protocols (Laemelli, 1970). The column was stripped using 250mM 
EDTA following each use to prevent cross-contamination and stored in 20% 
ethanol. 
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2.6.2 Dialysis of MAC purified protein for further purification 
Fractions containing >98% target protein were pooled and dialysed to remove 
any traces of imidazole that must be removed prior to in vivo studies. Dialysis 
tubing with a molecular weight cut-off point of 14kDa (Medicell International 
Ltd, London, UK) was previously boiled in 2% sodium bicarbonate solution with 
1mM EDTA for 10 min, thoroughly washed in distilled water and stored in 20% 
ethanol at 4ºC. Prior to use, a section of dialysis tubing was cut and washed in 
distilled water to remove ethanol traces, one end was sealed with two dialysis 
clips and the MAC purified protein transferred into the tubing and sealed with 
two clips. The pooled proteins fractions were dialysed at least three times 
against a greater than 50-fold volume of PBS at 4ºC and concentrated using 
Amicon Ultra Centrifugal Concentration columns with 10 or 30kDa molecular 
weight cut-off (Millipore, Watford, UK). Samples were centrifuged in the 
concentration columns at 100g at 4ºC and the concentrated samples pooled 
together. 
2.6.3 Anion exchange chromatography 
The concentrated sample from overnight dialysis was further purified by AEC 
using Poros® HQ20 Micron media and the BioCAD® 700E workstation (Applied 
Biosystems Ltd, Warrington, UK). 5 x 5ml volumes of purified protein in PBS were 
introduced to the column. The column was washed with PBS and the purified 
protein emerged in the wash step. The contaminating DNA and LPS remained 
bound to the column until the NaCl gradient was increased from 0M to 1M NaCl. 
As PsaAPLY precipitates in the absence of NaCl, the NaCl gradient was instead 
used to bind contaminating DNA and LPS rather than the purified protein. 
Purified protein emerging in the wash step was pooled and stored in small 
aliquots at -20ºC. Samples were not repeatedly freeze/thawed. 
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2.7 Analysis of purified proteins 
2.7.1 Quantification by absorbance scan 
Total protein concentration and the presence of aggregates were quantified 
using an UV2-100 spectrometer (Unicam, England, UK). 100 µl of PBS in both 
quartz cuvettes was used to zero the spectrophotometer. The sample cuvette 
was then filled with the sample protein. The OD of the protein was read over a 
range of wavelengths from 220nm to 320nm. The ratio between the absorbance 
at 240 nm and 260 nm allows for the quantification as in the calculation below. 
A peak at 320 nm represented aggregates of protein that remain in 
solution.Equation 2-1 Calculation of protein concentration using a 
spectrophotometer. A260nm represents DNA contamination. 
Concentration (mg/ml) 

1.55 A260nm  0.76 A280nm  
2.7.2 SDS-PAGE and Western blotting of purified proteins 
SDS-PAGE was used to assess the purity of fractions at each stage of purification. 
Unless otherwise stated, all gels were 10%. Samples were diluted two fold in 
sample buffer and boiled for 5 min prior to loading on gels. Kaleidoscope 
Precision Plus marker (Bio-Rad) was used for all SDS-PAGE intended for Western 
blotting. Gels were run for 40 min at 200 v and either stained with Coomassie 
Blue or transferred to Hybond-C nitrocellulose membrane (Amersham 
Biosciences, Buckinghamshire, UK) and blotted for 60 min at 100 v. For detection 
of PLY, Western blots were blocked overnight at RT in 3% skimmed milk in Tris-
NaCl pH 7.4 with shaking and then incubated at 37ºC with shaking for 2 h in 3% 
skimmed milk with 1:2000 polyclonal rabbit anti-PLY serum (Mitchell et al. 
1989). Membranes were then washed 4 x in Tris-NaCl pH 7.4 and incubated for 1 
h in 3% skimmed milk with 1:1000 HRP-linked anti-rabbit IgG (Amersham 
Biosciences), washed 4 x and developed in developing solution. The reaction was 
stopped with distilled water. For all recipes see Appendix I. 
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2.7.3 Quantification of lipopolysaccharide (LPS) using the 
Limulus Amebocyte Lysate assay 
Lipopolysaccharide (LPS) content of purified protein was determined using the 
Limulus Amebocyte Lysate assay (LAL) Kinetic-QCL® Kit (Cambrex, Nottingham, 
UK), which was run according to the manufacturers instructions and with the 
help of Dr. Gill Douce. The LAL assay is a standardised protocol approved by the 
Food and Drug Administration in the United States for the measurement of 
endotoxin levels in pharmaceuticals and biological products. In 1964 Drs Bang 
and Levin discovered that circulating amebocytes in the horseshoe crab (Limulus 
polyphemus) swarm to the site of an injury and coagulate in the presence of 
Gram-negative bacteria. The protein responsible was purified by Levin et al. in 
1972 for exploitation of its enzymatic reaction and was shown to be a coagulase. 
Samples are mixed with a LAL substrate reagent (Ac-Ile-Glu-Ala-Arg-pNA) and 
the time taken for the conversion of this colourless substrate to p-nitroaniline, 
which is yellow in colour, is measured photometrically at 405nm. The reaction 
time is inversely proportional to the amount of endotoxin present in the samples 
and a standard curve is provided with each lot using known amounts of 
endotoxin from E. coli 055:B5 to determine endotoxin levels in test samples.  
All test tubes, pipette tips, plates and water were endotoxin free (Cambrex). 
The supplied LPS was reconstituted in endotoxin free water and vortexed for 15 
min at RT to give a solution containing 50EU (Endotoxin Units)/ml. Four 10-fold 
dilutions of this were prepared to give a standard curve between 50EU/ml and 
0.005EU/ml, with thorough vortexing between dilutions as endotoxin has a 
tendency to stick to glass. Samples were diluted by 1/100 and 1/10000. Samples 
and standards were added in quadruplicate to a flat-bottomed 96 well plate. 
Two wells for each sample were then spiked with a known amount of endotoxin. 
Including a known amount of endotoxin allows for investigators to establish 
whether the sample itself enhances or inhibits the enzymatic reaction, which is 
automatically calculated by the Kinetic-QCL software. The blank was endotoxin 
free water, which was the last sample to be added. The plate was then 
incubated at 37ºC in the plate reader for 10 min. The supplied lysate was 
reconstituted with the appropriate amount of endotoxin free water and 100µl 
was added to each well. The plate was then read at an absorbance of 405nm 
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over the course of 90 min. The time taken for each well to reach saturation was 
recorded and samples within the range were selected for reading from the 
standard curve to give the amount of EU/ml. 
2.7.4 Haemolytic assay 
The haemolytic activity of purified proteins was assessed using a modification of 
the haemolysis assay developed by Walker et al. 1987) using a 2% (vol/vol) sheep 
erythrocyte suspension (E&O Laboratories) in PBS. Two-fold dilutions of samples 
in PBS were prepared in duplicate in round-bottomed 96 well plates. For purified 
protein 50µl of sample and 50µl of PBS were placed in the first well. Following 
dilution, 50µl of 10µM dithiothreitol in PBS (DTT: Sigma-Aldrich) was added as a 
reducing agent for any oxidised PLY then the plate was incubated for 15 min at 
37ºC (with the lid on to prevent evaporation). 50µl of a 2% sheep erythrocyte 
suspension was then added and the plate incubated at 37ºC for a further 30 min 
before addition of a further 50µl of PBS, and centrifugation at 500g for 1 min. 
100µl of supernatant was removed from each well and added to the 
corresponding well of a fresh flat-bottomed 96 well plate (Costar, UK) and a 
spectrophotometer reading at 540nm taken in a FLUOstar Optima plate reader 
(BMB Labtech, UK) to measure the levels of haemoglobin released in each well. 
From this measurement, the percentage (%) lysis in each well was calculated 
using the PBS as the mean negative control value as the 0% lysis value, and using 
0.04% ammonia as the mean positive control value as the 100% lysis value. A 
curve of lysis against well number was plotted for each protein, giving a 
typically sigmoid curve, using GraphPad Prizm 4 software (GraphPad software, 
USA). The concentration of the sample protein in each well is known and from 
this the concentration of protein required to cause lysis of 50% of the 
erythrocytes from the assay can be calculated, and the reciprocal of the dilution 
at which 50% lysis is reached is used to give Haemolytic Units (HU) per mg of 
sample. 
2.7.5 Transmission Electron Microscopy 
1ml of fresh human blood was washed three times in PBS by centrifugation for 3 
min at 100g in a micro centrifuge. Washed erythrocytes were diluted to 2% v/v 
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with PBS. Proteins were diluted to a concentration of 20µg/ml in 200µl PBS and 
added to 1ml of 2% erythrocyte suspension. Reactions were incubated for 5 min 
at 37ºC and washed three times in 0.5M Tris 150mM NaCl pH 7.4. The 
membranes were then resuspended in 50µl dH2O. 5µl of sample was spotted onto 
glow-discharged carbon-coated formvar nickel grid and negatively stained with 
Nanovan® (Nanoprobes, Yaphank, USA) according to manufacturers instructions. 
Grids were viewed at x85000 magnification using a Zeiss 912AB Energy Filter 
Transmission Electron Microscope (TEM). 
2.8 Mouse infection studies 
2.8.1 Mice 
All in vivo experiments were carried out in accordance with the UK Animals 
(Scientific Procedures) Act 1986. All MF1 and Balb/c mice were obtained from 
Harlan Olac (UK). Mice were allowed to acclimatise for a minimum of a week 
prior to being placed on procedure. Mice were permitted food and water ab 
libitum and were kept at a constant room temperature of 20-22ºC and with a 12 
h light/dark cycle. All procedures were performed under Home Office project 
and personal licence approval. The Ethics Committee of the University of 
Glasgow approved the programme of work. Mice were used at 6-8 weeks of age. 
Challenge of vaccinated mice was at 16-18 weeks of age.  
2.8.2 Preparation of mouse passaged standard inocula 
Single colonies of S. pneumoniae TIGR4 (serotype 4), A66.1 Xen 10 (serotype 3), 
TIGR4 Xen 35 (serotype 4), GSK strain 60 (serotype 16F) and GSK strain 98 
(serotype 33F) were selected and grown up to mid-log phase in BHI as described 
in section 2.1. 1ml aliquots were stored in 10% glycerol at -80ºC for at least 16 h 
then viable counts were assessed and 5x106 cfu/200µl injected intraperitoneally 
(i.p.) into an MF1 mouse as previously described (Alexander et al. 1994). At 6 hpi 
the animal was sacrificed by terminal exsanguination via cardiac puncture under 
general anaesthesia and blood was incubated overnight in 20 ml BHI at 37ºC and 
plated onto BAB plates as a sterility check. A 1:50 dilution of the overnight 
culture was inoculated into pre-warmed BHI with 15% fetal calf serum (FCS) and 
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statically grown at 37ºC to an OD600nm 0.6. These standard inocula were then 
frozen at -80ºC in cryovials for at least 16 h before viable counts were 
performed. Cultures were checked for purity and optichin sensitivity by 
streaking a loop of culture onto BAB plates prior to freezing. The colony forming 
units (cfu)/ml in each culture were calculated as described below. 
2.8.3 Viable counts from standard inocula 
24 h post freezing, at least three vials for each strain were defrosted rapidly in a 
37ºC water bath for 2 min. The vials were then centrifuged at RT for 5 min at 
13000g for 5 min using a bench top centrifuge. The supernatant was discarded 
and the cell pellet resuspended in 1ml PBS. 10-fold dilutions were made in 
sterile Dulbecco‟s PBS (DPBS; Sigma-Aldrich) in a round-bottomed 96 well plate 
to give dilutions ranging from 10-1 to 10-8. 3 x 20µl of each dilution was spotted 
onto BAB plates divided into eight sectors and allowed to dry. Plates were 
incubated anaerobically overnight in a candle jar at 37ºC. The dilution sector 
where there were 10-70 colonies/20µl were then counted in order to calculate 
the cfu/ml for each strain as shown in the example below: 
Equation 2-2 Calculation of colony forming units per ml from serial dilutions 

 1st spot  2 nd spot  3 rd spot  3 average60l
 average
60l


 

 50 cfu /ml 104 dilution  average/ml
or
 54  48 42  3  48
 48  50 104  2.4 107cfu /ml
 
 
Immediately before challenge, the standard inocula were thawed and prepared 
in the same way as described above and diluted in sterile DPBS to the desired 
dose. Viable counts of the inocula were assessed prior and post challenge to 
ensure that the bacteria remained viable during challenge and that the correct 
dose was given. 
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2.9 Challenge of mice 
2.9.1 Intranasal challenge (i.n.) of mice 
Six to eight week old out bred female MF1 mice (Harlan, Bichester, UK), or 
Balb/c inbred mice (Harlan), were lightly anaesthetised with 3.5% 
isofluorane/1.5% oxygen (1.5 litre/min) (Astra-Zeneca, Macclesfield, UK) until 
the limb movement reflex had been lost and challenged i.n. with the relevant 
dose and strain of S. pneumoniae in 50µl of sterile DPBS. 25µl was administered 
to each nare. Mice were permitted to recover in the ventral position within their 
cage. Mice were older (16-18 weeks) when challenged post vaccination due to 
the length of the active vaccination protocol 
2.9.2 Intranasal colonisation challenge of mice 
Six to eight week old out bred female MF1 mice (Harlan) were lightly 
anaesthetised as described in section 2.9.1 and challenged i.n. with the relevant 
dose and strain of S. pneumoniae in 10µl of sterile DPBS which was administered 
to the left nare only. Mice were permitted to recover in the ventral position 
within their cage. Mice were older (16-18 weeks) when challenged post 
vaccination due to the length of the active vaccination protocol. 
2.9.3 Intraperitoneal (i.p.) challenge of mice 
Six to eight week old out bred female MF1 mice (Harlan) were scruffed at the 
neck and challenged i.p. by injection with the relevant dose and strain of S. 
pneumoniae in 200µl of sterile DPBS.  
2.9.4 Imaging of infected mice following challenge with 
bioluminescent strains of S. pneumoniae 
Six to eight week old out bred female MF1 mice (Harlan) were challenged as in 
sections 2.9.1, 2.9.2 or 2.9.3 with bioluminescent strains of S. pneumoniae as 
detailed in section 2.8.2. Mice were anaesthetised as in section 2.9.1. and 
positioned within the Xenogen IVIS 200 (IVIS: Caliper Life Sciences, Cheshire, UK) 
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imaging chamber inside masks delivered a constant flow of anaesthetic. The IVIS 
200 was upgraded during the course of this project to a Spectrum with 3D 
fluorescence imaging capability and this will be detailed in text where relevant. 
Living Image® 3.1 software (Caliper Life Sciences) was used in the acquisition of 
images from the IVIS. Initial bioluminescent images were acquired after 5 min 
exposure on large binning and Field of View (FOV) and these were used in all 
figures. Further images with adjusted settings were taken should the initial 
images show saturated pixels in the regions of interest.  
2.9.5 Retrieval of infected organs and fluid for viable counts from 
infected mice 
Following challenge with S. pneumoniae, mice were bled from the lateral tail 
vein at 24 hourly intervals post infection (hpi) to monitor development of 
bacteræmia. Samples were diluted in sterile DPBS immediately to prevent 
clotting. Methods used for BALF and lung retrieval and processing were similar to 
those described before (van der Poll et al., 1996). At terminal time points, blood 
was taken directly from the chest cavity, rather than from the lateral tail vein, 
and diluted in sterile DPBS immediately to prevent clotting. To carry out lavage 
of the lungs, mice were culled by cervical dislocation, taking care not to damage 
the trachea. The skin and muscles above the trachea were separated. The thin 
membrane over the trachea was removed and forceps placed underneath to lift 
it. A small incision was made between two rings of cartilage and a fine tipped 
pastette containing 1ml sterile DPBS was inserted, taking care to avoid air 
bubbles. The lungs were lavaged twice with a recovery volume of approximately 
750µl. For removal of the lungs, the chest cavity was opened and the lungs 
rinsed in situ with 70% ethanol. They were then removed, rinsed in fresh 70% 
ethanol and sterile DPBS and placed into 3ml pre-weighed sterile DPBS. For 
removal of the liver and spleen, the peritoneal cavity was opened and the organs 
were treated in a similar fashion to the lungs, except the spleen was placed into 
1ml pre-weighed sterile DPBS. For lavage of the nasopharynx, the head was 
severed and the lower jaw removed with sharp scissors. A fine tipped pastette 
containing 1ml sterile DPBS was inserted into the nasopharynx just behind the 
hard palette and rinsed through the nares twice. To recover nasal tissue the skin 
of the head was removed and the bones of the snout were cut and lifted. The 
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fine nasal tissue and bones was then scraped out with forceps into 1ml sterile 
DPBS. To recover the brain, the skullcap was cut away using sharp scissors and 
the brain was then treated in the same way as the lungs and other organs before 
being placed into 3ml pre-weighed sterile DPBS. All organs and fluids were kept 
on ice prior to processing. 
2.9.6 Processing of infected organs and fluids for viable counts 
from infected mice 
Whole organs were weighed and then homogenised using an Ultra-Turrax T25 
Basic electric homogeniser (IKA-Werke, Staufen, Germany) to reduce tissues to a 
single cell suspension. Homogenates were then diluted in sterile DPBS and plated 
out in the same way as described in section 2.8.3, with the exception that neat 
homogenate was used in the first well and diluted after that. Nasal tissue was 
ground between two glass slides as the quantity of tissue present was too small 
to use the electric homogeniser and then it was diluted as above. BALF and NL 
were diluted as for homogenates and, along with blood samples, were plated 
immediately. Bacterial limits of detection (LOD) depend upon the number of 
spots and the dilution factor. For example, 1 cfu from three spots of dilution 10-1 
equals 166.6 cfu/ml or log10 2.22, or 1 cfu from three spots of neat dilution 
equals 16.6 cfu/ml or log10 1.22. We cannot therefore say there are no cfu in a 
sample, only that there is fewer than the detection limit. For statistical analysis 
samples below the detection limit are ascribed a value just beneath the 
detection limit. In these cases a value of 2.2 and 1.2 respectively. The cfu/g of a 
homogenised organ is plotted as a log value with a detection limit of 1.2, the 
cfu/ml of BALF and NL is plotted as a log value with a detection limit of 1.2 and 
the cfu/ml of blood is plotted as a log value with a detection limit of 2.2. 
2.9.7 Assessment of survival and management of clinical 
symptoms of mice during infection with S. pneumoniae 
Within our laboratory, we do not use death as an endpoint. Instead, a clinical 
scoring system has been in place for a number of years. This consists of close 
monitoring for symptoms that include piloerection, hunching and lethargy. If an 
animal reached a point at which it would not move when encouraged, the mouse 
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would be deemed moribund and humanely culled using a Schedule 1 method. 
Mice were also culled if 20% of their body weight was lost during the course of 
an infection. If an animal was found dead, which was not often, the survival 
time was calculated as the intermediate time between when the animal was last 
clinical scored and the time it was found dead to give an estimate of when the 
animal became moribund. 
2.9.8 In vivo imaging as a guide to clinical end points 
During the course of my PhD studies, the University acquired a Xenogen IVIS 200 
that was then upgraded to an IVIS Spectrum. This allows the course of 
pathogenesis to be followed in real time within individual animals. This has a 
clear benefit as it means that time course studies can be done in smaller 
numbers of animals (reduction). It reduces the statistical aberrations caused by 
culling separate groups of animals at different time points (refinement). It also 
enables us to select more appropriate points at which to cull (refinement). For 
example, in pneumonia models an individual mouse might show severe clinical 
symptoms (especially if the mouse is part of an aged mouse study) but the in 
vivo imaging shows a low signal in the chest. A decision could then be made not 
to cull the animal, as it would survive the night, thus ensuring that the animal is 
culled at the point when it is truly moribund, rather than as a precaution. It was 
also possible to see novel disease patterns that would otherwise be missed e.g. 
neurological disturbances in movement that are confirmed with in vivo imaging 
of severe meningitis.  
2.10 Vaccination of mice 
2.10.1 Active intramuscular vaccination of aged mice with 
either detoxified PLY or PhtD followed by i.n. challenge with 
S. pneumoniae 
Eight to twelve month old ex-breeder MF1 mice (Harlan) were caged into group 
sizes of 12. Mice were bled from the lateral tail vein one day prior to 
immunisation to provide a baseline for antibody titres (day 0). Blood was 
allowed to clot at RT for 1 h or overnight at 4ºC. The blood was then centrifuged 
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at 13000g using a bench top centrifuge for 5 min. The supernatant (serum) was 
then transferred to a fresh tube. All serum samples were stored at -80ºC prior to 
analysis. The mice were then vaccinated intramuscularly in the rear leg with 
50µl either of sterile DPBS, ASO2V alone, 10µg detoxified PLY (dPLY) with 
ASO2V, 3µg dPLY with ASO2V, 1µg dPLY with ASO2V or 0.3µg dPLY with ASO2V, 
or the same doses using PhtD as the antigen. Mice received a further two boosts 
at fortnightly intervals in alternate legs. Bleeds were taken for antibody analysis 
a fortnight after the final boost (data not shown) and the mice were left for a 
further fortnight before challenge. The mice were anesthetised as in section 
2.9.1 and challenged i.n. with 5 x 107 cfu/50µl dose S. pneumoniae GSK strain 98 
and groups of six from each vaccination group were culled at 6, 24 & 48 hpi. At 
each time point mice were processed for lung tissue as described in section 2.9.6 
and 2.9.7. 
2.10.2 Active intramuscular vaccination of aged mice with 
detoxified PLY and PhtD followed by i.n. challenge with S. 
pneumoniae 
Eight to twelve month old ex-breeder MF1 mice (Harlan) were caged into group 
sizes of 12. Mice were bled from the lateral tail vein one day prior to 
immunisation to provide a baseline for antibody titres (day 0). Blood was 
allowed to clot at RT for 1 h or overnight at 4ºC. The blood was then centrifuged 
at 13000g using a bench top centrifuge for 5 min. The supernatant (serum) was 
then transferred to a fresh tube. All serum samples were stored at -80ºC prior to 
analysis. The mice were then vaccinated intramuscularly in the rear leg with 
50µl of either sterile DPBS, ASO2V alone, 10µg each of dPLY and PhtD with 
ASO2V, 3µg each of dPLY and PhtD with ASO2V, 1µg each of dPLY and PhtD with 
ASO2V or 0.3µg each of dPLY and PhtD with ASO2V. Mice received a further two 
boosts at fortnightly intervals in alternate legs. Bleeds were taken for antibody 
analysis a fortnight after the final boost and the mice were left for a further 
fortnight before challenge. The mice were anesthetised as in section 2.9.1 and 
challenged i.n. with 5 x 107 cfu/50µl dose S. pneumoniae GSK strain 98 and 
groups of six from each vaccination group were culled at 6, 24 & 48 hpi. At each 
time point mice were processed for lung tissue as described in section 2.9.6 and 
2.9.7. 
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2.10.3 Active intranasal vaccination of young mice with 
detoxified PLY followed by i.n. colonisation with S. 
pneumoniae 
Eight to twelve week old MF1 mice (Harlan) were caged into group sizes of 12. 
Mice were bled from the lateral tail vein one day prior to immunisation to 
provide a baseline for antibody titres (day 0). Blood was allowed to clot at RT 
for 1 h or overnight at 4ºC. The blood was then centrifuged at 13000g using a 
bench top centrifuge for 5 min. The supernatant (serum) was then transferred to 
a fresh tube. All serum samples were stored at -80ºC prior to analysis. The mice 
were then anaesthetised as in section 2.9.1 and vaccinated i.n. with 10µl across 
both nares either of sterile DPBS, ASO2V alone, 10µg detoxified PLY (dPLY) with 
ASO2V, 3µg dPLY with ASO2V, 1µg dPLY with ASO2V or 0.3µg dPLY with ASO2V. 
Mice received a further two boosts at fortnightly intervals. Bleeds were taken for 
antibody analysis a fortnight after the final boost and the mice were left for a 
further fortnight before challenge. The mice were anesthetised as in section 
2.9.1 and challenged i.n. with 5 x 106 cfu/10µl dose S. pneumoniae GSK strain 60 
in one nostril and groups of ten from each vaccination group were culled at 2 or 
6 days post infection (dpi). At each time point mice were processed for NL as 
described in section 2.9.6 and 2.9.7. The analysis of the serology and how it 
correlated with the challenge data was performed by the author, Kirsty Ross but 
the vaccinations and challenge in this were conducted by Dr. Clare Blue and the 
ELISA were performed to in house protocols by GSK. 
2.10.4 Active intranasal vaccination of young mice with dPLY 
and PhtD followed by i.n. colonisation with S. pneumoniae 
Eight to twelve week old MF1 mice (Harlan) were caged into group sizes of 12. 
Mice were bled from the lateral tail vein one day prior to immunisation to 
provide a baseline for antibody titres (day 0). Blood was allowed to clot at RT 
for 1 h or overnight at 4ºC. The blood was then centrifuged at 13000g using a 
bench top centrifuge for 5 min. The supernatant (serum) was then transferred to 
a fresh tube. All serum samples were stored at -80ºC prior to analysis. The mice 
were then anaesthetised as in section 2.9.1 and vaccinated i.n. with 10µl across 
both nares either of sterile DPBS, ASO2V alone, 10µg each of dPLY and PhtD with 
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ASO2V, 3µg each of dPLY and PhtD with ASO2V, 1µg each of dPLY and PhtD with 
ASO2V or 0.3µg each of dPLY and PhtD with ASO2V. Mice received a further two 
boosts at fortnightly intervals. Bleeds were taken for antibody analysis a 
fortnight after the final boost and the mice were left for a further fortnight 
before challenge. The mice were anesthetised as in section 2.9.1 and challenged 
i.n. with 5 x 106 cfu/10µl dose S. pneumoniae GSK strain 60 in one nostril and 
groups of ten from each vaccination group were culled at 2 or 6 dpi. At each 
time point mice were processed for NL as described in section 2.9.6 and 2.9.7. 
2.10.5 Active intranasal vaccination with PLY fusion proteins 
and challenge with S. pneumoniae 
Six-week-old MF1 or Balb/c mice (Harlan) were caged into group sizes of 5. Mice 
were bled from the lateral tail vein one day prior to immunisation to provide a 
baseline for antibody titres (day 0). Blood was allowed to clot at RT for 1 h or 
overnight at 4ºC. The blood was then centrifuged at 13000g using a bench top 
centrifuge for 5 min. The supernatant (serum) was then transferred to a fresh 
tube. All serum samples were stored at -80ºC prior to analysis. The mice were 
then lightly anaesthetised as described in section 2.9.1 and immunised i.n. 
across both nares with 20µl dose of either 100ng eGFPPLY, 100ng PsaAPLY, 
equimolar PsaA or PBS alone. PsaA concentration was adjusted to be the same as 
provided by the fusion protein. Bleeds were taken for antibody analysis a day 
before each boost, of which there were two more approximately 14 days apart. 
The second boost was equivalent to 200ng toxin/dose and the third boost was 
equivalent to 400ng toxin/dose. The animals were left for a month before a final 
bleed to check antibody titres before challenge. The mice were challenged i.n. 
with either 5 x 105cfu/50µl or 5 x 106 cfu/50µl dose S. pneumoniae TIGR4 and 
monitored for survival until the control mice reached morbidity at approximately 
48 hpi, at which point all mice were culled and processed for blood, brain, NL, 
nasal tissue, BALF and lungs. At 24 hpi, blood was taken from the lateral tail 
vein of each mouse to assess the levels of bacteræmia in cfu/ml as described in 
section 2.9.6 and 2.9.7. 
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2.10.6 Active vaccination with PLY fusion proteins and 
challenge with bioluminescent S. pneumoniae 
Six-week-old MF1 mice (Harlan) were vaccinated as in section 2.10.1 but 
received a challenge of 5 x 106 cfu/50µl dose S. pneumoniae A66.1 Xen 10 or 5 x 
106 fu/50µl dose S. pneumoniae TIGR4 Xen 35. Mice were monitored for survival 
until control mice reached morbidity at approximately 72 hpi, at which point all 
mice were culled and processed for blood, brain, NL, lung, liver and spleen as in 
section 2.9.6 and 2.9.7. At 24 and 48 hpi, mice were bled from the lateral tail 
vein to assess the levels of bacteræmia in cfu/ml as described in section 2.8.3. 
At 0, 24, 48 and 72 hpi mice were imaged as in section 2.9.4. 
2.10.7 -PsaA IgG ELISA of serum following active 
vaccination 
Serum from each day before vaccination or boosting was collected from the 
lateral tail vein and analysed for anti-PsaA IgG by ELISA using 40µg/ml PsaA to 
coat the plates overnight and HRP-labelled anti-mouse IgG as the detection 
antibody (Amersham). Five fold dilutions of serum were prepared from a starting 
dilution of 1:50. The negative control on each plate was coating buffer with no 
antigen and then positive sera was added. This gave a background level that was 
subtracted from each reading. Absorbance was read at 450nm and titres were 
calculated as the reciprocal of the dilution at which absorbance is at least OD 
0.3 above the background values. Typical background values were between 0.25 
and 0.75.  
2.11 Treatment of pneumococcal infection 
2.11.1 Prophylactic treatment using oseltamivir phosphate 
(Tamiflu®) 
The pro-drug oseltamivir phosphate oral suspension (Roche Products) was diluted 
in sterile water and administered by oral gavage, at a dosage of 20 mg/kg/day, 
in a daily 200l dose. The dose was calculated from supplied guidelines for 
human prophylactic treatment. Doses were administered daily for 5 days in 
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total, starting two days prior to infection. Control mice were mock treated with 
sterile water. Mice were then challenged as in section 2.9.5. 
2.11.2 Pre-treatment with neuraminidase A (NanA) prior to 
challenge 
In some experiments animals were given an intranasal treatment with NanA 24 h 
prior to intranasal challenge with S. pneumoniae A66.1 Xen 10. Mice were 
anaesthetised as in section 2.9.1 and inoculated with 50µl across both nares of 
either 10µg purified NanA or sterile DPBS. This inoculation was then repeated 
half an hour before intranasal challenge and imaging with bioluminescent S. 
pneumoniae as in section 2.9.5. 
2.12 Analysis of data from vaccination and challenge 
studies 
2.12.1 Statistical analysis 
Bacterial loads and ELISA titres were expressed as the mean ± the standard error 
of the mean (SEM) and groups of two were analysed by non-parametric Mann-
Whitney. For groups of three or more, the mean data was compared using Non-
parametric Kruskal-Wallis with Dunn‟s post-test, which allows comparison of 
individual columns with control data. P<0.05 is considered significantly (*) and P 
test value of P<0.01 is considered highly significant (**). 
2.12.2 Analysis of in vivo bioluminescent images 
The units used in the in vivo images in this thesis are photons per sec per cm2 
per steradian (p/s/cm2/sr). Using photons as a unit of measurement permits 
direct comparison between images taken with different settings, as it is 
essentially measuring the rate at which photos arrive at the camera from a given 
area and angle. All images are presented on a photon scale that corresponds to 
the linear range of the camera (300-65000 counts or 1.59 x 103-3.45 x 105 
p/s/cm2/sr respectively on 5 min exposure on FOV E with large binning). The 
lower limit is set to the limit of detection (LOD), rather than the limit of 
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measurement (LOM) to allow for the visualisation of signals that are not yet 
within the measurable range but are still detectable. However, in situations 
where an intense signal from one individual spills onto others around it (despite 
the presence of blackout bars between each mouse) and obscures the image, the 
LOM limit is used as the lower limit of the scale to minimise this artifact. It is 
worth noting here that the change in scale bar does not affect the quantification 
of ROIs.  
It is possible for individual pixels to exceed this linear limit but this occurs when 
individual pixels are binned together to increase the sensitivity of the camera 
(for example at large and medium binning). Thus, the mean of the pixels within 
the super pixel may exceed the linear range of the camera, despite individual 
pixels within the super pixel falling below the linear range.  
2.12.3 Quantification of Regions of Interest 
To quantify images from the IVIS Spectrum, a number of Regions of Interest 
(ROI) were applied to images where the camera was not saturated. Use of 
images with saturated pixels will lead to incorrect quantification, as it is 
impossible to measure the extent to which a signal extends above the upper 
limit of the camera. Settings should therefore be adjusted and quantification 
performed on subjects with signals below the point of saturation. Subject ROI 
were drawn round each individual animal. Within each subject ROI, one 
background ROI was applied to the image taken at 0 hpi. This was a circle drawn 
on the lower abdomen of each mouse, an area predicted not to have any 
substantial signal during intranasal infections. This allows each animal act as an 
internal bioluminescence control for subsequent bioluminescence 
measurements. Measurement ROIs were also drawn. These were square 
measurement ROI and were placed over the thoracic region of the mouse. If 
signal was observed spilling over from a neighbouring individual, the 
measurement ROI was drawn to exclude this as much as reasonably possible, or 
the offending individual was removed and the neighbour‟s measurements 
quantified using this second image. The background was not subtracted from 
mean measurements to avoid negative data. Sources that rose above both the 
LOD and LOM were considered to be valid signals.
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Chapter 3 Purification and in vitro characterisation of 
pneumolysin fusion proteins 
  
3.1 Construction of PLY fusion proteins by Gateway™ 
technology 
PsaA was successfully fused genetically to PLY and expressed in a recombinant E. 
coli system. eGFPPLY and PLY was a kind gift from Dr Graeme Cowan. Full length 
PsaA was expressed from a pQE31PsaA vector, which was a kind gift from Dr. 
Cathy Rush. 
3.2 Purification of PsaAPLY 
3.2.1 Metal affinity chromatography and anion exchange 
chromatography 
PsaAPLY was over-expressed in E. coli and purified in a two-step process from 
clarified cell lysate. Fractions that retained haemolytic activity were analysed 
by SDS-PAGE and fractions of sufficient purity were pooled and dialysed prior to 
AEC. Inclusion of AEC exchange had previously been shown to reduce endotoxin 
levels 100-fold (Kirkham et al., 2006). 
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Figure 3-1 Graphical representation of AEC purification of PsaAPLY. 
Red line = conductance. Green line = NaCl concentration. Pink line = pressure. Blue line = absorbance at 280nm, corresponding to the eluted protein. The peak 
between breakpoint 7 and 8 is the target protein, which is washed through the column and the non-specific protein and contaminating LPS are retained on the 
column until it is washed with 3M NaCl after breakpoint 9.
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3.2.2 SDS PAGE and Western Blotting of the purified proteins 
All proteins were dialysed against PBS to remove imidazole prior to storage at -
80C. All proteins were shown to be greater than 95% pure by SDS-PAGE. 
 
A 
 
B 
Figure 3-2 Examples of Coomassie Blue stained SDS-PAGE of  (A) MAC and (B) AEC 
purification of PsaAPLY protein.  
MW is Kaleidoscope Precision Plus molecular weight marker (Bio-Rad, UK). 20 µl of each 
sample was loaded per lane. Lane 1 is marker, lane 2 is PLY, lane 3 is PsaA and lane 3 is 
PsaAPLY. Faint bands corresponding to E. coli proteins can clearly be seen in (A) lane 4 
after MAC, and these are greatly reduced following AEC as seen in (B) lane 4. 
1          2            3           4               1          2           3         4 
 250kD 
150 
100 
75 
 
50 
 
 
37  
 
 
 
25 
 
 
20 
 
 
 
 
15 
 
 
 
10 
 
Chapter 4   
 
91
  
 
A                                              B 
Figure 3-3 Western blots of vaccine proteins. 
All primary and secondary antibodies were diluted to 1:3000. (A) Anti-eGFPPLY primary 
antibody detects PLY, eGFP, eGFPPLY and PsaAPLY. Lane 1 marker, lane 2 eGFP, lane 3 
eGFPPLY, lane 4 PsaA, lane 5 PsaAPLY and lane 6 PLY.  (B) Anti-PsaA primary antibody 
detects only PsaA and PsaAPLY. MW is See Blue (Invitrogen, UK). Lane 1 marker, lane 2 
eGFP, lane 3 eGFPPLY, lane 4 PsaA, lane 5 PsaAPLY and lane 6 PLY. Contaminating E. coli 
proteins are not recognised by the anti-sera.  
All antigens were recognised by their corresponding anti-sera. Each of the single 
protein controls are only recognised by their companion antibodies. eGFPPLY 
and PsaAPLY are recognised by polyclonal antibodies to both of the fusion 
partners. This confirms that epitopes of each antigen are still recognised by 
their polyclonal sera. 
3.3 In vitro characterisation of fusion proteins 
Haemolytic activity is a defining property of PLY. It was unknown whether 
attaching 30+ kDa of extra protein to the N terminus would affect its ability to 
form pores on eukaryotic cell membranes. Following purification, the proteins 
were assessed in a haemolytic assay to determine their specific activity. Figure 
3-4 shows the appearance of the erythrocytes following incubation with toxin. 
Dithiothreitol (DTT) was present to ensure all the PLY molecules were fully 
active and a 2% vol/vol horse blood cell suspension was then added.  
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Figure 3-4 Haemolytic assay of vaccine proteins.  
0.1 µg protein was added to the first well and then doubling dilutions were made.  Samples 
were laid out as follows: (1 & 2) and (9 & 10) PBS, (3 & 4) and (11 & 12) PLY, 5 & 6) eGFP, (7 
& 8) PsaA, (13 & 14) eGFPPLY and (15 & 16) PsaAPLY. Only wells that contained PLY or its 
fusions were haemolytic. 
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Following incubation the release of haemoglobin was measured by reading 
absorbance at 540 nm and the percentage haemolysis plotted in Figure 3-5 
below.  
 
% lysis PLY
 
% lysis eGFP
 
% lysis PsaA
 
% lysis eGFPPLY
 
% lysis PsaAPLY
 
% lysis PBS
 
Figure 3-5 Log10 protein concentration versus percentage lysis of horse red blood cells.  
 
eGFP and PsaA are non-haemolytic, even at concentrations 100 times higher 
than used in the haemolytic assay above and PLY, eGFPPLY and PsaAPLY are 
haemolytic. The amount of toxin that causes 50% lysis is called 1 Haemolytic 
Unit (HU). The specific activity of the toxins in HU/mg can be calculated by 
taking the reciprocal of the concentration causing 50% lysis (e.g. 1/activity in 
mg/ml). The haemolytic units for the vaccine toxins are detailed in Table 3-1. 
There was no statistically significant difference between the haemolytic activity 
of native PLY and its fusion proteins, despite the additional protein on the N 
terminus.  
 
 
 
 
Chapter 4   
 
94
 
Table 3-1 Haemolytic units for vaccine proteins. 
Protein Initial 
concentration 
Dilution at which 50% lysis 
occurs 
Haemolytic 
units/mg 
PLY 5.56x10-5mg/ml 6.05x10-7 mg/ml 1.651x106 HU/mg 
eGFP 5.56x10-5mg/ml 0 0 
PsaA 5.56x10-5mg/ml 0 0 
eGFPPLY 5.56x10-5mg/ml 9.12x10-7 mg/ml 1.096x106 HU/mg 
PsaAPLY 5.56x10-5mg/ml 5.44x10-7 mg/ml 1.836x106 HU/mg 
 
3.3.1 Binding of PLY and fusions to erythrocyte membranes 
As the fusions were made at the N terminal of PLY protein and it retained its 
haemolytic activity, then logically the binding activity of the toxin should not be 
altered. This was investigated using a modified binding assay (Owen et al., 
1994). A horse erythrocyte suspension was incubated with 0.2 mg/ml of the 
fusion proteins and their subunits, washed thoroughly to remove unbound toxin 
and lysed via osmotic stress. The samples were then analysed via 10% SDS PAGE 
and Western blotting with polyclonal PLY antibody as previously described 
(Owen et al., 1994). PLY, eGFPPLY and PsaAPLY remained bound to the 
membranes. eGFP and PsaA do not bind to the membranes and were washed 
away. 
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Figure 3-6 SDS-PAGE and Western Blot of vaccine proteins bound to erythrocyte 
membranes.  
(A) SDS-PAGE of membrane bound proteins. (B) Western blot with anti-PLY polyclonal 
primary antibody. (C) Western blot with anti-PsaA polyclonal primary antibody. Only 
eGFPPLY, PsaAPLY and PLY are capable of binding to the cell membranes. eGFP and PsaA 
are washed away. MW is See Blue molecular weight marker. 10 µl of ladder and sample was 
loaded in each lane. Lane 1 is PLY loading control, lane 2 is PBS treated membranes, lane 3 
is eGFP treated membranes, lane 4 is eGFPPLY treated membranes, lane 5 is PsaA treated 
membranes, lane 6 is PsaAPLY treated membranes and lane 7 is PLY treated membranes. 
Primary and secondary antibodies were diluted 1:3000.  
All proteins run slightly smaller than their predicted weights. When the SDS-
PAGE lanes are overloaded it is possible to see a ladder of larger sizes at the top 
of the gel, corresponding to multimeric forms of the protein that were still 
bound together when the sample was boiled. Only the fusion proteins containing 
PLY, and the PLY control, are capable of binding to the red blood cells. This 
confirms that PsaA and eGFP fused to PLY does not prevent the binding of PLY to 
cholesterol in the erythrocyte membranes. 
3.3.2 Investigation of pore formation by fusion proteins 
While the fusion proteins retain their ability to bind to and lyse horse 
erythrocytes, it still wasn‟t clear whether the fused antigens would interfere 
with the formation of pores. It was possible that the lysis was simply due to 
many monomers binding to the cholesterol in the membranes and disrupting the 
fluidity of the plasma membrane, rather than pore formation.  The ghost 
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membranes used in the SDS-PAGE and Western blot above were then applied to 
glow discharged carbon coated nickel coated grids and stained with Nanovan for 
examination under the electron microscope for pores. Negative stains are 
absolutely required for electron microscopy as biological samples are otherwise 
transparent to the electrons used. Stains containing heavy metals such as uranyl 
and tungstate compounds are used coat biological samples to increase electron 
scattering. Other properties such as granulation in the electron beam, specimen 
preservation and resistance to alterations are also important. Uranyl compounds, 
for example, have a tendency to form coarse grains and other surface artifacts 
at higher concentrations and requires a pH of 4. Nanovan (or methylamine 
vanadate) offers a near physiological pH of 8 and allows for much smoother 
background, comparable to superior resolution and visualisation of 1.4 nm gold 
clusters.  
Images of the negatively stained membranes can be seen in Figure 3-7 below. 
Arcs and pores were detected with both eGFPPLY and PsaAPLY with similar 
appearance to the positive PLY control, demonstrating for the first time that the 
fusion of an exogenous protein to the N terminus of PLY is not sufficient to 
disrupt the pore forming ability of the toxin partner. PsaA did not appear to bind 
to the surface of the cells. PBS was included as a control.  
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Figure 3-7 Transmission electron micrographs of erythrocyte ghost membranes incubated with vaccine proteins.  
These membranes are the same as those probed in section 3.3.1 above. (A) PBS treated membranes. (B) eGFP treated membranes. (C) PsaA treated 
membranes. (D) PLY treated membranes. (E) eGFPPLY treated membranes. (F) PsaAPLY treated membranes. Arcs in the membranes are indicated with white 
arrows and full pores are indicated with black arrows. At least five distinct regions of the grids were examined for pore formation on single layers of 
erythrocyte ghost membrane. Grey scale bar is 50 nm.  
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Discussion 
Pneumolysin is a malleable protein that lends itself to genetic manipulation. 
Other bacterial toxins depend on the interaction with other subunits for their 
full toxicity, whereas pneumolysin does not. Formation of oligomeric pores is 
important but other data from our group has shown that this is not crucial to the 
adjuvanticity of the toxin (Douce et al., 2010, accepted). Current pneumococcal 
vaccines depend on the production of capsular polysaccharide from S. 
pneumoniae cultures. This is a biological product that therefore increases the 
amount of batch-to-batch variation. Once the capsular polysaccharide has been 
purified, it is then subjected to complex chemistry to conjugate a carrier 
protein to the polysaccharide. It is then suitable for inclusion in the vaccine. 
Each of these processing steps increases the cost of the final vaccine. 
Furthermore, these capsular polysaccharide based vaccines can only protect 
against the serotypes included in the vaccine. Coverage varies from one country 
to the next. Capsular polysaccharide vaccines have proven to be an imperfect 
solution to a complex problem that includes factors such as serotype 
replacement disease, herd immunity and the question whether sterilising 
immunity of commensal organisms is actually desirable? Novel vaccines currently 
in development for protection against pneumococcal disease need to be capable 
of protecting the most vulnerable populations against as broad a spectrum of 
serotypes as possible and at a cost that is affordable. 
Using common protein purification techniques that should prove to be cost 
effective, the data has shown for the first time that genetically attaching 30-40 
kDa exogenous proteins to pneumolysin fails to impact on the toxin‟s principal 
property of pore formation. It remains able to bind and insert into cells. It is 
possible that the genetic fusion impacts on other properties of pneumolysin but 
there was insufficient time to investigate this fully. These fusions are stable in 
storage and remain capable of binding mammalian cells without degradation and 
loss of the attached antigen. The fusion proteins are recognised by polyclonal 
anti-sera to both adjuvant and carried protein.  These fusions represent a 
potential new mucosal adjuvant and delivery system for proteins from a variety 
of sources, from viruses and parasites to cancer and autoimmune diseases. 
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Chapter 4 In vivo responses to intranasal vaccination 
with pneumolysin fusion proteins 
4.1 Determining an infectious i.n. dose of S. pneumoniae  
In order to ensure that the challenge dose of S. pneumoniae to vaccinated mice 
would be fatal for the control groups, infectious doses were established in naïve 
animals. This allowed for any increase in protection given by the vaccine to be 
determined. 
4.1.1 Determining bacterial load due to i.n. infection with TIGR4 S. 
pneumoniae in young BALB/c mice 
Previous experience has shown that 5 x 106 cfu of TIGR4 is suitable for intranasal 
infection of BALB/c mice, but little was known about the bacterial burden in 
different organs during infection, and so a time course experiment was done. 
BALB/c mice were given 5 x 106 cfu TIGR4 S. pneumoniae intranasally (i.n.) in a 
50 µl dose (n=6). Symptoms experienced by the animals are plotted in Figure 
4-1. At 24 and 48 hours post infection (hpi) three mice were culled by cervical 
dislocation and processed for blood, brochoalveolar lavage (BALF), lungs, nasal 
tissue and nasal lavage (NL). Blood was taken from the lateral tail vein of 
surviving mice to assess Bacteræmia (see Figure 4-1). Bacteræmia increased 10 
fold between the two time points. The number of cfu recovered from nasal 
lavage and nasal tissue was equivalent. There was a greater variation in the 
counts recovered from BALF than from lung tissue. This may be ascribed to 
occasional air locks whilst flushing with PBS and differences in recovered volume 
and so average lung counts are also shown where the two sets of data are 
combined to give an average value. 
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Figure 4-1 Clinical scores, Bacteræmia and bacterial load in nasopharynx and lungs in 
BALB/c mice challenged intranasally with 5 x 10
6
 cfu/50 l of S. pneumoniae TIGR4.  
(A) Clinical scores of mice at different time point post infection. The bar is the mean ± SEM. 
(B) Bacteræmia in mice at 24 and 48 hpi. Bacteræmia counts are approximately 10 fold 
higher at the later time point, although this does not reach statistical significance. (C) 
Bacterial loads in nasal lavage and nasal tissue. Bacterial counts in nasal tissue are 
representative of those bacteria that remained in more intimate association with the tissues 
following lavage. (D) Bacterial loads in BALF and lung tissue. As there are issues with the 
variation produced by BALF, the total cfu from BALF and lung tissue were added together 
before division by the volume of PBS the tissues were homogenised in, therefore giving an 
average cfu/ml value Mice were culled at 24 and 48 hpi. All points represent a single 
individual. Horizontal bars represent the median. Horizontal dotted lines represent the 
detection limit of the assay. (N=5). 
4.1.2 Determining an infectious i.n. dose of TIGR4 S. pneumoniae 
in young MF1 mice 
Previous experience has shown that 5 x 106 cfu of TIGR4 is suitable for intranasal 
infection of MF1 mice, but little was known about the bacterial burden in 
different organs during infection, and so a time course experiment was done. 
MF1 mice were given either 5 x 105 or 5 x 106 cfu TIGR4 S. pneumoniae 
intranasally (i.n.) in a 50 µl dose (n=6). 24 and 48 hpi blood was taken from the 
lateral tail vein to assess bacteræmia. Symptoms experienced by the animals are 
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plotted in Figure 4-2. At 24 and 48 hours hpi three mice were culled by cervical 
dislocation and processed for blood, brochoalveolar lavage (BALF), lungs and 
nasal lavage (NL). Blood was taken from the lateral tail vein of surviving mice to 
assess bacteræmia (see Figure 4-2). There is no difference between the 
different compartments despite the different starting inoculum. Bacteræmia 
increased approximately 10 fold between the two time points. Following the 
discovery that nasal lavage and nasal tissue are essentially equivalent, only 
bacterial load in nasal lavage was determined on this occasion. There was a 
greater variation in the counts recovered from BALF than from lung tissues. This 
may be ascribed to occasional air locks whilst flushing with PBS and differences 
in recovered volume and so average counts are also shown where the two sets of 
data are combined. 
 
Figure 4-2 Bacteraemia and bacterial load in nasopharynx and lungs in MF1 mice 
challenged intranasally with either 5 x 10
5
 or 5 x 10
6
 cfu/50 l of S. pneumoniae TIGR4.  
(A) Bacteraemia in mice at 24 hpi. (B) Bacteraemia in mice at 48 hpi. (C) Bacterial loads in 
BALF, lung tissue and average cfu in.the lungs. As there are issues with the variation 
produced by BALF, the total cfu from BALF and lung tissue were added together before 
division by the volume of PBS the tissues were homogenised in, therefore giving an 
average cfu/ml value. (D) Bacterial loads in nasal lavage. Mice were culled at 48 hpi. All 
points represent a single individual. Horizontal bars represent the median. Horizontal dotted 
lines represent the detection limit of the assay. There is no significant difference between 
the groups despite the difference in starting inoculum. (N=3). 
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4.2 Active vaccination of mice with fusion proteins 
BALB/c mice are inbred and were used for initial responses to ensure groups 
were tight. Due to cost constraints MF1 were used for further large-scale 
vaccinations and challenges later in this thesis. However, the out bred nature of 
MF1 mice did lead to more variation in the biological data. 
4.2.1 Immunological responses in young BALB/c mice to 
intranasally delivered fusion proteins 
BALB/c mice were intranasally vaccinated with either 0.1 µg eGFPPLY, 0.1 µg 
PsaAPLY, equimolar PsaA alone or PBS (n=4). They were boosted on day 24 and 
day 36. To avoid adverse toxicity due to the PLY portion of the vaccines, doses 
were kept small for the initial dose and it was then increased to 0.2 µg and 0.4 
µg respectively in subsequent doses. The quantity of PsaA was adjusted so that it 
would be equivalent to the amount delivered using the PsaAPLY fusion. Sample 
bleeds were taken before immunisation, before each boost, one month after the 
final boost and at termination for BALF and NL. 
Anti-eGFP and anti-PsaA IgG antibody levels were measured in the sample bleeds 
(Figure 4-3). PsaAPLY vaccinated mice had a statistically significant response to 
PsaA at day 35 (p<0.05), day 58 (p<0.01) and day 77 (p<0.01) following 
vaccination. All mice had seroconverted by day 58. eGFPPLY vaccinated mice 
had a statistically significant response to eGFP at day 35 (p<0.05), day 58 
(p<0.01) and and day 77 (p<0.01) following vaccination. All mice seroconverted 
by day 35. There was some cross-reactivity to eGFP in mice that received 
PsaAPLY at day 58 but this response was not present at day 77.  Both vaccine 
proteins were therefore capable of generating significant levels of systemic IgG 
in response to an intranasally delivered protein antigen. 
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Figure 4-3 (A) Anti—eGFP and (B) anti-PsaA IgG titres in sera post vaccination. 
 Antigen specific IgG responses were measured in sera taken from vaccinated animals at 
different time points. Each bar represents the mean ± SEM for each group. Horizontal dotted 
line represents the detection limit of the assay. Asterix mark statistical significance 
compared with the control group. Groups were compared via Kruskal-Wallis with Dunn’s 
post test (GraphPad Prizm 4.0, USA). There was a statistically significant difference in anti-
eGFP titre between PsaA and eGFPPLY vaccinated animals at day 35 (p<0.05), day 58 
(p<0.01) and day 77 (p<0.01). There was a statistically significant difference in anti-PsaA titre 
between PsaA and PsaAPLY vaccinated animals at day 35 (p<0.05), day 58 (p<0.01) and day 
77 (p<0.01). Antigen specific titres increased markedly following booster doses of the fusion 
proteins. (N=4). 
As the vaccine was mucosally delivered it was reasonable to suppose that there 
might be antigen specific IgA in the mucosal tissues. All mice were culled and 
processed for secretory IgA in nasal lavage (NL) and brocheoalveolar lavage 
(BALF). Antigen specific IgA was only detected in mice that received the fusion 
proteins and reached statistical significance for both fusion proteins in BALF and 
NL (Figure 4-4). Levels of antigen specific IgA were approximately 10 fold higher 
in the BALF than in the NL. This may be a reflection of the greater surface 
sampling area. Intriguingly, anti-eGFP IgA levels were 5 fold higher than anti-
PsaA IgA in BALF.  
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Figure 4-4 Anti—eGFP and anti-PsaA IgA titres in NL (A) and BALF (B) post vaccination.  
Each bar represents the mean ± SEM for each group. Horizontal dotted line represents the 
detection limit of the assay. Asterix mark statistical significance compared with the control 
group. Groups were compared via Kruskal-Wallis with Dunn’s post test (GraphPad Prizm 
4.0, USA). Antigen specific IgA titres increased only in groups that received the fusion 
proteins and were significantly different to both the PsaA alone and other fusion protein 
group in all cases (p<0.05). (N=4). 
4.2.2 Reproducibility of immunological response in young 
BALB/c mice to intranasal vaccination with fusion proteins 
From the data above it was clear that significant quantities of anti-PsaA 
antibodies were generated mucosally and systemically with this vaccine 
formulation. The role of these antibodies in protection from challenge was then 
evaluated. BALB/c mice were intranasally vaccinated as before (n=8). Mice were 
boosted on day 23 and day 41. To avoid adverse toxicity due to the PLY portion 
of the vaccines, doses were kept small for the initial dose and then it was 
increased to 0.2 µg and 0.4 µg respectively in subsequent doses. The quantity of 
PsaA was adjusted so that it would be equivalent to the amount delivered using 
the PsaAPLY fusion. Sample bleeds were taken before immunisation (day 0), 
before each boost (days 20 and 40) and one month after the final boost (day 57).  
Anti-eGFP and anti-PsaA IgG antibody levels were measured in the sample bleeds 
(Figure 4-5). PsaAPLY vaccinated mice had a statistically significant response to 
PsaA at all days (p<0.01) following vaccination. All mice had seroconverted after 
three doses. A small number had yet to seroconvert after two doses and so it is 
possible that extra doses would have increased the median titre even further. 
eGFPPLY vaccinated mice had a highly statistically significant response to eGFP 
at all days (p<0.001) following vaccination. All mice seroconverted after just one 
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dose. Both vaccine proteins were therefore capable of generating significant 
levels of systemic IgG in response to an intranasally delivered protein antigen.  
 
Figure 4-5 (A) Anti—eGFP and (B) anti-PsaA IgG titres in sera post vaccination.  
Antigen specific IgG responses were measured in sera taken from vaccinated animals at 
different time points. Each bar represents the mean ± SEM for each group. Horizontal dotted 
line represents the detection limit of the assay. Asterix mark statistical significance 
compared with the control group. Groups were compared via Kruskal-Wallis with Dunn’s 
post test (GraphPad Prizm 4.0, USA). There was a highly statistically significant difference 
in anti-eGFP titre between PBS and eGFPPLY vaccinated animals at all days following initial 
vaccination (p<0.001). There was a statistically significant difference in anti-PsaA titre 
between PBS and PsaAPLY vaccinated animals all days following initial vaccination 
(p<0.01). Antigen specific titres increased markedly following booster doses of the fusion 
proteins. (N=8). 
4.2.3 Immunological response in young BALB/c mice to 
subcutaneous vaccination with fusion proteins 
The reproducibility of the intranasal vaccination data was extremely 
encouraging. However, it was possible that the route of immunisation was 
important for the generation of systemic antibodies. It was also unknown as to 
the sustainability of the antibody levels generated. It was possible that the 
immunity would be short lived and dissipate without regular boosts. A small 
study was designed to compare subcutaneous delivery of the same antigens with 
that of intranasal delivery. The same antigen doses were given subcutaneously in 
100 l volume. Vaccine doses were delivered on days 0, 23 and 48, with sample 
bleeds taken prior to vaccination on days 22, 47, 58 and 110. The bleed on day 
110 was done to investigate the longevity of the immune recognition. 
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Anti -PsaA IgG antibody levels were measured in the sample bleeds (Figure 4-6) 
and compared to the homologous animals vaccinated intranasally in section 
4.2.2. All mice vaccinated subcutaneously with PsaAPLY had seroconverted after 
two doses. The third dose had little impact on titres. The titre after three 
vaccinations was approximately 3 fold lower than the titre in mice that received 
the same doses intranasally. The largest increase in titre was following the first 
booster dose, suggesting that minimum of two subcutaneous doses are required 
for substantial antigen specific response. There was a response to PsaA alone 
that was relatively substantial, but this may be expected as PsaA has previously 
been shown to be immunogenic. All mice vaccinated intranasally with PsaAPLY 
had seroconverted after three doses. Each dose saw an incremental increase in 
titre. It is possible that further doses may have seen another increase. The 
largest increase in titre was after the initial prime dose, suggesting that a 
reasonable antigen specific response can be generated with a single intranasal 
dose. There was a small response to PsaA alone, but this was fairly minor in 
comparison to the PsaAPLY response.  
 
Figure 4-6 (A) Intranasally and (B) subcutaneously vaccinated anti-PsaA IgG titres in sera 
post vaccination.  
Antigen specific IgG responses were measured in sera taken from vaccinated animals at 
different time points. Each bar represents the mean ± SEM for each group. Horizontal dotted 
line represents the detection limit of the assay. Asterix mark statistical significance 
compared with the control group. Groups were compared via Mann-Whitney (GraphPad 
Prizm 4.0, USA). There was a highly statistically significant difference in anti-PsaA titre 
between PsaA and PsaAPLY intranasally vaccinated animals at day 20 (p 0.0281), day 40 (p 
0.0002) and day 57 (p 0.0002). There was a statistically significant difference in anti-PsaA 
titre between PsaA and PsaAPLY subcutaneously vaccinated animals at day 47 (p 0.0159) 
and day 58 (p 0.0317) and almost reached significance on day 22 (p 0.0556). There was no 
statistically significant difference between the final titres obtained via the different 
vaccination routes. (N=5). 
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Mice that were vaccinated subcutaneously were also bled at day 110 following 
the initial vaccination. This provided a useful indication as to the longevity of 
the immune response generated. It was possible that there might not be a 
memory response that maintained antigen specific IgG levels in sera. As can be 
seen in Figure 4-7, anti-PsaA IgG levels were only maintained at their previously 
high levels in animals that received PsaAPLY. No other doses of antigen were 
given following dose 3. 
 
Figure 4-7 Subcutaneously vaccinated anti-PsaA IgG titres in sera post vaccination.  
Antigen specific IgG responses were measured in sera taken from vaccinated animals at 
different time points. Each bar represents the mean ± SEM for each group. Horizontal dotted 
line represents the detection limit of the assay. Asterix mark statistical significance 
compared with the control group. Groups were compared via Mann-Whitney (GraphPad 
Prizm 4.0, USA). There was a highly statistically significant difference in anti-PsaA titre 
between PsaA and PsaAPLY vaccinated animals at day 47 (p 0.0159), day 58 (p 0.0317) and 
day 110 (p 0.0079). It almost reached statistical significance on day 22 (p 0.0556). (N=5). 
 
4.2.4 Active vaccination of young MF1 mice with fusion proteins  
From the data above it was clear that significant quantities of anti-PsaA 
antibodies were generated mucosally and systemically in BALB/c with this 
vaccine formulation. The generation of these antibodies and their role in 
protection from challenge in young MF1 mice was then evaluated. MF1 mice 
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were intranasally vaccinated as before (n=9). They were boosted on day 21 and 
day 41. To avoid adverse toxicity due to the PLY portion of the vaccines, doses 
were kept small for the initial dose and then it was increased to 0.2 µg and 0.4 
µg respectively in subsequent doses. The quantity of PsaA was adjusted so that it 
would be equivalent to the amount delivered using the PsaAPLY fusion. Sample 
bleeds were taken before immunisation (day 0), before each boost (days 20 and 
40) and on day 103.  
Anti-eGFP and anti-PsaA IgG antibody levels were measured in pooled sample 
bleeds (Figure 4-8). After the first immunisation, there were detectable levels of 
anti-eGFP and anti-PsaA in the animals vaccinated with the fusion proteins. By 
day 20 after one boost, anti-eGFP and anti-PsaA titres in sera from groups 
vaccinated with the fusion proteins were high and plateaued after two boosts 
(day 40). There was a very small anti-PsaA response in the sera from the mice 
that received PsaA alone, but this did not reach significance. There were no 
anti-eGFP or anti-PsaA IgG antibodies found in the mice vaccinated with PBS.  
 
Figure 4-8 Intranasally vaccinated (A) anti-eGFP and (B) anti-PsaA titres in sera post 
vaccination.  
Antigen specific IgG responses were measured in sera taken from vaccinated animals at 
different time points. Each bar represents the mean ± SEM for each group. Horizontal dotted 
line represents the detection limit of the assay. (N=9). 
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4.3 Intranasal challenge of vaccinated mice 
4.3.1 Intranasal challenge of intranasally vaccinated young 
BALB/c mice with S. pneumoniae TIGR4 
Vaccinated young BALB/c mice were split into groups of 4. Whilst under general 
anaesthesia, one group received 5 x 106 cfu in 50 µl across both nares and the 
other group received 5 x 105 cfu in 50 µl. As previously determined, the control 
mice reached morbidity at 48 hpi and so all mice were culled via cervical 
dislocation at this point. Samples of nasal lavage and blood were taken. At this 
point BALF and lung tissues were processed separately and the lung tissue was 
not weighed. To remain consistent, the BALF and lung tissue values were 
combined and the mean expressed in cfu/ml.  
In vaccinated mice that received an i.n. dose of 5 x 105 cfu, significant 
differences between the vaccination groups were observed. Clinical scores in 
mice that received PsaAPLY were lower at the later time points than any of the 
other groups but no significant weight loss was observed in any of the groups 
(Figure 4-9). 
 
Figure 4-9 (A) Clinical scores and (B) weight changes in mice vaccinated with fusion 
proteins and challenged i.n. with 5 x 10
5
cfu/50 l S. pneumoniae TIGR4.  
Bars represent the mean ± SD. Weight change data is plotted as a box and whiskers plot 
with the horizontal line in the box representing the mean. Weight changes were compared 
by paired t-test (GraphPad Prizm 4.0, USA). Mice that were vaccinated with PsaAPLY 
experienced fewer symptoms at 48 hpi. There was no significant difference in weight loss 
between the groups. (N=4). 
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Mice that received PsaAPLY had no detectable counts in the blood at 24 or 48 
hpi. This reached statistical significance at 48 hpi (p<0.05). There were also 
significantly lower counts in the lung tissue and this was maintained when the 
BALF and lung tissue results were combined (p<0.05). No difference was 
observed in the nasal lavage between any of the groups (Figure 4-10). The data 
was encouraging and the decision was made to repeat the experiment in BALB/c 
mice (n=5) and also in duplicate in MF1 mice (n=5).  
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Figure 4-10 Bacterial loads in various body compartments in mice vaccinated with fusion 
proteins and challenged i.n. wit5 x 10
5
cfu/50 l S. pneumoniae TIGR4.  
Circles mark individuals. Horizontal lines represent the median. Dotted line represents the 
limit of detection of the assay. Groups were compared by Kruskal-Wallis with Dunn’s post 
test (GraphPad Prizm 4.0, USA). (A) Bactaeremia counts at 24 hpi. Due to the spread of the 
control data no statistical difference could be ascribed this did not reach statistical 
significance. (B) Bactaeremia counts at 48 hpi. There was a significant difference between 
the PBS control and PsaAPLY vaccinated mice. (C) Nasal lavage counts at 48 hpi. No 
statistical difference between groups. (D) Nasal tissue counts at 48 hpi. No statistical 
difference between groups. (E) BALF counts at 48 hpi. No statistical difference between 
groups. (F) Lung tissue counts at 48 hpi. There was a statistical difference (p<0.05) between 
PBS and PsaAPLY vaccinated animals. (G) Average lung counts at 48 hpi. There was a 
statistical difference (p<0.05) between PBS and PsaAPLY vaccinated animals that were 
retained once the lung tissue and BALF results were combined. (N=4). 
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Mice that received an i.n. dose of 5 x 106 cfu did not experience any protection 
from invasive pneumococcal disease (data not shown). This was despite anti-
PsaA titres equivalent to those that were protected. It is possible that it is a 
bacterial dose related response and that protection is only afforded when a dose 
of 5 x 105 cfu is given i.n.  
4.3.2 Reproducibility of protection from intranasal challenge in 
intranasally vaccinated young BALB/c mice to S. 
pneumoniae TIGR4 
PsaAPLY vaccinated BALB/c mice experienced some protection from challenge 
with 105 cfu. This experiment was therefore repeated to see if the protection 
was reproducible. As no significant differences were found in either nasal wash 
or tissue, these compartments were not investigated. Young BALB/c mice were 
vaccinated as before (n=7-8). 
Clinical scores in mice that received PsaAPLY were lower at the earlier time 
points than any of the other groups and significant weight loss was observed in 
all of the groups (Figure 4-11). No further significant differences between the 
vaccination groups were observed. 
 
 
Figure 4-11 (A) Clinical scores and (B) weight changes in BALB/c mice vaccinated with 
fusion proteins and challenged i.n. with 5 x 10
5
cfu/50 l S. pneumoniae TIGR4.  
Bars represent the mean ± SD. Weight change data is plotted as a box and whiskers plot 
with the horizontal line in the box representing the mean. All groups lost weight (PBS (p 
0.0065), PsaA (p 0.002), eGFPPLY (p 0.0053) and PsaAPLY (p 0.0031)) when compared by 
paired t-test (GraphPad Prizm 4.0, USA). Mice that were vaccinated with PsaAPLY 
experienced fewer symptoms at 24 hpi. (N=7-8). 
A B 
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Bacterial loads are plotted in Figure 4-12 below. The only statistical difference 
between any of the groups was between PBS and PsaA in BALF (p<0.05). Despite 
initially encouraging results, this experiment was unable to reproduce the 
previous result in young BALB/c mice. 
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Figure 4-12 Bacterial loads in various body compartments in mice vaccinated with fusion 
proteins and challenged i.n. with 5 x 10
5
cfu/50 l S. pneumoniae TIGR4.  
(A) Bacteraemia counts at 24 hpi. No statistical difference between groups. (B) Bacteraemia 
counts at 48 hpi. No statistical difference between groups. (C) BALF counts at 48 hpi. There 
was a statistical difference (p<0.05) between PBS and PsaA vaccinated animals. (D) Lung 
tissue counts at 48 hpi. No statistically significant difference between groups. (E) Average 
lung counts at 48 hpi. No statistically significant difference between groups. Circles mark 
individuals. Horizontal lines represent the median. Dotted line represents the limit of 
detection of the assay. Groups were compared by Kruskal-Wallis with Dunn’s post test 
(GraphPad Prizm 4.0, USA). (N=7-8). 
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4.3.3 Intranasal challenge of vaccinated young MF1 mice with S. 
pneumoniae TIGR4 
As some protection was observed in initial experiments with young BALB/c mice, 
it was hypothesised that this protection might extend to out bred strains of 
mice. The data presented here represents two replicates that were then 
combined (n=8). A separate group were also allowed to reach morbidity to 
investigate the effect of the vaccinations on survival (n=5). Young MF1 mice 
were vaccinated as before.  
Bacterial loads are plotted in Figure 4-13. The only statistical difference 
between any of the groups was between PBS and eGFPPLY in nasal lavage 
(p<0.01).   
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Figure 4-13 Bacterial loads in various body compartments in MF1 mice vaccinated with 
fusion proteins and challenged i.n. with 5 x 10
5
cfu/50 l S. pneumoniae TIGR4.  
(A) Bacteraemia counts at 24 hpi. No statistical difference between groups. (B) Bacteraemia 
counts at 48 hpi. No statistical difference between groups. (C) Nasal lavage counts at 48 hpi. 
No statistically significant difference between groups. (D) Total lung tissue counts at 48 hpi. 
No statistically significant difference between groups. Circles mark individuals. Horizontal 
lines represent the median. Dotted line represents the limit of detection of the assay. 
Groups were compared by Kruskal-Wallis with Dunn’s post test (GraphPad Prizm 4.0, USA). 
(N=8).  
A separate group of vaccinated animals was also monitored for survival. Sample 
bleeds were taken at daily intervals to monitor bacteræmia. Bacteræmia is 
detailed in Figure 4-14. There were no statistical differences except between 
PBS and eGFPPLY at 24 hpi. Survival times are detailed in Figure 4-15. Median 
times to morbidity were 29.5 hpi for PBS vaccinated animals, 44 hpi for PsaA 
vaccinated animals, 28.5 hpi for eGFPPLY-vaccinated animals and 56.75 hpi for 
PsaAPLY vaccinated animals. There was a trend towards increased survival in 
those that received PsaAPLY, although this did not reach statistical significance. 
However, this experiment would bear repeating as the survival curves appear to 
have a different shape, with PsaAPLY mice surviving longer at the beginning and 
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then reaching morbidity rapidly, whereas the control mice have a more 
measured step-wise decrease in survival. 
 
Figure 4-14 Bacteræmia at 24 hpi (left panel) and 48 hpi (right panel) in MF1 mice vaccinated 
with fusion proteins and challenged i.n. with 5 x 10
5
cfu/50 l S. pneumoniae TIGR4.  
Circles mark individuals. Horizontal lines represent the median. Dotted line represents the 
limit of detection of the assay. Groups were compared by Kruskal-Wallis with Dunn’s post 
test (GraphPad Prizm 4.0, USA). There was a statistically significant difference between PBS 
and eGFPPLY vaccinated animals at 24 hpi (p<0.05). (N=5) 
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Figure 4-15 Survival of MF1 mice vaccinated with fusion proteins and challenged i.n. with 5 
x 10
5
cfu/50 l S. pneumoniae TIGR4.  
All data plotted as percentage survival as a staircase line with points for all observations 
against hours post infection. Median survival times were 29.5 hpi for PBS vaccinated 
animals, 44 hpi for PsaA vaccinated animals, 28.5 hpi for eGFPPLY vaccinated animals and 
56.75 hpi for PsaAPLY vaccinated animals as compared by log rank test (GraphPad Prizm 
4.0, USA). (N=5). 
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Discussion 
Mucosal induction of immunity is notoriously difficult. Bacterial toxins are 
capable of subverting tolerance in favour of the colonising or invading organism 
by virtue of their specific properties. Other toxins such as CT and LT have been 
utilised as mucosal adjuvants and shown some promise. Unfortunately, LT was 
shown to cause Bell‟s palsy in human volunteers as it bound to GM1 gangliosides 
in the olafactory bulb (Lewis et al., 2009). CT and LT consist of sub units that 
are required for their toxic activity. This limits the extent to which they can be 
genetically modified to deliver immunogenic antigens. We have previously shown 
that 100 ng of eGFPPLY delivered mucosally is capable of generating a systemic 
immune response to eGFP that takes 3 equivalent doses of LT co-administered 
with eGFP to generate a fraction of the response (Ma, 2006).  
The data presented above show that a genetically malleable toxin, pneumolysin, 
is capable of retaining its immunogenic properties despite the addition of more 
than 30 kDa of extra protein at the N terminus of the protein. This adjuvant 
property is not limited to eGFP, but could be potentially used to generate 
immunity to a wide range of protein-based antigens. By genetically fusing 
pneumolysin and PsaA, it was possible to create a single vaccine containing two 
known pneumococcal antigens.  
Delivery of antigen to the mucosal surface was simple. Increasing doses of 
antigen ensured that there was no adverse toxicity due to the PLY partner. 
Mucosally delivered antigen resulted in a steadily increasing titre of systemic IgG 
to the fused antigens (in this case eGFP and PsaA). It showed no sign of 
plateauing after three intranasal doses and so the potential was there to 
increase the final titre even further. However, the data generated by 
subcutaneously delivered antigen suggests that there is a plateau in the 
response. The third dose delivered subcutaneously failed to deliver further gains 
in titre that were seen with the intranasally delivered antigen. There was no 
statistical difference in titre after three doses between animals that received 
the vaccine intranasally or subcutaneously. Most vaccines delivered 
subcutaneously are injected adsorbed to an adjuvant such as alum. This forms a 
depot of antigen that is steadily released to the cells of the immune system and 
prolonging the antigen specific response. It is possible that the membrane 
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binding activity of domain 4 of pneumolysin is responsible for a „micro-depot‟ 
effect. Time permitting, it would have been interesting to investigate how long 
this protein antigen persists on the surface of cells and in the location in which 
it is introduced, by labelling the protein with infrared fluorescent marker. 
Pneumolysin is capable of acting as an adjuvant but this is not well understood, 
although it has many properties that may explain this ability. Binding to cells 
appears to be crucial, as eGFP labelled sub-units are incapable of generating an 
immune response following intranasal delivery except in the presence of small 
quantities of full length pneumolysin (Ma, 2006). Pore formation is one of the 
principal activities of pneumolysin at high concentrations. The known haemolytic 
activity of pneumolysin allowed me to demonstrate earlier in this thesis that 
genetically fusing antigens to the N terminal end failed to impact significantly on 
the toxin‟s haemolytic activity. However, a deletion of two amino acids 
(discovered by Dr Lea-Ann Kirkham in this lab and detailed in Kirkham et al, 
2005) known as ∆6 (∆A146R147) has recently been shown to still be capable of 
generating an immune response on the mucosal surface, although this was 
admittedly 10 fold lower than the fully toxic form of pneumolysin. Ablating the 
pore forming ability is clearly not the be all and end all of the properties of 
pneumolysin. ∆6PLY has been shown to be completely non-toxic, even at mg/ml 
concentrations. It is able to bind to the cell surface but is unable to oligomerise 
and form pores that would otherwise damaged the host cells. This detoxified 
form of pneumolysin could therefore be used at higher concentrations than used 
in the data above and would be more acceptable for inclusion in a vaccine 
formulation. It may be that higher concentrations would overcome the 10-fold 
lower antigen specific response that we have recently seen.  
Pneumolysin possesses other properties that may contribute to the residual 
adjuvant activity of ∆6PLY. There is currently a lack of model systems that 
would allow for the evaluation of such novel vaccine candidates in vitro in a way 
that mimics what would happen in a whole animal. In an ideal situation, we 
would possess an in vitro model for vaccine efficacy that would also be reflected 
by its activity in vivo. These systems would then allow us to modify our 
candidate adjuvants and investigate all their properties in vitro without having 
to resort to animal models. This is also desirable as a way of reducing the 
number of animals used in research. It would also allow using to study the 
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unanswered questions that I have detailed above as to which portion of 
pneumolysin contributes to which property. Deleting regions responsible for 
these properties could narrow down the optimum combination to be used in an 
ideal plastic vaccine adjuvant with none of the negative side effects of LT.  
These data presented above show that the systemic response to mucosal 
vaccination with antigens fused to Ply is not limited to eGFP and could 
potentially be adapted to any protein antigen. Systemic antigen specific IgG are 
generated after a single 100 ng dose applied to the mucosal surface. Despite an 
initially promising protective response from challenge of a small number of 
vaccinated BALB/c mice in a pneumonia model, this was not shown to be 
reproducible in other BALB/c or MF1 mice. However, the technology is still 
capable of generating high titres of antibodies that may be used with other 
protective antigens.  
Antibodies to PsaA were not shown to be protective in a pneumonia model. 
However, PsaA has been shown to be more involved in colonisation than invasion 
and might be expected to be more protective in that model. It is also possible 
that it is not exposed to the antibodies during the infection. Pneumococci 
possess a capsule that covers the surface of the bacterial cell, undergo phase 
variation and are capable of modifying capsular expression throughout growth 
and it is possible that this obscures PsaA from recognition by specific IgG. Time 
permitting, it would have been interesting to investigate the extent to which 
PsaA is exposed on the bacterial cell surface using flow cytometry analysis. It is 
likely that the failure of the antibodies to PsaA to protect from challenge is 
more likely due to the choice of antigen rather than a fault of the vaccine 
technology. 
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Chapter 5 In vivo response to vaccination with PhtD and 
detoxified PLY in young and aged mice 
  
5.1 Vaccination with PhtD and dPLY is protective in an in 
vivo clearance aged mouse model 
Intramuscularly vaccinated aged MF1 mice were challenged intranasally with 5 x 
106 cfu of GSK strain 98 in 50 µl applied to both nostrils under general 
anaesthesia. Mice did not display any significant symptoms of pneumococcal 
infection. Complete protection was defined as cfu counts that were below the 
detection limit of the assay. Incomplete protection was defined as a significant 
decrease in cfu counts in comparison to the controls, but not below the 
detection limit of the assay. There was a significant difference in protection 
between the mice that received 0.3 & 1 µg each of PhtD and dPLY at 6 hpi 
(p>0.05) in comparison to adjuvant only controls as determined by ANOVA with 
Dunnett‟s post test in Figure 5-1 (A). Due to the spread of the control data, it 
was not possible to establish significance between the vaccine groups and the 
controls at 24 and 48 hpi, despite a clear trend towards low or no lung counts 
Figure 5-1(B & C), with three out of four vaccine groups showing almost 
complete 100% protection. Administration of PhtD and dPLY individually did not 
result in any protection in this model (data not shown).  
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Figure 5-1 Bacterial load in aged mouse lungs at (A) 6,  (B) 24 and  (C) 48 hpi following 
challenge with GSK strain 98.  
Data represents counts from individual animals. Bars represent mean values and the dotted 
line represents limit of detection. PBS and adjuvant groups were compared by unpaired 
Student’s t-test. The adjuvant only control was then compared to all other groups. Asterix 
represent values that are statistically different (P<0.05) and highly significant (P<0.01) from 
Adjuvant only control as determine by ANOVA with Dunnett’s post test using GraphPad 
Prizm 4.0 (GraphPad® Software Inc., San Diego, USA). (N=6). 
 
5.2 Vaccination with PhtD and dPLY is protective in an in 
vivo clearance young mouse model 
Intramuscularly vaccinated young MF1 mice were challenged intranasally with 5 
x 106 cfu of GSK strain 60 in 50 µl applied to both nostrils under general 
anaesthesia. Mice did not display any symptoms of pneumococcal infection. 
Complete protection was defined as cfu counts that were below the detection 
limit of the assay. Incomplete protection was defined as a significant decrease in 
cfu counts in comparison to the controls, but not below the detection limit of 
the assay. 20% of mice that received 10 µg each of PhtD and dPLY were 
completely protected at 6 hpi, 40% at 18 hpi and 100% at 24 hpi. 40% of mice 
that received 3 µg each of PhtD and dPLY were completely protected at 6 hpi, 
40% at 18 hpi and 80% at 24 hpi. 40% of mice that received 1 µg each of PhtD and 
dPLY were completely protected at 6 hpi, 0% at 18 hpi and 80% at 24 hpi. 20% of 
mice that received 0.3 µg each of PhtD and dPLY were completely protected at 6 
hpi, 40% at 18 hpi and 60% at 24 hpi. This data is displayed graphically in Figure 
5-2 and summarised in Table 5-1. 
Chapter 5  123 
 
 
Figure 5-2 Bacterial load in young mouse lungs at (A) 6, (B) 18 and (C) 24 hpi following 
challenge with GSK strain 60.  
Data represents counts from individual animals. Bars represent mean values and the dotted 
line represents limit of detection. PBS and adjuvant groups were compared by unpaired 
Student’s t-test. The adjuvant only control was then compared to all other groups. Asterix 
represent values that are statistically different (P<0.05) and highly significant (P<0.01) from 
Adjuvant only control as determine by ANOVA with Dunnett’s post test using GraphPad 
Prizm 4.0 (GraphPad® Software Inc., San Diego, USA). (N=6) 
Table 5-1 Summary of the extent of complete protection from intranasal challenge following 
intramuscular vaccination with PhtD and dPLY.  
Each percentage corresponds to the number of individuals that were completely protected 
e.g. no recoverable cfu. (N=6). 
       PhtD & dPLY dose 
(µg) 
 
Time post infection 
20 6 2 0.6 
6 hpi 20% 40% 40% 20% 
18 hpi 40% 40% 0% 40% 
24 hpi 100% 80% 80% 60% 
 
All doses of PhtD and dPLY was very significantly protective (p>0.01) in 
comparison to adjuvant only controls as determined by ANOVA with Dunnett‟s 
post test at 24 hpi. No statistical difference was seen between PBS and adjuvant 
only controls as determined by unpaired t-test. Due to the spread of the control 
data, it was not possible to establish significance between the vaccine groups 
and the controls at 18 hpi, despite a trend towards lower lung counts especially 
at the higher vaccine doses (Figure 5-2). Administration of PhtD and dPLY 
individually did not result in any protection in this model (data not shown). 
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5.3 Vaccination with PhtD is protective in an in vivo 
colonisation young mouse model 
Intranasally vaccinated young MF1 mice were challenged intranasally with 5 x 
106 cfu of GSK strain 60 in 10 µl applied to one nostril under general anaesthesia. 
The nasal lavage was serially diluted in PBS and plated onto BAB plates 
containing gentamycin (4 µg/ml final concentration) to avoid the growth of 
commensal bacteria. Complete protection was defined as cfu counts that were 
below the detection limit of the assay. Incomplete protection was defined as a 
significant decrease in cfu counts in comparison to the controls, but not below 
the detection limit of the assay. Mice did not display any symptoms of 
pneumococcal infection. 80% of mice that received 10 µg PhtD were completely 
protected at 2 dpi, and this rose to 90% at 6 dpi. 80% of mice that received 3 µg 
PhtD were completely protected at 2 dpi, and this rose to 90% at 6 dpi. 90% of 
mice that received 1 µg PhtD were completely protected at 2 dpi and 6 dpi. Just 
40% of mice that received 0.3 µg PhtD were completely protected at 2 dpi, but 
this rose to 90% at 6 dpi. This data is displayed graphically in Figure 5-3 and 
summarised in Table 5-2. 
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Figure 5-3 Bacterial load in PhtD vaccinated young mouse nasopharynx at 2 and 6 dpi 
following colonisation with GSK strain 60.  
The individual cfu/ml for 2 and 6 dpi are plotted in (A) and (B) respectively. (C) and (D) 
represent a bar graph of group mean values ± SEM and the dotted line represents limit of 
detection. PBS and adjuvant groups were compared by unpaired Student’s t-test. The 
adjuvant only control was then compared to all other groups. Asterix represent values that 
are statistically different (P<0.05) and highly significant (P<0.01) from Adjuvant only control 
as determine by ANOVA with Dunnett’s post test using GraphPad Prizm 4.0 (GraphPad® 
Software Inc., San Diego, USA). (N=10). 
Table 5-2 Summary of the extent of protection from intranasal colonisation following 
intranasal vaccination with PhtD.  
Each percentage corresponds to the number of individuals that were completely protected 
e.g. no recoverable cfu. (N=10). 
                  PhtD dose (µg) 
 
Time post infection 
10 3 1 0.3 
2 dpi 80% 80% 90% 40% 
6 dpi 90% 90% 90% 90% 
 
 10 µg, 3 µg and 0.3 µg doses were very significantly protective (p>0.01) in 
comparison to adjuvant only controls at 6 dpi and 1 µg dose was significantly 
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protective (P>0.05) as determined by ANOVA with Dunnett‟s post test. It was not 
possible to attribute statistical relevance to the decline in counts at 2 dpi. This 
was due to individual outliers with high bacterial counts but it is clear that there 
is an overall trend towards lower counts especially at higher vaccine doses 
where protection varied between 80 to 90% (Figure 5-3). In this model, an 
immune response to PhtD appears to be more efficacious at the later time point. 
No statistical difference was seen between PBS and adjuvant only controls as 
determined by unpaired t-test.  
 
5.4 Vaccination with dPLY is protective in an in vivo 
colonisation young mouse model 
Intranasally vaccinated young MF1 mice were challenged intranasally with 5 x 
106 cfu of GSK strain 60 in 10 µl applied to one nostril under general anaesthesia. 
The nasal lavage was serially diluted in PBS and plated onto BAB plates 
containing gentamycin (4 µg/ml final concentration) to avoid the growth of 
commensal bacteria. Mice did not display any symptoms of pneumococcal 
infection. Complete protection was defined as cfu counts that were below the 
detection limit of the assay. Incomplete protection was defined as a significant 
decrease in cfu counts in comparison to the controls, but not below the 
detection limit of the assay. 60% of mice that received 10 µg dPLY were 
completely protected at 2 dpi, but this fell to 40% at 6 dpi. 80% of mice that 
received 3 µg dPLY were completely protected at 2 dpi, but this fell to 60% at 6 
dpi. 80% of mice that received 1 µg dPLY were completely protected at 2 dpi and 
6 dpi. 70% of mice that received 0.3 µg dPLY were completely protected at 2 
dpi, but this fell to 50% at 6 dpi. This data is displayed graphically in Figure 5-4 
and is summarised in Table 5-3. 
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Figure 5-4 Bacterial load in dPLY vaccinated young mouse nasopharynx at 2 and 6 dpi 
following colonisation with GSK strain 60.  
The individual cfu/ml for 2 and 6 dpi are plotted in (A) and (B) respectively. (C) and (D) are 
bar graphs of group mean values ± SEM and the dotted line represents limit of detection. 
PBS and adjuvant groups were compared by unpaired Student’s t-test. The adjuvant only 
control was then compared to all other groups. Asterix represent values that are statistically 
different (P<0.05) and highly significant (P<0.01) from Adjuvant only control as determine by 
ANOVA with Dunnett’s post test using GraphPad Prizm 4.0 (GraphPad® Software Inc., San 
Diego, USA). (N=10). 
Table 5-3 Summary of the extent of complete protection from intranasal colonisation 
following intranasal vaccination with dPLY. 
Each percentage corresponds to the number of individuals that were completely protected 
e.g. no recoverable cfu. (N=10). 
           dPLY dose (µg) 
 
Time post infection 
10 3 1 0.3 
2 dpi 60% 80% 80% 70% 
6 dpi 40% 60% 80% 50% 
 
All doses were very significantly protective (p>0.01) in comparison to adjuvant 
only controls at 2 dpi as determined by ANOVA with Dunnett‟s post-test. It was 
not possible to attribute statistical relevance to the decline in counts at 6 dpi 
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but it is clear that there is an overall trend towards lower counts, particularly in 
the middle vaccine doses groups where protection varied between 60 and 80% 
(Figure 5-4). In this model, an immune response to dPLY appears to be more 
efficacious at the earlier time point and it does not appear to be dependent on 
increasing concentrations of vaccine. No statistical difference was seen between 
PBS and adjuvant only controls as determined by unpaired t-test. 
 
5.5 Vaccination with dPLY and PhtD is protective in an in 
vivo colonisation young mouse model 
Intranasally vaccinated young MF1 mice were challenged intranasally with 5 x 
106 cfu of GSK strain 60 in 10 µl applied to one nostril under general anaesthesia. 
The nasal lavage was serially diluted in PBS and plated onto BAB plates 
containing gentamycin (4 µg/ml final concentration) to avoid the growth of 
commensal bacteria. Mice did not display any symptoms of pneumococcal 
infection. Complete protection was defined as cfu counts that were below the 
detection limit of the assay. Incomplete protection was defined as a significant 
decrease in cfu counts in comparison to the controls, but not below the 
detection limit of the assay. 40% of mice that received 3 µg each of PhtD and 
dPLY were completely protected at 6 dpi. 30% of mice that received 0.3 µg each 
of PhtD and dPLY were completely protected at 6 dpi. Mice that received either 
10 µg or 1 µg of PhtD and dPLY were incompletely protected at both time point. 
This data is displayed graphically in Figure 5-5 and summarised in Table 5-4. 
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Figure 5-5 Bacterial load in PhtD & dPLY vaccinated young mouse nasopharynx at 2 and 6 
dpi following colonisation with GSK strain 60.  
The individual cfu/ml for 2 and 6 dpi are plotted in (A) and (B) respectively. (C) and (D) 
represent a bar graph of group mean values ± SEM and the dotted line represents limit of 
detection. PBS and adjuvant groups were compared by unpaired Student’s t-test. The 
adjuvant only control was then compared to all other groups. Asterix represent values that 
are statistically different (P<0.05) and highly significant (P<0.01) from Adjuvant only control 
as determine by ANOVA with Dunnett’s post test using GraphPad Prizm 4.0 (GraphPad® 
Software Inc., San Diego, USA). (N=10). 
Table 5-4 Summary of protection from intranasal colonisation following intranasal 
vaccination with PhtD and dPLY. 
Each percentage corresponds to the number of individuals that were completely protected 
e.g. no recoverable cfu. If all individuals within a group had recoverable cfu but it was a 
significant difference from the adjuvant only control, then those groups are marked as 
incompletely protected. (N=10). 
       PhtD & dPLY dose 
(µg) 
 
Time post infection 
20 6 2 0.6 
2 dpi Incomplete Incomplete Incomplete Incomplete 
6 dpi Incomplete 40% Incomplete 30% 
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However, all doses were very significantly protective (P>0.01) at 2 dpi in 
comparison to adjuvant only controls, as determined by ANOVA with Dunnett‟s 
post test, and all doses were significantly protective (P>0.05) at 6 dpi. This was 
despite few individuals completely clearing the colonising bacteria (Figure 5-5). 
The combined effect of the vaccine containing both proteins appears to be that 
clearance is slower than observed with both proteins given in isolation, but with 
more consistently significant results. No statistical difference was seen between 
PBS and adjuvant only controls as determined by unpaired t-test. 
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Discussion 
Pneumococcal histidine triad protein D (PhtD) is a surface exposed protein that 
is involved in virulence. It was recently found to bind to Factor H (Ogunniyi et 
al., 2009). It has a number of histidine triad residues that are responsible for 
binding zinc. PLY, as previously discussed, is a well-characterised virulence 
determinant for the pneumococcus. Attempts have been made to generate 
detoxified forms that still retain immunogenicity by both chemical and genetic 
processes. The dPLY used in this set of studies has been detoxified using 
formalin. Antigens were given at either 10, 3, 1 and 0.3 µg. Intranasal 
vaccinations deployed Labile Toxin (LT) from E. coli as the adjuvant in each 20µl 
dose, except for the final vaccination when it was omitted to avoid any non-
specific protection afforded by the adjuvant alone. Intramuscular vaccinations 
used the same quantity of antigen in a 50 µl volume, but used a proprietary 
adjuvant from GSK called AS02V instead of LT. The antigens were given singly or 
in combination. Both proteins were protective singly and in combination in the 
colonisation model, but only the combination of PhtD and dPLY was protective in 
the clearance model in both aged and young mice, demonstrating the potential 
for these proteins in a vaccine against S. pneumoniae. 
The in vivo data presented above indicate intramuscular administration of PhtD 
and dPLY together in the presence of AS02V increases the rate of clearance of a 
pneumococcal strain from the lungs in both young and aged mice. This 
protection is not seen when the proteins are given individually. The data also 
shows that both PhtD and dPLY are protective in a colonisation model in young 
mice at 2 and 6 days following challenge, when administered singly or in 
combination to the mucosal surface in the presence of LT. It is likely that this is 
due to the presence of antigen specific IgG and secreted IgA at the mucosal 
surface. The bacteria were more readily cleared from mucosal surfaces that 
were the inductive source of the immune response. This is the first time that 
intranasal administration of PhtD individually, in the presence of an appropriate 
adjuvant, has been proved to provide protection in a young murine model of 
pneumococcal disease. It is also the first time that the combination of PhtD and 
dPLY, administered intramuscularly and in the presence of an appropriate 
adjuvant, has been shown to provide protection against in intranasal model of 
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pneumococcal clearance in both young and aged mice. However, it is possible 
that there is some competition between the antibodies against PhtD and dPLY, 
as clearance was not as rapid in those that received the combined antigens. On 
the other hand, bacterial counts were approaching the detection limit of the 
assay (fewer than 20 counts at the neat dilution) and therefore the data became 
less robust. Until now, protection with PhtD has only been shown by 
intraperitoneal vaccination and challenge in young mice. Our data shows 
protection in a more physiological relevant model in both young and old mice, 
with parental and mucosal vaccinations, that might be more readily applied to 
the clinic.  
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Chapter 6 Development and characterisation of 
bioluminescent Streptococcus pneumoniae in vivo 
models 
  
6.1 Confirmation of properties of bioluminescent S. 
pneumoniae  
The bioluminescent activity of Xenogen strain 35 TIGR4 (TIGR4 Xen 35) and 
Xenogen strain 10 A66.1 (A66.1 Xen 10) were confirmed by streaking the strains 
onto BAB plates. Both plates were then imaged in the IVIS (Figure 6-1). Colonies 
that were undergoing active growth were brightly bioluminescent. In the paper 
by Francis et al, the bioluminescence output of the strains dropped rapidly once 
stationary phase was reached. This observation may account for the lack of 
bioluminescence at the start of the streaking pattern.  
 
Figure 6-1 Bioluminescent activity of (A) A66.1 Xen 10 and (B) TIGR4 Xen 35 on BAB plates. 
  
6.2 Intraperitoneal passage for increased virulence of S. 
pneumoniae TIGR4 Xen 35  
All pneumococcal isolates for use in infection models are passaged i.p. prior to 
use to ensure the maintenance of virulence of the organism. In the case of 
Chapter 6  134 
 
bioluminescent organisms, it also provides a useful source of information about 
the expression of the lux cassette in vivo. 
TIGR4 Xen 35 was passaged through a female MF1 mouse. To establish the extent 
of the infection and any potential tissue trophism, a number of body 
compartments were excised and imaged. There was a rapid progression of 
symptoms. Bioluminescence was clearly observed over the entire body at 6 hpi. 
Imaging the animal in different positions identified a number of strong sources, 
including in the approximate position of the spleen, liver, ears and nasopharynx. 
The signal detected in the paws and tail is likely to be due to the extensive 
bacteræmia. However, after the animal was culled at 18 hpi the only 
bioluminescent signal detectable on the surface of the animal was the 
nasopharynx (Figure 6-2).  
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Figure 6-2 Bioluminescence from an infected MF1 mouse at (A) 6 hpi and (B) 18 hpi.  
(1) Ventral view. (2) Right side view. (3) Dorsal view. (4) Left side view. Bioluminescence is 
distributed over the entire surface of the mouse at 6 hpi, representing a wholesale 
bacteræmia and dissemination of the pneumococcus throughout the body. Particularly 
strong signals are present around the liver (white arrow), spleen (black arrow), ears (blue 
arrow) and nasopharynx (red arrow). At 18 hpi the mouse was culled prior to imaging. At 
this point the only source of bioluminescence is the nasopharynx (blue arrow).  
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Bacterial cells were present and easily recovered from organs so the apparent 
loss of bioluminescence was not due to the absence or death of bacterial cells. 
Bioluminescence was restored once the abdominal and thoracic skin and muscles 
were reflexed back. Organs continued to emit light following excision.  
 
Figure 6-3 Bioluminescence from an infected MF1 mouse with organs (A) in situ or (B) 
excised. 
(1) Liver. (2) Body fat. (3) Thymus. (4) Lungs. (5) Heart. (6) Spleen. Organs were more readily 
viewed and bioluminescence quantified once they were removed. Of all the organs the most 
intense signal comes (in descending order) from the liver, lungs, heart, spleen, body fat and 
thymus.  
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Francis et al hypothesised that the steep decline in bioluminescence during 
stationary phase in vitro may be due to a decrease of reduced flavin 
mononucleotide to feed the bioluminescent reaction. Reduced flavin 
mononucleotide is generated via components of the electron transport chain. 
However, as a facultative anaerobe S. pneumoniae may make these components 
less efficiently. They note that this phenomenon did not appear to occur in vivo 
in living animals. This is therefore the first time that this observation has been 
made post mortem. Later in this chapter I will demonstrate that the loss of 
bioluminescence may be directly linked to time of death and cessation of host 
respiration.  
Bacterial load and photon emission could be directly correlated (Figure 6-4). The 
bacterial load in the blood was very high (>1 x 109 cfu/ml) at 18 hpi and 
represented a 15-fold increase on bacteræmia at 6 hpi. As the route of infection 
was intraperitoneal, it is likely that the bacteria invaded the blood stream and 
this led to the high bacterial load in the liver and spleen, which are responsible 
for removing particulate antigens from the blood. Interestingly, there were also 
significant bacterial loads in the brain, nasal tissue and lungs. The photon 
emission from the lungs was equivalent to that from the heart (2.59 x 105 
p/s/cm2/sr and 1.99 x 105 p/s/cm2/sr respectively), and so the bacterial load 
could come from the blood within the lungs. In the case of nasal tissue, upon 
removal of the skin from the skull, a bioluminescent signal could be detected in 
the nasopharynx. It was also seen along the sutures of the skull, which 
correspond to areas of the brain where CSF is trapped within ventricular spaces. 
Visual blood contamination of these organs appeared to be low and so the 
bioluminescent signal could be an example of „seeding‟ from the blood stream 
into the nasopharynx and CSF.  
This is of particular interest in the case of the nasopharynx. During colonisation 
of a human host, transmission is via coughs, sneezes and other mechanisms that 
release droplets from the respiratory tract. In this case the mouse is bacteræmic 
with few signs of respiratory involvement. The mouse is a „dead-end‟ for the 
invading pneumococcus. It is logical that the pneumococcus may have evolved 
mechanisms for escape from such a situation by colonising the nasopharynx in a 
retrograde fashion from the blood to begin the transmission cycle again.  
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Figure 6-4 Positive correlation between bacterial load and photon emission from infected 
MF1 mouse organs.  
Dashed lines represent LOD for photon emission. Dotted lines represent LOM for photon 
emission. Points represent individual compartments. Spotting differing volumes onto a 
glass slide and measuring photon emission with the IVIS allowed quantification of photon 
emission in the blood. Photon emission from organs was quantified by ROI drawn around 
the excised organs. (N=1). 
6.3 Intraperitoneal passage for increased virulence of S. 
pneumoniae A66.1 Xen 10  
All pneumococcal isolates for use in infection models are passaged i.p. prior to 
use to ensure the maintenance of virulence of the organism. In the case of 
bioluminescent organisms, it also provides a useful source of information about 
the expression of the lux cassette in vivo. 
A66.1 Xen 10 was passaged for virulence through a female MF1 mouse. There 
was a rapid progression of symptoms over the course of 20 hours. 
Bioluminescence was clearly observed in the abdomen at 4 hpi although the 
average radiance was 10-fold lower than the equivalent point in the TIGR4 Xen 
35 passage (2.446 x 104 p/s/cm2/sr versus 3.407 x 105 p/s/cm2/sr). This was due 
to a lower inoculum of A66.1 Xen 10 injected at 0 hpi. Imaging the animal in 
different positions identified a strong source in the approximate position of the 
liver. In this instance at 20 hpi the mouse was imaged ante mortem and 
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therefore bioluminescence could be detected over the whole abdomen (Figure 
6-5).  
 
Figure 6-5 Bioluminescence from an infected MF1 mouse at (A) 4 hpi and (B) 20 hpi.  
(1) Dorsal view. (2) Ventral view. The progress of the peritoneal infection is visualised by 
bioluminescence from the abdomen of the mouse at 4 hpi and 20 hpi. At 20 hpi the mouse 
was imaged prior to culling. Particularly strong signals are present around the liver (white 
arrow) and spleen (black arrow).  
Another property of the IVIS technology is the ability to use 3D reconstruction to 
localise the bioluminescent source. This enables us to visualise where the 
infection has spread within the living animal. It is a refinement that allows the 
reduction in the number of animals used in a particular experiment. Sequential 
images are taken with an open excitation filter and in combination with emission 
filters of different wavelengths. These images, combined with structural light 
images, create a mask of the mouse over which the measured reflectance 
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photon emission, an organ map and individual source voxels (volume pixels) can 
be laid. As can be seen in Figure 6-6, source voxels in this individual are 
localised to the liver, the source of the strongest bioluminescent signal.  
 
Figure 6-6 3D reconstruction of bioluminescent point sources within the mouse from 
previous sections infected i.p. with A66.1 Xen 10. 
 Individual voxels are shown as greyscale cubes. The measured photon emission at 580 nm 
is shown by the rainbow scale on the surface of the mask. Individual organs have been 
fitted to their predicted location using an organ atlas provided with Living Image® 3.0 
(Almeda, USA). The coronal, sagittal and transaxial slices have been set to intersect the 
source voxels within the liver. 
6.4 Background bioluminescence in naïve MF1 mice 
Fluorescent in vivo imaging requires spectral unmixing and other techniques to 
give an accurate signal to noise ratio. In the case of bioluminescence, most 
objects have low background noise. Personal communications with D. 
Whittemore (Whittemore, 2009) established that the background 
bioluminescence of an empty IVIS chamber at large binning and after a five 
minute exposure is roughly equivalent to ±10 counts. The linear range of the CCD 
camera, as detailed in the specifications of the IVIS, is 600-65000 counts. This 
lower limit of measurement (LOM) is a general guide used for measurement but 
not necessarily detection. The key for detection is signal versus noise ratio. 
Once a signal is above the noise level then it is above the limit of detection 
(LOD) of the system. As mentioned above, the noise floor of the IVIS is ± 10 
counts, even on the longest exposures. The only other noise that would be seen 
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at the maximum sensitivity would be the luminescent background of the mouse. 
This would show up as signal covering the entire mouse instead of a localised 
source within the animal. Very weak signals, above the background 
luminescence of the mouse and below the 600 count LOM, can still be detected, 
but a higher percentage of the dim signal will be noise and the error of any 
measurements made will be higher. It was therefore necessary to establish the 
typical background noise that could be expected from MF1 mice. 
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Figure 6-7 Background bioluminescence in uninfected female MF1 mice. 
Mice were imaged for 5 mins on large binning and FOV E. The upper limit of the scale in 
each case is set to 65000 counts. Each panel differs only in the lower limit of the scale. (A) 
Lower limit set to 50 counts. (B) Lower limit set to 100 counts. (C) Lower limit set to 200 
counts. (D) Lower limit set to 300 counts. (N=5). 
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Five uninfected female MF1 mice were used to generate bioluminescent 
background images with large binning and 5 min exposure at FOV E. The images 
in Figure 6-7 above are identical in every sense except the scale has been 
adjusted. The maximum is set to 65000 counts in each case. At a lower limit of 
50, 100 and 200 counts background luminescence is visible over the surface of 
each individual as predicted. Once the lower limit of measurement reaches 300 
counts, the vast majority of the background has been excluded. 300 counts were 
therefore defined as the LOD for images taken with these settings. Typical 
background on other settings may vary. Counts are uncalibrated units that refer 
to the raw amplitude of the signal detected by the CCD camera. A signal 
measured in counts is related to the number of photons incident on the CCD and 
therefore the signal level varies, depending upon camera settings such as 
exposure time, binning, f/stop and field of view. Thus, if these settings are 
changed in the middle of an experiment to keep the signal below the saturation 
limit of 65000 counts, then ROI are no longer directly comparable. 
Bioluminescent images can also be compared using photon radiance. Individual 
cells produce photon flux (photons/sec). When these cells are placed in tissue, 
the photon emission from the tissue surface is called surface radiance or photons 
per second per cm2 per steradian (p/s/cm2/sr) as shown in Figure 6-8. In 
summary, a steradian can be thought of as a three-dimensional cone of light 
emitted from the surface that has a unit solid angle. 
 
Figure 6-8 Photon radiation from an individual cell is known as flux.  
Once the cell is placed in tissue, the photon emission from the tissue surface is called 
surface radiance. From Living Image 3.01 manual. 
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A very important distinction between the absolute physical units of photon 
radiance and the relative units of counts is that the radiance units refer to 
photon emission from the subject animal itself, as opposed to photons incident 
on the detector. As a result, the measurements in units of radiance have already 
taken into account image settings such as binning and FOV. The signal amplitude 
would remain the same, even if image settings changed, because the radiance 
on the surface of the animal is not changing. The 300 count LOD and 600 count 
LOM on FOV E converted to p/s/cm2/sr are 1.59 x 103 and 3.45 x 103 p/s/cm2/sr 
respectively. The 65000 counts saturation limit on FOV E converted to 
p/s/cm2/cr is 3.45 x 105 p/s/cm2/sr. 
6.5 Establishment of an intranasal pneumonia model in 
young MF1 mice with S. pneumoniae TIGR4 Xen 35 
Based on past experience with non-bioluminescent TIGR4, the null hypothesis 
was that disease progression would advance at a similar pace in the 
bioluminescent strain. To date, TIGR4 Xen 35 has not been tested in vivo by 
Caliper Life Sciences (http://www.caliperls.com/assets/010/6117.pdf). To test 
this hypothesis, differing doses were administered to MF1 mice that were then 
monitored for bacteræmia (by blood sampling) and for progression of disease 
(using IVIS and monitoring symptoms). Mice that received doses of 103 cfu/50 l 
or 104 cfu/50 l did not become bacteræmic at any point after infection, no 
bioluminescent sources were detected at any point (data not shown) and the 
mice survived the infection. However, a small number of bacteria were 
recovered in nasal tissues removed 14 days post infection (dpi), demonstrating 
that nasal colonisation with bioluminescent TIGR4 Xen 35 is possible and that 
size of initial inoculum has little impact on the number of colonising organisms 
at 14 dpi (Figure 6-9). 
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Figure 6-9 Colonisation of the nasal tissues 14 dpi of mice inoculated i.n. with TIGR4 Xen 35 
10
3
 cfu/50 l or 10
4
 cfu/50 l. 
Individuals are shown as points. The horizontal line represents the median. Dotted line is 
the limit of detection. Despite a 10-fold difference in initial inoculum, the number of cfu at 14 
dpi is not significantly different. (N=2). 
 
Despite the bioluminescent nature of the colonising bacteria, it was not possible 
to detect a signal from the nasopharynx of these animals at any point after 
initial infection. It is possible that the light emitted is too weak to be detected, 
and therefore this ascribes a lower limit to the IVIS. Another possibility rests on 
the observation that these bioluminescent pneumococci cease producing light 
once stationary phase in growth is reached. It is possible that the bacteria are 
not actively metabolising and growing, but are simply persisting in the 
nasopharynx of these mice. In summary, TIGR4 Xen 35 is detectable by 
quantification of cfu in the nasopharynx of mice 14 days post inoculation with 
103 cfu/50 l or 104 cfu/50 l but these bacteria are undetectable using in vivo 
imaging. 
50% of mice inoculated with 105 cfu/50 l or 106 cfu/50 l survived the infection 
and showed no evidence of IPD at any point during challenge. It is possible that 
these mice may have ingested a large portion of inoculum and therefore failed 
to inhale sufficient organisms to cause invasive disease as the model intended. 
Luminescence has been observed in faeces of infected individuals demonstrating 
that bioluminescent pneumococci can survive the gastrointestinal tract.  
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Figure 6-10 Bacteræmia in mice inoculated i.n. with TIGR4 Xen 35 10
5
 cfu/50 l or 10
6
 cfu/50 
l.  
Bar is mean ± SEM. Horizontal dotted line represents limit of detection. (N=2). 
50% of mice inoculated with 105 cfu/50 l or 106 cfu/50 l became bacteræmic 
after 48 hpi (Figure 6-10). Evidence of pneumonia became visible using in vivo 
imaging at 72 and 48 hpi respectively (Figure 6-11). Individuals with pneumonia 
became progressively more bacteræmic and were culled at 116 hpi. As noted in 
the above section, it was not possible to detect 103 or 104 cfu of bioluminescent 
TIGR4 Xen 35 in the nasopharynx, a relatively small and shallow site within the 
body. Lungs lie deeper within the body and occupy more volume than the 
nasopharynx. It is possible that a higher bacterial load per gram of lung is 
required before bioluminescence becomes detectable. As this experiment 
followed the progression of disease, lung bacterial counts were not performed.  
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Figure 6-11 In vivo imaging of mice inoculated i.n. with TIGR4 Xen 35 10
5
 cfu/50 l or 10
6
 
cfu/50 l at 48, 72 and 96 hpi. 
 Images taken at medium binning for 2 min at FOV C. Background of uninfected MF1 mice 
on these settings is approximately 2.15 x 10
3
 p/s/cm
2
/sr and this is used as the LOD. Upper 
linear limit of 65000 counts is equivalent to 2.15 x 10
6
 p/s/cm
2
/sr. 50% of mice demonstrate 
the onset of pneumonia. Black arrow indicates ambient light cast from the heavily infected 
neighbouring mouse. (N=2). 
All mice inoculated with 107 cfu/50 l were bacteræmic at 24 hpi and remained 
so for the course of infection (Figure 6-12).  
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Figure 6-12 Bacteræmia in mice inoculated i.n. with TIGR4 Xen 35 10
7
 cfu/50 l.  
Horizontal line is median. Horizontal dotted line represents limit of detection. (N=2). 
The first individual in the in vivo images in Figure 6-13 exhibited early signs of 
pneumonia at 24 hpi with bacteræmia load peaking at 48 hpi before declining. 
The second rather unfortunate individual exhibited bioluminescent signals in a 
number of locations that altered during the progression of disease; from 
apparent otitis media at 24 hpi, to pneumonia at48 hpi with apparent resolution 
at 72 hpi, before the onset of meningitis at 96 hpi. Meningitis was accompanied 
by neurological symptoms such as problems with balance and unsteady 
locomotion.  
 
Figure 6-13 In vivo imaging in mice inoculated i.n. with TIGR4 Xen 35 10
7
 cfu/50 l at 24, 48, 
72 and 96 hpi.  
Images taken at medium binning for 2 min at FOV C. Background of uninfected MF1 mice on 
these settings is approximately 2.15 x 10
3
 p/s/cm
2
/sr and this is used as the LOD. Upper 
linear limit of 65000 counts is equivalent to 2.15 x 10
6
 p/s/cm
2
/sr. 50% of mice demonstrate 
the onset of otitis media, pneumonia and meningitis. Black arrow indicates ambient light 
cast from the heavily infected neighbouring mouse. (N=2). 
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In the above situation the in vivo imaging during infection provided extra 
information that would otherwise be missed with conventional techniques. It 
was also possible to use smaller group sizes that were studied longitudinally 
rather than culling a group at each time point after infection. In this way it was 
possible to use internal controls for individual-to-individual variation in 
bioluminescence. The time to morbidity for TIGR4 Xen 35 infected mice was 
elongated in comparison to non-bioluminescent TIGR4 (approximately 72-96 hpi 
rather 48 hpi). The aim of this experiment was to select a dose that was 
appropriate for causing pneumonia with limited dissemination in the blood. 103 
and 104 cfu/dose was unable to cause a visible pneumonia or bacteræmia. 107 
cfu/dose caused a number of other disease patterns that may prove useful in the 
future but over-complicate this model. 105 and 106 cfu/dose both cause 
pneumonia and bacteræmia in 50% of individuals in this study. In line with 
previous work with TIGR4 in this thesis and in the Francis paper, it was decided 
to use 106 cfu as the infecting dose for future studies with TIGR4 Xen 35 and to 
cull individuals at 72 hpi.  
6.6 Establishment of an intranasal pneumonia model in 
MF1 mice with S. pneumoniae A66.1 Xen 10 
A66.1 Xen 10 was initially investigated in the paper by Francis et al and found to 
be excellent in a pneumonia model. To verify this, differing doses were 
administered to MF1 mice that were then monitored for bacteræmia (by blood 
sampling) and for progression of disease (using IVIS and monitoring symptoms). 
50% of mice that received doses of 105 cfu/50 l or 106 cfu/50 l did not become 
bacteræmic at 72 hpi and no bioluminescent signals were detected in the 
thoracic cavity. A bioluminescent signal was observed at 96 hpi without 
accompanying bacteræmia. Those mice that became bacteræmic at 72 hpi 
experienced very similar bacterial load (around 103-104 cfu/ml) despite a 10-fold 
difference in starting inoculum. However, bacteræmia at 72 hpi was lower than 
in mice infected with the equivalent dose of TIGR4 Xen 35. This is an example of 
variation between strains. Thoracic cavity signals were also much more intense 
in A66.1 Xen 10 infected mice. In this instance lung counts were not performed 
and so it was not possible to correlate cfu/g with p/s/cm2/sr to give the average 
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radiance produced by each cell. As Figure 6-14 shows, radiance from the 
thoracic cavity of infected mice increased dramatically over time.  
 
Figure 6-14 In vivo imaging in mice inoculated i.n. with A66.1 Xen 10 10
5
 cfu/50 l or 10
6
 
cfu/50 l at 48, 72 and 96 hpi.  
Images taken at medium binning for 2 min at FOV C. Background of uninfected MF1 mice on 
these settings is approximately 2.15 x 10
3
 p/s/cm
2
/sr and this is used as the LOD. Upper 
linear limit of 65000 counts is equivalent to 2.15 x 10
6
 p/s/cm
2
/sr. Pneumonia becomes 
measurable at 72 hpi in 50% of mice and at 96 hpi the remaining 50% develop a measurable 
pneumonia. (N=2). 
Prior to 72 hpi it was not possible to detect bioluminescence from the thoracic 
cavity. At 72 hpi 50% of mice had a strong signal and this increased even further 
at 96 hpi. At 96 hpi the remaining mice also had a strong signal in the thoracic 
cavity. A dose of 106 resulted in the strongest signal in both individuals and so 
this was used in subsequent invasive challenges. To create Figure 6-15 below, 
measurement ROI were drawn around the rib cage of each individual using Living 
Image® 3.1 (Caliper Life Sciences, USA) and the median radiance was plotted 
against time. The median radiance rapidly rises above the mean background of 
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2.15 x 103 and the LOD at 3.45 x 103 p/s/cm2/sr to reach a maximum of 106 
p/s/cm2/sr.  
 
Figure 6-15 Quantification of in vivo imaging in mice inoculated i.n. with A66.1 Xen 10 10
5
 
cfu/50 l or 10
6
 cfu/50 l at 0, 24, 48, 72 and 96 hpi.  
Images taken at medium binning for 2 min at FOV C. Background of uninfected MF1 mice on 
these settings is approximately 2.15 x 10
3
 p/s/cm
2
/sr and this is used as the LOD. LOM lower 
limit is at 3.45 x 10
3
 p/s/cm
2
/sr. Upper linear limit of 65000 counts is equivalent to 2.15 x 10
6
 
p/s/cm
2
/sr. Pneumonia becomes measurable at 72 hpi in 50% of mice and at 96 hpi the 
remaining 50% develop a measurable pneumonia. (N=2). 
When mouse 1 in the group that received 106 cfu/dose reached morbidity there 
was an opportunity to study how rapidly bioluminescence was lost following the 
cessation of host respiration. The mouse was culled by cervical dislocation and 
immediately imaged for 30 sec on medium binning at 1 min intervals. The 
bioluminescent output dropped 15-fold within one min of death, and below the 
LOM after two min post mortem. The images and the corresponding ROI data can 
be seen below in Figure 6-16. This data suggests that bioluminescence from an 
infection in the lungs in the intact animal is heavily dependent on oxygen 
tension in the lung of the host.  
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Figure 6-16 In vivo imaging in (A) mouse inoculated i.n. with A66.1 Xen 10 10
6
 cfu/50 l at 0, 
1, 2 and 3 min post mortem.  
(B) Quantification of thoracic ROI from images in (A) and plotted against time. Images were 
taken at medium binning for 30 s at FOV C.  Background of uninfected MF1 mice on these 
settings is approximately 2.15 x 10
3
 p/s/cm
2
/sr and this is used as the LOD (dashed line). 
LOM lower limit is at 3.45 x 10
3
 p/s/cm
2
/sr (dotted line). Upper linear limit of 65000 counts is 
equivalent to 2.15 x 10
6
 p/s/cm
2
/sr. Thoracic signal drops below the LOM within 2 min post 
mortem. (N=1). 
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6.7 Application of in vivo imaging to protection from 
invasive pneumococcal disease 
To date, in vivo bioluminescent imaging has yet to be used to monitor protection 
from invasive pneumococcal disease provided by established and new vaccines. 
In this pilot study, MF1 mice were vaccinated subcutaneously with Prevnar or the 
equivalent amount of alum and CRM197. Prevnar contains CPS from seven 
different serotypes, including serotype 4. This is the CPS carried by TIGR4 Xen 
35. The null hypothesis for this experiment is that subcutaneous vaccination with 
Prevnar provides no protection from challenge with TIGR4 Xen 35.  
Vaccinated animals were challenged with TIGR4 Xen 35 and monitored until 72 
hpi. Symptoms were more severe in the control animals and they also 
experienced significant weight loss (p 0.0221) (Figure 6-17). Prevnar vaccinated 
mice experienced significant weight loss (p 0.0478) despite showing few 
symptoms but it was 0.68% compared to the 1.36% loss in the controls. 
 
Figure 6-17 (A) Clinical score and (B) weight loss in vaccinated animals challenged 
intranasally with TIGR4 Xen 35.  
Alum vaccinated mice experienced more severe symptoms and significant weight loss of 
1.36% (p 0.0221) by paired t test. Prevnar vaccinated animals experienced few symptoms of 
disease but significant weight loss of 0.68% (p 0.0478) was experienced. (N=5). 
2/5 control mice were bacteræmic at 24 hpi and all mice were bacteræmic at 48 
and 72 hpi. In contrast, no Prevnar vaccinated mice became bacteræmic (Figure 
6-18). 
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Figure 6-18 Bacteræmia in vaccinated mice following infection with TIGR4 Xen 35.  
20% of alum vaccinated mice are bacteræmic at 24 hpi and 100% are bacteræmic at 48 and 
72 hpi. 0% of Prevnar vaccinated mice are bacteræmic at 24, 48 or 72 hpi. (N=5). 
All control mice had bacteria in the lung at 72 hpi whereas no Prevnar 
vaccinated mice had any bacteria in the lung. Prevnar vaccinated mouse lungs 
were below the measurement limit for both bacteriological counts and photon 
emission. This disparity was an accurate reflection of the imaging data (Figure 
6-19).  
 
Figure 6-19 Correlation between bacterial load in lungs ex vivo and photon emission from in 
vivo imaging.  
Prevnar vaccinated mice were below the limit of detection for both the bacteriological 
counts and the IVIS. (N=5). 
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3/5 control mice had bacteria in the liver at 72 hpi whereas no bacteria were 
found in the liver of Prevnar vaccinated mice. No bacteria were detected in the 
brain or spleen of either group. Prevnar vaccination had no impact on bacterial 
load in the nasal wash. Bacterial counts in Prevnar vaccinated samples were 
below the detection limit of the assay. In these cases low values are ascribed to 
the individuals but because the values used were identical it was not possible to 
find a statistically significant difference using GraphPad Prizm. In future 
analyses, using Mann-Whitney as a statistical test should be possible if these 
ascribed values are not identical in value. However, the absence of bacteria in 
the lungs, blood and liver of Prevnar vaccinated mice is a scientifically valid 
result. In conclusion, Prevnar vaccination does protect MF1 mice from invasive 
disease caused by a bioluminescent pneumococcal strain, and it is possible to 
visualise this protection using an IVIS. 
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Discussion 
Current models have worked well for many years, but there is always more that 
can be done to refine, reduce and replace the number of animals used. In vivo 
imaging is one of these techniques. It is possible to design vectors that will make 
any strain bioluminescent. In this way clinical isolates can also be examined for 
their ability to cause disease in murine models. 
One of the great advantages of in vivo imaging is that the number of animals 
used is reduced and so inter-animal variation is reduced. It is also possible to 
monitor disease progression more accurately. As shown in Figure 6-13, it was 
possible to watch the order in which disease progressed, from colonisation to 
AOM, to pneumonia, to apparent resolution and ending in spontaneous 
meningitis. Use of in vivo imaging shows that murine pneumococcal disease isn‟t 
a simple case of inducing pneumonia, bacteræmia or both, but that there are 
other pathologies that would otherwise be missed. One experiment that could be 
done would be to correlate disease with host response, using the images to 
accurate match animals according to disease severity. This has already been 
used to investigate the pathology caused by these bioluminescent strains (data 
not shown). 
Clinical end points are also refined. Prior to the introduction of the IVIS, 
decisions on morbidity and overnight survival during invasive disease depended 
heavily on the clinical symptoms displayed by an individual mouse. I noted on a 
number of occasions that animals that had a terrible appearance did not match 
the extent of IPD. It was therefore possible to decide that the animal would in 
fact survive until the following day. In this way survival endpoints are refined as 
mice are not culled earlier than they might have been „just in case‟. In vivo 
imaging provides an extra source of information that can be quantified and 
verified by the use of traditional bacteriology. With further experiments and 
greater numbers it should be possible to predict what the bacterial load is in an 
animal purely by imaging a small blood sample or the living animal. 
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Chapter 7 In vivo response to oral treatment of invasive 
pneumococcal disease using oseltamivir phosphate 
prophylaxis 
  
7.1 Treatment with NanA alters the course of 
pneumococcal pneumonia 
Construction of gene knock-outs in the neuraminidase genes of the 
pneumococcus has demonstrated that the neuraminidase proteins play an 
important role in colonisation (Parker et al., 2009) and invasive disease 
(Uchiyama et al., 2009). Absence of NanA caused a reduction in the ability to 
colonise the nasopharynx, infect the lungs and to cause bacteræmia. In order to 
determine a role for NanA in the development of pneumonia, mice were pre-
treated twice with the recombinant purified enzymatic domain of NanA (residues 
318-792) before bacterial challenge with S. pneumoniae A66.1 Xen 10. Pre-
treatment of animals with NanA resulted in more severe symptoms of infection 
at both 48 and 72 hpi as shown in Figure 7-1A. There was also a large weight loss 
from a mean of 37 g to 32 g (-14%) in the NanA treated group that did not occur 
in the mock treatment group (Figure 6-1B). This was highly significant (p<0.001) 
by paired Student‟s t-test. 
 
Figure 7-1 (A) Clinical score and (B) weight loss in mice pre-treated with either PBS or NanA 
and infected intranasally with A66.1.  
Clinical score of mice pre-treated with either PBS or NanA against time are plotted as mean 
± SEM. Weight loss is a box and whiskers plot between 0 and 72 hpi. There is a significant 
decrease in weight in mice that received NanA pre-treatment (p<0.001) when calculated by 
paired Student’s T test. (N=10). 
Chapter 7   
 
158
The onset of pneumonia was visualised using the IVIS and a signal from the 
thoracic cavity was detectable in 4/10 mice in the mock treated group, with one 
death overnight, and 9/10 mice in the NanA treated group, with one death 
overnight at 72 hpi (Figure 6-2). These data assume a positive signal in the two 
mice that died before 72 hpi, as they were positive at 48 hpi (data not shown). 
Mice pre-treated with NanA had a much stronger thoracic signal than those that 
received an equal volume of PBS. 
 
Figure 7-2 In vivo imaging of mice infected with A66.1 Xen 10 at 72 hpi.  
Top row shows mice that were pre-treated with PBS and there is a detectable thoracic signal 
in 3/10 mice, with one death overnight. Mouse 1 and 3 in the right hand image show 
evidence of light spilling on the side that is in close proximity to mouse 2, which has a large 
signal present. Bottom row shows mice that were pre-treated with NanA. There is a 
detectable signal in 8/10 mice, with one death overnight. Mouse 5 in the left hand image 
shows evidence of light spilling over from mouse 4. The scale used is photons per second 
per cm
2
 per steradian (p/s/cm
2
/sr). Mice that died before 72 hpi are marked with a white 
cross. (N=10). 
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Living Image 3.0® software is provided by Caliper Life Sciences for analysis of 
regions of interest (ROI). This enables the quantification and comparison of 
photon emissions emerging from mice. Images taken of uninfected control mice, 
quantified and plotted in a similar way revealed that the intrinsic background is 
approximately equivalent to 1.65 x 102 p/s/cm2/sr (data not shown). This is 
marked by a dotted line in the photon quantification figures. There was a 
positive correlation between strength of photon emission and the bacterial 
burden experienced by the mice. This is seen in Figure 6-3, where photon 
emission and bacterial burden is positively correlated at 72 hpi once the critical 
level of approximately 1 x 106 cfu/g is reached.  
 
Figure 7-3 In vitro measurement of bacterial burden in the lung versus in vivo measurement 
of photon emission from the thoracic cavity of mice infected with A66.1 Xen 10 at 72 hpi. 
Once the bacterial burden reaches approximately 10
6
 cfu/g it is possible to detect light 
emitted by the actively growing bacteria within the thoracic cavity of the mice. This is a 
positive correlation. (N=10). 
Quantification of the photon emission from the thoracic ROI is possible at earlier 
time points, as seen in Figure 7-4. From previous experience and relating back to 
Figure 7-3, it is possible to say that any measurable thoracic signal is likely to 
represent a bacterial burden of 106 cfu/g or greater. There was a statistically 
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significant difference in photon emission (p=0.0188) between PBS treated mice 
and NanA treated mice by Mann Whitney.  
 
Figure 7-4 In vivo measurement of bioluminescence detected in the thoracic cavity of pre-
treated mice infected with A66.1 Xen 10 at 0, 24, 48 and 72 hpi.  
The horizontal bar represents the mean for each group and the error bars represent the 
standard error of the mean (SEM). Photon data does not follow a Gaussian distribution, as 
determined using GraphPad Instat program and so group medians were compared pair-wise 
using the Mann-Whitney test. There was a significant difference between PBS and NanA 
treated mice at 72 hpi (p=0.0188). (N=10). 
The quantification of ROI as used in Figure 7-4 can also be used to predict which 
animals will go on to show more invasive disease and allow for closer monitoring, 
as seen for the selected NanA individuals in Figure 7-5. The individuals chosen 
represent animals that displayed a high, medium and low signal and cfu/g count 
at 72 hpi. It also allows animals to be matched for further processing such as 
immunohistochemistry. 
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Figure 7-5 Graphical representation of in vivo photon emission from the thoracic cavity of 
mice infected with A66.1 Xen 10 over time.  
There is a clear positive correlation between the quantifiable photon signal and the surface 
reflectance false colour graphical representation, demonstrating the course of the infection 
and predict the future course using in vivo imaging. All settings for the images were the 
same and the same scale was used. (N=3). 
7.2 NanA treated mice experience a higher bacterial 
burden at 72 hours post infection 
All surviving mice were culled after imaging at 72 hpi. Brain, nasal lavage, lungs, 
liver, spleen, and blood samples were removed under aseptic conditions as in 
section 2.9.7. Figure 7-6 summarises the bacterial loads counted for the organs 
and body fluids. Pre-treatment with NanA caused a highly significant (p=0.0188) 
increase in counts in the lung and also in the blood (p=0.0142) at 72 hpi. There 
was an almost significant difference in the spleen (p=0.0701) and also a trend 
towards higher counts in the NanA treated mice in the liver.
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Figure 7-6 In vitro quantification of bacterial burden in different bodily compartments in mice challenged with A66.1 72 hpi following either PBS or NanA 
pre-treatment.  
The horizontal bar represents the mean for each group and the error bars represent the standard error of the mean (SEM). Bacterial load does not follow a 
Gaussian distribution, as determined using GraphPad Instat program and so group medians were compared pair-wise using the Mann-Whitney test. There 
was a significant difference between PBS and NanA treated mice at 72 hpi in the blood (p=0.0188) and lungs (p=0.0142). Counts in the spleen almost 
reached statistical significance (p=0.0701) and there was a trend towards higher counts in the liver as well. There was one death overnight in each group 
and they are excluded from the analysis. (N=9).
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These data point to an important role for NanA enzymatic activity in the 
development of lung infection in a mouse model of pneumonia as pre-treatment 
of the respiratory tract with purified NanA enhances the infection. The precise 
mechanism for this is unknown but may reflect exposure of new receptors for 
the pneumococcus on the host cell by removal of sialic acid. Alternatively the 
released sialic acid could act as a nutrient source or as an environmental signal 
to the pneumococcus to alter gene expression and enhance virulence. 
7.3 Inhibition of NanA with OC reduces pneumonia in 
vivo 
Prompted by structural results performed in collaboration with Martin Walsh and 
Heinz Gut in Grenoble, and confirmed by recent papers (Xu et al., 2008a; Xu et 
al., 2008b; Hsiao et al., 2009), the reasonably high inhibitory potency of OC and 
the enhanced infection obtained from pre-treatment of mice with NanA, our null 
hypothesis was that inhibition of NanA by OC in vivo would not reduce the 
severity of infection. OC is an influenza neuraminidase inhibitor and had been 
crystallised in the active site of NanA (data not shown). This experiment relied 
on being able to maintain inhibitory levels of OC in the mouse during the course 
of infection. Mice were therefore given oseltamivir phosphate 2 days prior to 
infection and 3 days after, mimicking the prophylaxis of a human exposed to 
swine „flu. Analysis of bacterial counts in the animals was done 3 days post 
infection. A mock treated control group of mice was included in the experiment. 
The overall survival time of mice infected with S. pneumoniae strain A66.1 Xen 
10 was 64 hours compared to 94 hours for the OC group. Although this was not 
statistically significant, there is a trend towards an increase in overall survival. A 
protective effect of treatment with the inhibitor was supported by the fact that 
the OC group progressed through the disease symptoms more slowly (i.e. 
appeared less sick at a given time point (Figure 7-7).  
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Figure 7-7 Clinical score in mice mock treated or OC treated and infected intranasally with 
A66.1 Xen 10 against time post infection. 
Mice that received OC experienced lower clinical scores than those that were mock treated. 
This was especially evident at 72 hpi. (N=20). 
The onset of pneumococcal pneumonia was visualised using the IVIS as previously 
described. A signal from the ventral thoracic cavity was detectable in 9/20 mice 
in the mock treated group and 5/19 mice in the Tamiflu treated group at 48 hpi. 
At 72 hpi, 13/20 mice in the mock treated group had a signal (assuming a 
positive signal in the two mice that died before 72 hpi as they were positive at 
48 hpi). The OC treated mice had a detectable signal in 5/19 mice, with no 
deaths prior to 72 hpi (Figure 7-8). 
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Figure 7-8 In vivo imaging of mice infected with bioluminescent A66.1 Xen 10 using IVIS at 
72 hpi.  
(A-D) show mice that were mock treated and there is a detectable thoracic signal in 9/20 
mice at 48 hpi and in (E-H) 13/20 mice at 72 hpi with two deaths (assuming a positive signal 
in the two mice that died before 72 hpi as they were positive at 48 hpi). (I-L) show mice that 
were pre-treated with OC. There is a detectable signal in 5/19 mice at 48 hpi and in (M-P) 
5/19 mice at 72 hpi. There were no deaths in the OC treated group. The scale used is 
photons per second per cm
2
 per steradian (p/s/cm
2
/sr). Mice that died before 72 hpi are 
marked with a white cross. (N=20). 
Quantification of the thoracic ROI over time revealed a trend towards lower 
photon counts in mice treated with OC, particularly at 72 hpi, but this did not 
quite achieve statistical significance (Figure 7-9). 
A    B      C       D 
E    F      G            H 
I    J     K       L 
M    N      O       P 
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Figure 7-9 In vivo measurement of bioluminescence detected in the thoracic cavity of pre-
treated mice infected with A66.1 Xen 10 at 0, 24, 48 and 72 hpi.  
The horizontal bar represents the mean for each group and the error bars represent the 
standard error of the mean (SEM). Photon data does not follow a Gaussian distribution, as 
determined using GraphPad Instat program, and so group medians were compared pair-
wise using the Mann-Whitney test. (N=20) 
7.4 Lower bacterial load in OC treated mice at 72 hours 
post infection 
All surviving mice were culled after imaging at 72 hpi and bacterial loads 
assessed and the cfu/g or cfu/ml were plotted in Figure 7-10. There was a 
highly significant difference (p=0.0099) between mock and OC treated mice in 
bacterial load in the lung, supporting the imaging data. There was almost 
significant difference in the liver (p=0.0789) and a trend towards lower counts 
in the spleen and blood at 48 and 72 hpi in the OC treated mice (48 hpi data 
not shown for organs). Therefore, inhibition of the pneumococcal NanA 
protein with OC significantly reduces the development of pneumococcal 
disease after intranasal challenge in a mouse model of pneumonia. 
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Figure 7-10 In vitro quantification of bacterial burden in different bodily compartments in mice challenged with A66.1 Xen 10 for 72 hpi following either 
mock or OC pre-treatment.  
The horizontal bar represents the mean for each group and the error bars represent the standard error of the mean (SEM). Bacterial load does not follow a 
Gaussian distribution, as determined using GraphPad Instat program and so group medians were compared pair-wise using the Mann-Whitney test. There 
was a highly significant difference between mock and OC treated mice at 72 hpi in the lungs (p=0.0099). There was also a trend towards lower counts in the 
liver, spleen and blood at 48 and 72 hpi as well. (N=15). 
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Discussion 
NanA has been identified as a key virulence factor of the human pathogen S. 
pneumoniae and is essential for colonisation of the respiratory tract and 
persistence of the bacterium in the blood. Comprehensive structural studies of 
NanA have been carried out. The structure (Xu et al., 2008a; Xu et al., 2008b; 
Hsiao et al., 2009) of NanA complexed with sialic acid, zanamivir and OC show 
that, although distinct from the influenza virus NA active site, the plasticity of 
the NanA active site enables the protein to accommodate the influenza virus 
specific inhibitors.  
Here, I have established that the soluble, enzymatically active, 55 kDA fragment 
of NanA plays an important role in the progression and severity of pneumococcal 
disease in a mouse model of pneumonia. Nasal treatment with NanA before 
challenge enhances the infection and disease, especially bacteræmia and 
pneumonia. Purified protein with a PBS challenge did not affect the weight or 
clinical score of the mice (data not shown). Importantly, additional in vivo 
experiments demonstrated that this aggravating effect of the NanA enzymatic 
activity can be overcome by use of OC, a micromolar inhibitor of NanA, which 
results in a significant reduction in the severity and extent of pneumococcal 
disease in animals.  
Inhibition of NanA by OC provides an explanation for the beneficial effects of 
oseltamivir treatment in reducing lower respiratory tract infections, in particular 
bronchitis and pneumonia, as well as reducing the incidence of otitis media 
which is the main secondary complication arising in young children following 
influenza infection (McCullers & Bartmess, 2003; McCullers, 2004). To date, 
these observations have ascribed solely to the action of OC on the preceding 
viral infection. The hypothesis proposed was that the viral NA primes the host 
cell surfaces for secondary bacterial infection, and inhibition of the viral NA 
reduces the severity and/or likelihood of secondary infection. (Johnston, 2009) 
showed that OC inhibits S. pneumoniae NanA with an IC50 of 1.6 µM. 
Furthermore; the data presented here shows that in a mouse model of 
pneumococcal infection this is adequate to reduce pneumonia in vivo. 
Therefore, it is reasonable to conclude that the beneficial effects observed with 
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oseltamivir treatment in the mouse model of secondary pneumonia after 
influenza were due to oseltamivir inhibiting both the viral NA protein and the 
pneumococcal NanA. In fact, it is likely that oseltamivir also inhibits the 
secondary pneumococcal neuraminidases, NanB and C. The high bioavailability of 
OC seems to overcome the relatively low inhibitory potency of the viral NA 
inhibitor towards the NanA protein and leads to a significant fraction of NanA 
proteins that are inactivated. These results indicate that inhibitors with a higher 
affinity for the pneumococcal enzyme could be used as a bacteriostatic 
treatment for pneumococcal infections and establish the NanA protein as a 
potential drug target. 
From these results the effects are more likely due to the combined action of OC 
against both viral and bacterial neuraminidases. Therefore, it is reasonable to 
suggest that changes to oseltamivir treatment regimes could help curtail or 
significantly reduce the risk of secondary bacterial infection following a viral 
infection. Investigation of extending the use of OC to direct treatment of 
pneumococcal disease though combination with antibiotics is also justified and 
could aid in treatment of pneumococcal resistance, which have been 
complicated by increased rates of antibiotic resistance. S. pneumoniae is the 
leading cause of CAP, secondary bacterial pneumonia and other bacterial 
complications such as otitis media and sinusitis. The first line of treatment for 
these diseases are antibiotics and finding ways of reducing their intake would 
prolong their effectiveness and manage the emergence of antibiotic resistant 
strains. A null hypothesis would be that the use of OC would not increase the 
effectiveness of shortened antibiotic regimes for such infections and aid in 
reducing antibiotic consumption. Further studies investigating the use of OC as a 
prophylatic for primary or secondary pneumococcal infections and/or in 
treatment of these infections either alone or in combination with antibiotics are 
required to assess the usefulness of OC in these cases.  
In parallel, development of more potent inhibitors of the pneumococcal enzymes 
will clarify whether inhibiting its neuraminidases can successfully treat S. 
pneumoniae infections. Taken together, these data may have the potential to 
provide better treatments for S. pneumoniae diseases provoked either by a 
primary bacterial infection or as secondary complications arising from influenza. 
This is the first demonstration that NanA alone is capable of increasing 
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experimental pneumococcal disease severity, without the further modifications 
of the host immune system by a full-blown influenza infection. 
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Chapter 8 
Final discussion 
A novel N terminal genetic fusion of pneumococcal surface antigen A (PsaA) to 
pneumolysin (PLY) was successfully constructed and expressed. It was shown to 
retain the ability to bind to erythrocytes, form pores with a native appearance 
and lyse cells. Creation of this fusion permitted its use in a novel mucosal 
vaccine formulation. Previous work had used PLY and its toxids as single antigens 
or chemically conjugated to other pneumococcal factors such as cell wall and 
administered in the presence of an adjuvant. This is the first time that PLY has 
been proven to act as an adjuvant of its own accord, both mucosally and 
systemically. Mucosal induction leads to the generation of antigen specific IgG 
and IgA in mucosal washes. We‟ve shown that it is essential for PLY to be 
genetically fused to its carried antigen.  
Our work has also shown that PhtD and dPLY are capable of generating 
protective immune responses when delivered intramuscularly or intranasally in 
the presence of Labile Toxin (LT). When administered intramuscularly as single 
antigens there was no increase in clearance of the pneumococci from the lungs 
of aged mice (data not shown). Delivered together, there was a synergistic 
effect that significantly increased the rate of clearance of pneumococci in old 
mice. The combination was capable of protection in both young and old murine 
clearance models. However, when the antigens were delivered mucosally, 
protection was seen with both antigens alone and when they were given 
together. This demonstrates the importance of the inductive site when 
stimulating immunity against mucosal pathogens. In its current form it is unlikely 
that PsaAPLY would be used in an intranasal vaccine. Kirkham et al have 
mutated PLY and discovered a non-haemolytic PLY that would be suitable for 
inclusion in a mucosal vaccine, as the toxicity has been abrogated. Other fusion 
partners may also be more suitable than PsaA, and the data from the more 
traditional study conducted with PhtD and dPLY implies that PhtD might be a 
reasonable candidate for fusing to PLY. Studies are currently underway to 
explore this in more depth. 
   
 
172
During the course of these studies, an in vivo imager called an IVIS was installed. 
This took our work in a slightly different direction, as it afforded us 
opportunities to refine our in vivo models still further to reduce the number of 
animals we use and minimise suffering. A bioluminescent model using S. 
pneumoniae serotype 3 and 4 strains were established. Until now, no one had 
used bioluminescent imaging as a method for monitoring response to IPD in 
vaccinated animals. Serotype 4 is included in Prevnar and so it afforded us the 
opportunity to run a Prevnar vaccination as a „gold standard‟ for future novel 
vaccine developments. Mice were completely protected from IPD and 
bacteræmia, although there was no significant impact of vaccination on 
persistence in the nasopharynx. Other models were also established during the 
course of this study (intraperitoneal and colonisation) but there was insufficient 
room to detail them here. The impact of oseltamivir phosphate (better known as 
Tamiflu®) on IPD was also investigated. Inhibition of pneumococcal Nan was 
sufficient to reduce bacterial load in the lung and prolong survival. The converse 
experiment, adding exogenous NanA to the surface of the mucosa prior to 
infection, enhanced the subsequent pneumonia. Neuraminidases of the 
pneumococcus therefore represent novel targets for pharmaceutical 
intervention. 
Orihuela et al have successfully managed to use D39 Xen 7 in their IPD models. 
They found that it established a high-grade sepsis. However, discussions with Dr. 
Kevin Francis and Dr. David Panzerella confirmed my findings that D39 Xen 7 is 
extremely poor in vivo, which is why Xenogen transformed other strains 
following the creation of D39 Xen 7. We have observed that the time to 
morbidity with TIGR4 Xen 35 is extended in comparison to our laboratory TIGR4. 
Upon further investigation, it was discovered that a large number of genes are 
differentially expressed between the two, despite the genetic background 
supposedly being identical. One key feature was the down-regulation of the pilus 
islet in TIGR4 Xen 35. Ms. Jenny Herbert discussed this on her poster at 
Europneumo in Bern, Switzerland in June 2009.  
Insertion of the lux operon into the S. pneumoniae chromosome disrupts two 
hypothetical genes. This, combined with the observation that bioluminescence is 
lost upon stationary phase of growth, encourages us to consider remaking these 
strains. It would be logical to use one of the strongest constitutive promoters as 
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the regulator of the lux operon and insert it into a „quiet‟ region of the genome 
where there will be no disruption to existing genes. In this way it will be 
potentially be possible to monitor bacterial cells in vivo when they are no longer 
growing actively but merely persisting (as in the nasopharynx). Another idea 
might be to use a different firefly luciferase in combination with the one that is 
inserted into the Xenogen strains. The IVIS is capable of separating these two 
bioluminescent signals, and then it will be able to monitor where the bacterial 
cells are at all times and whether they are metabolising. This could also be 
combined with infra-red fluorescent reporters to increase the amount of data 
recovered even further. This would be ideal for the establishment of our next in 
vivo model, which will allow us to investigate the utility of our mucosal vaccine 
against an AOM model. 
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Appendix I 
Buffers and Recipes 
Unless otherwise stated, all reagents are from Sigma-Aldrich, Dorset, UK 
A. Media 
Terrific broth (TB) 
Bacto-tryptone  
Bacto-yeast extract  
Glycerol 
12g 
24g 
4 ml 
  
in 900 ml dH2O 
Autoclave 
In a separate flask dissolve in 90 mL H2O:  
KH2PO4 monobasic 
K2HPO4 dibasic  
(for trihydrate) 
2.31g 
12.54 g 
(16.45g) 
  
Adjust volume to 100 
mL with H2O 
Add to 900ml TB just prior to use 
B. BioCAD buffer 
3M NaCl 
175.32g NaCl in 1L millipore dH2O 
20% Ethanol 
200ml Ethanol A. R. in 800ml millipore dH2O 
C. SDS-PAGE gel recipes 
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Stacking gel (two gels) 
dH2O 3.21 ml 
0.5M Tris pH 6.8 1.25 ml 
10% SDS 0.05 ml 
30% polyacrylamide 0.488 ml 
10% ammonium persulphate 0.025 ml 
TEMED 0.005 ml 
10% Resolving gel (two gels) 
dH2O 4.05 ml 
1.5M Tris pH 8.8 2.5 ml 
10% SDS 0.1 ml 
30% polyacrylamide 3.3 ml 
10% ammonium persulphate 0.05 ml 
TEMED 0.005 ml 
10 Running buffer 
SDS 
Glycine 
Tris base 
10g 
114g 
30g 
 
 
 
 
In 1L dH2O 
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D. Western blot recipes 
Transfer Buffer (4C) 
Methanol 
Glycine 
Tris base 
200 ml 
14.4g 
3.03g 
 
 
 
 
In 1L dH2O 
20 x Tris NaCl pH7.4 
Tris base 
NaCl 
Concentrated HCl                           ~ 
24g 
174g 
800 l 
 
 
 
 
In 1L dH2O 
Developer (prepare just before use) 
4-chloro-1-napthol 
Methanol 
30 mg 
10 ml 
 
Dissolve 
In methanol 
  
 
 
Tris NaCl pH7.4 
H2O2 (30% w/v) 
40 ml 
30l 
 
 
 
Add together 
Mix. Stop reaction with H2O.  
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 G. ELISA buffers 
Coating antigen concentrations (50 l/well) 
eGFP 1 g/well  
20 g/ml 
PsaA 2 g/well  
40 g/ml 
PLY 1 g/well  
20 g/ml 
Coating buffer 
1 x PBS 
Washing solution 
1 x PBS with 0.05% Tween (v/v) 
Blocking buffer 
1% BSA in 1 x PBS 
Antibody dilution buffer 
1 x PBS with 0.05% Tween plus 0.1% BSA 
 Developer 
1 OPD tablet set in 20 ml dH2O 
Stop solution 3M HCl 
Concentrated HCl 
dH2O 
129.3 ml 
370.7 ml 
 
 
 
Add acid to dH2O in hood 
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